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Uitnodiging
Hierbij wil ik u en uw partner 
graag uitnodigen voor het 
bijwonen van de verdediging van 
mijn proefschrift, getiteld:
Impact and therapeutic 
options of  sclerotic skin 
diseases
De promotieplechtigheid zal 
plaatsvinden op 
donderdag 11 december 2008 
om 15.30 uur in Aula Major 
van de Radboud Universiteit 
Nijmegen, Comeniuslaan 2 te 
Nijmegen.
Aansluitend zal er een receptie 
plaatsvinden. 
Gezien de aard van de 
plechtigheid wordt u vriendelijk 
verzocht geen kinderen mee te 
nemen naar de promotie. Bij de 
receptie zijn ze vanzelfsprekend 
van harte welkom.
The scleroderma skin disorders comprise a heterogeneous group of  
conditions linked by the presence of  sclerotic skin lesions. It can manifest 
itself  as a small indurated plaque to conditions that may cause a signifi cant 
functional and cosmetic deformity. Localized scleroderma is a primary 
cutaneous sclerosis. Examples of  localized scleroderma are plaque 
morphea, linear morphea and deep morphea. Additional eosinophilic 
fasciitis can be distinguished, although the question remains whether 
eosinophilic fasciitis is a seperate disease or a variant of  deep morphea. 
Scleroderma-like disorders, also called pseudoscleroderma or secondary 
scleroderma, are disparate conditions mimicking cutaneous localized 
scleroderma, e.g. chronic sclerodermic graft-versus-host disease, drug-
induced scleroderma-like disorders, mucinosis such as scleredema of  
Buschke/adultorum and scleromyxedema. 
This thesis is focused upon localized scleroderma, eosinophilic fasciitis and 
pseudoscleroderma and does not only give a detailed description of  the 
physical burden and psychological distress in patients with a sclerotic skin 
disease, but also studied the therapeutic effectiveness and tolerability of  
different classes of  treatment for sclerotic skin diseases. 
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1.1  CLINICAL AND EPIDEMIOLOGIC CHARACTERISTICS OF   
 SCLEROTIC SKIN DISEASES
1.1.1  Sclerotic skin diseases
Scleroderma is derived from the Greek words skleros (indurated) and derma (skin).
Scleroderma is characterized by a thickened/large amount of  collagen in the skin. 
The disease scleroderma includes a wide range of  disorders, ranging from localized 
scleroderma and cutaneous sclerosis as a component of  eosinophilic fasciitis, to 
systemic sclerosis. This thesis is focused upon localized scleroderma, eosinophilic 
fasciitis and pseudoscleroderma, also referred to as sclerotic skin diseases in this 
text. 
Chapter 1.1.2 describes the epidemiology, aetiology, clinical presentation, 
classiﬁ cation and diagnosis of  localized scleroderma (A) and eosinophilic fasciitis 
(B). 
Chapter 1.1.3 describes the classiﬁ cation of  pseudoscleroderma. 
A short introduction to systemic sclerosis is given in chapter 1.1.4. 
It should be noted that systemic sclerosis is not included within the investigations 
in this thesis. 
1.1.2  Localized scleroderma and eosinophilic fasciitis
Epidemiology
Localized scleroderma, also called morphea, is an uncommon disease. The only 
population based study to determine the epidemiology of  localized scleroderma 
was being undertaken by Peterson et al.1 in Olmsted County, Minnesota with a 
study period of  33 years. This study includes all types of  morphea. The incidence 
rate of  morphea was 2.7 per 100,000 population. The prevalence of  morphea was 
2 per 1,000 population. Morphea is more common in females than males (2.6:1), 
although in linear morphea, the sex distribution is equal. 
The onset of  morphea generally happens between the ages of  20 and 40. However 
in linear morphea the disease starts at a young age (<18 years) and the mean age of  
onset in deep morphea is 46 years.1,2
Regarding the duration of  the active phase of  the disease, the shortest duration, 
only 2.7 years, was seen in the plaque morphea group. Deep morphea showed 
the longest period of  duration of  5.5 years. This was based on 50% resolution or 
skin softening. Some complications that accompanied morphea were arthralgias, 
synovitis, uveitis, and joint contractures, but these were more frequent in the linear 
and deep forms of  morphea than in all other forms of  localized scleroderma.1
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Aetiology
Athough the cause of  scleroderma remains unknown, an auto-immune mechanism 
is suspected. Many auto-immune conditions have been described in association 
with morphea, including type I diabetes mellitus, Hashimoto’s thyreoiditis and 
vitiligo.3 This supports the role played by auto-immunity in the pathogenesis of  
morphea. Also, several antibodies have been shown to exist in the blood of  patients 
with localized scleroderma, which will be further reviewed under the headline 
diagnosis.4-7 Morphea lesions may appear or grow during pregnancy. Morphea has 
occured after BCG vaccination and at the site of  radiotherapy for previous breast 
cancer. In 1985, Aberer8 debated about a possible association of  Borrelia Burgdorferi 
with localized scleroderma, because of  the resemblance between morphea and 
acrodermatitis chronica atrophicans. The association with borrelia is still a debate. 
Longo et al.9 reported 4 cases of  localized scleroderma after an Epstein Barr virus, 
however there have been no further studies after this possible aetiological agent 
of  morphea. Additionally, repetitive trauma10 has been reported as an aetiological 
agent of  morphea. Trauma could release inﬂ ammatory mediators and cytokines, 
which can give rise to ﬁ brosis.
In 1992 Press et al.11 related the occurrence of  morphea to the implantation of  
silicon prothesis for breast augmentation. A familial incidence of  morphea has 
been demonstrated occasionally, but signiﬁ cant HLA associations have not been 
demonstrated so far. 
In summary, the aetiology is unknown, but an auto-immune aetiology, trauma, 
BCG vaccination, radiotherapy, implantation of  silicon prothesis, hormonal, 
infectious or toxic agents and neurogenic factors have been mentioned. The 
connection between these factors and localized scleroderma however has never 
been proven.12 
Clinical presentation
The typical lesion begins with a patch of  erythema. After this inﬂ ammatory stage 
the lesions often become indurated and the centre shows a yellowish white shine. 
Later a typical ivory white central area surrounded by a circumscribed sclerotic 
hyper-pigmented plaque is seen. A violet ring, also called the lilac ring, borders the 
ivory coloured hardened area. While the sclerotic areas are usually permanent, over 
many years the lesions can become atrophic, a depigmentated or hyper-pigmentated 
patch will persist. 
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Classifi cation
A. Localized scleroderma
The classiﬁ cation of  localized scleroderma according to Peterson et al.13 is based 
on ﬁ ve general types: plaque morphea, generalized morphea, bullous morphea, 
linear morphea and deep morphea. The classiﬁ cation according to Chung et al.2 is 
shown in Table 1.
1 Plaque morphea
Guttate
Generalized
Keloidal (nodular)
Atrophoderma of  Pasini and Pierini
Overlap with lichen sclerosus (et atrophicans)
2 Bullous (vesicular) morphea
3 Linear morphea
En coup de sabre
Progressive facial hemiatrophy (Parry-Romberg syndrome)
4 Deep morphea
Subcutaneous
Morphea profunda
Disabling pansclerotic morphea (of  children)
Table 1: Classification of localized scleroderma according to Chung et al.2
1. Plaque morphea is described as one or two circumscript patches of  sclerotic 
skin in one or two anatomic sites. Generally this type of  morphea is located on the 
trunk. The face, neck or scalp may also be involved. Plaque morphea is the most 
common sub-type of  localized scleroderma and comprises more than 50%1 of  the 
cases of  morphea.2 This type of  morphea has more variants: guttate, generalized, 
keloidal, atrophoderma of  Pasini and Pierini and the overlap with lichen sclerosis 
(et atrophicans).
Guttate morphea consists of  multiple, small (2-10 mm diameter) lesions, and usually 
involves the shoulders and chest. 
Generalized morphea consists of  multiple plaques that affect more than three sites 
on the body or the individual plaques become more conﬂ uent. This type accounts 
for approximately 13% of  patients with morphea.1 It can progress and involve 
widespread areas of  the body. The multiple plaques eventually become indurated 
with hyper-pigmentation. 
Keloidal morphea, also known as “nodular morphea”, is a rare condition 
characterized by indurated plaques that resemble post-traumatic scars. Keloid 
morphea can be several centimeters in diameter, and is found either as a single 
lesion or as multiple lesions. 
Atrophoderma of  Pasini and Pierini. This type is thought by many to be a variant of  the 
plaque morphea, although the lesions usually lack inﬂ ammation or induration.14,15 
This sub-type usually involves the trunk, especially the buttocks and lower part 
of  the back and is characterized by hyper-pigmented atrophic patches with well-
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demarcated borders. Coexisting indurated lesions of  morphea are found in more 
than 20% of  the cases, supporting the relationship with mophea.14,15 
Overlap with lichen sclerosus (et atrophicans). Some authors consider the association of  
lichen sclerosus et atrophicans (LSA) and morphea to be a clue for the existence of  
a close relationship between the diseases16 or that LSA and morphea are different 
manifestations of  a single disease spectrum.17 Patterson and Ackerman18 believe 
that morphea and LSA are two distinct diseases. Some classiﬁ cations considered 
LSA as a pseudoscleroderma.13,19 Instead of  morphea, these lesions show 
histological follicular plugging and a lichenoid inﬁ ltrate. Clinically the lesions are 
characterized by white, sclerotic plaques. The relationship is confusing while classic 
forms of  morphea can be found to coexist with lesions of  lichen sclerosus et 
atrophicans.2 
2. Bullous morphea typically consists of  tense subepidermal bullae that occur in 
the plaque of  morphea. 
3. Linear morphea is characterized by a single, linear and unilateral band that 
involves the dermis and subcutaneous tissue and can also extend to the muscle 
and bone. Usually the localization of  the lesion is on an extremity. This type of  
morphea accounts for approximately 20% of  all cases of  morpha and is the most 
common form in children and adolescents.1
En coup the sabre: Linear morphea that affects the face or scalp is called ‘morphea/
scleroderma en coup de sabre’. It typically presents itself  as a linear hyper-pimented 
or ivory-colored depressed linear plaques on the paramedian forehead.13 Ocular 
complications, such as eyelid retraction, or glaucoma can occur in up to 15% of  
the cases.3 Neurologic involvement can manifest, such as seizures and vascular 
malformations. An area of  controversy is whether or not children with ‘en coup de 
sabre’ with neurologic abnormalities are in fact cases of  Parry-Romberg syndrome. 
It is unclear what the exact relationship is between ‘en coup de sabre’ and the 
‘Parry-Romberg syndrome’. 
Parry-Romberg syndrome or progressive facial hemiatrophy is thought to be a variant of  the 
linear morphea and affects the subcutis, muscle and bone resulting in a hemifacial 
atrophy.13 In patients with Parry-Romberg compared with those with ‘en coup de 
sabre’, there is usually greater involvement of  the lower face and the superﬁ cial skin 
is involved in a relatively minor fashion.20 Seizures, uveitis, and dental and ocular 
abnormalities are more common in Parry-Romberg syndrome. Parry-Romberg 
syndrome may represent the severe end of  the spectrum of  ‘en coup de sabre’ as 
supported by cases of  patients who have linear lesions on the face and other parts 
of  the body. However, in other reports, there is no evidence of  inﬂ ammation and/
or sclerosis preceding the severe atrophy seen in patients with Parry-Romberg 
syndrome, suggesting the two are separate entities. 
Chapter 1 - General Introduction
14
4. Deep morphea involves the deeper layers of  the skin, these are the deep 
dermis, subcutaneous tissue, fascia, or muscles and shows deep sclerotic plaques. 
The inﬂ ammation process is deep in the subcutaneous fat and fascia.2 Deep 
morphea includes three subtypes:
Subcutaneous morphea. In this subtype, the primary site of  involvement is the 
panniculus or subcutaneous tissue. The plaques are hyper-pigmented, symmetric, 
and somewhat ill deﬁ ned. Onset of  sclerosis is rapid over a period of  several 
months and the degree of  inﬂ ammation is more serious than in other subtypes. 
Morphea profunda. In patients with morphea profunda, the entire skin is thickened. 
Sclerosis is present in the connective tissue septae of  the subcutis and in the 
underlying muscle fascia. The skin has a bumpy, depressed surface.
Disabling pansclerotic morphea. This is a rare but extremely severe subtype. It is 
characterized by generalized full-thickness skin involvement of  the trunk, 
extremities, face, and scalp with sparing of  the ﬁ ngertips and toes. This variant 
occurs in children and is therefore also called disabling pansclerotic morphea of  
children. The involvement is so widespread and severe, that joint contractures will 
develop and severe deformaties occur on the trunk and later the face. 
Diagnosis
The diagnosis of  morphea is based on clinical ﬁ ndings, although histopathological 
examination is often necessary to exclude other types of  sclerotic disorders. 
Localized scleroderma is characterized by three outstanding features: an 
inﬂ ammatory cell inﬁ ltrate, increased deposition of  collagen in the dermis and 
subcutis and vascular changes.
Histopathological examination of  early lesions indicate they are characterized by a 
dense inﬂ ammatory inﬁ ltrate, which consists of  lymphocytes, some plasma cells, 
macrophages, and occasional mast cells and eosinophils.2 It is distributed around 
blood vessels or more diffusely through the lower dermis and subcutis, particularly 
at the borders of  active lesions.
The ﬁ brotic phase is characterized by an increased thickened dermis and composed 
of  broad sclerotic collagen bundles. Collagen also replaces fat around the sweat 
glands and extends into the subcutis. Eccrine glands are often situated at a relative 
high level in the dermis due to the collagen deposited below them.
The vascular changes are thickening of  the walls of  small blood vessels and thereby 
a narrowing of  their lumen. Various laboratory abnomalities may be found in 
patients with morphea. Eosinophilia may be found in patients with a generalized or 
linear morphea.4 Eosinophilia is a prominent laboratory ﬁ nding in patients with an 
eosinophilic fasciitis.
Polyclonal hypergammaglobulinemia can occur in 50% of  patients with linear 
scleroderma and most patients with an eosinophilic fasciitis.2,21 Besides these 
laboratory abnormalities, various circulating auto-antibodies can be found in 
morphea, including antinuclear antibodies, anti-single-stranded DNA antibodies, 
anti-histone antibodies and the presence of  rheumatoid factor. Less common 
anti-centromere antobodies could be detected and in only a few patients anti-
topoisomerase I antibodies have been reported, while anti-topoisomerase IIα 
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antibodies are frequently present in patients with morphea.4-7 A marked increase 
in tenascin, compared to normal skin, was found in the centre of  localized 
scleroderma lesions.22
B. Eosinophilic fasciitis
The question remains whether eosinophilic fasciitis is a seperate disease or a variant 
of  deep morphea. 
The ﬁ rst description of  the condition now known as eosinophilic fasciitis has 
been attributed to Shulman in 1974.23 Eosinophilic fasciitis (also called Shulman 
syndrome or diffuse fasciitis with eosinophilia) is an uncommon disorder of  
unknown aetiology. 
It is characterized in its early phase by limb or trunk erythema and edema. Early 
in the course of  the disease, the deep fascia and lower subcutis are edematous and 
inﬁ ltrated with lymphocytes, plasma cells, histiocytes, and especially eosinophils; 
these features are generally associated with an impressive but sometimes quickly 
fading peripheral eosinophilia and later by collagenous thickening of  the dermis 
and subcutaneous fascia occurs. The dermis becomes thickened and sclerotic.24,25 
The most common areas of  skin involvement include the extremities, neck, and 
trunk. Importantly, the skin of  the hands and feet, including the digits, is generally 
spared. Eosinphilic fasciitis usually affects people between the ages of  30-63 years, 
but can occur at any age.24 This disorder has been reported to be associated with 
multiple types of  hematological malignancies, although this association is not 
deﬁ nitive.26 
Diagnosis
Beside clinical ﬁ ndings, laboratory investigations are important. Eosinophilia is 
a prominent ﬁ nding. Hypergammaglobulinemia and elevated ESR (erythrocyte 
sedimentation rate) can also be found by laboratory investigation. A full-thickness 
incisional biopsy specimen should be obtained, to include the skin, fat, fascia, 
and superﬁ cial muscle in continuity. The earliest changes occur in the interlobular 
ﬁ brous septa of  the subcutis and deep fascia. Eventually there is striking thickening 
of  the deep fascia and septa of  the subcutis with ﬁ brosis and hyalinization of  
the collagen.27,28 In general, inﬂ ammation, edema, thickening, and sclerosis of  
the fascia are hallmarks of  eosinophilic fasciitis. The cellular inﬁ ltrate consists of  
lymphocytes, plasma cells, histiocytes, and eosinophils. 
Magnetic resonance imaging (MRI) of  the involved areas shows characteristic 
ﬁ ndings of  fascia thickening, and contrast enhancement. MRI helps to determine 
the diagnosis, locating the biopsy site, and monitoring the response to treatment. 
Electromyogram is the most sensitive test for myositis in eosinophilic fasciitis, and 
ﬁ ndings may be abnormal in the presence of  normal serum muscle enzymes.
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1.1.3  Pseudosclerotic skin diseases
Pseudoscleroderma or scleroderma-like disorders are disparate conditions 
mimicking localized scleroderma or systemic sclerosis. 
Table 2 shows the variants of  pseudoscleroderma according to Tufanelli.29
Chronic sclerodermic graft-versus-host disease
Drug-associated scleroderma-like disorders
Environmental chemical/toxin exposure associated
Traumatic
Metabolic
Genetic
Mucinosis
      scleredema of  Buschke
      sleromyxedema
Malignancy
Radiation exposure
Neurological
Post-infections
Table 2: Variants of pseudoscleroderma according to Tufanelli.
29
Chronic sclerodermic graft-versus-host disease. Graft-versus-host disease 
is a complication of  hematopoietic cell transplantation. Approximately 10% of  
patients suffering from chronic graft-versus-host disease develop sclerodermic 
graft-versus-host disease of  the skin. The most common clinical form of  chronic 
graft-versus-host is skin involvement. The lesions on the skin resemble cutaneous 
manifestations of  scleroderma.30 Both a generalized and localized form have been 
described; each has a characteristic histology. Histology of  the generalized form 
reveals hyperkeratosis and epidermal hypertrophy, occurring in association with 
a lichenoid reaction at the basal layer. In later stages of  the disease, the dermis 
becomes atrophic and the inﬂ ammatory changes are less striking. The ridges 
become absent, and the dermal-epidermal junction is straightened and obliterated. 
Fibrosis may be observed throughout the dermis and the adnexal structures. The 
localized form is associated with epidermal atrophy and dense focal dermal ﬁ brosis, 
but no signiﬁ cant inﬂ ammation.31
Drug-associated scleroderma-like disorders. Several medications could induce 
cutaneous sclerosis. Medications that could give ﬁ brotic reactions are: Vitamin 
K, bleomycin, interferon alfa, interleukine-2,19 hydroergotamine, Lyserginacid 
Diethylamine (LSD), hydralazine, procainamide, methyldopa, practolol, propanolol, 
metoprolol, analgesics, anticonvulsants and sulphonamides.32 Tuffanelli reported 
pentazocine, isoniazid, valproate sodium, l-5-hydroxytryptophan and carbidopa, 
bromocriptine, nitrofurantoin and L-tryptophan.29 Additionally, Haustein and 
Haupt33 describes scleroderma-like disorders after docetaxel (a chemotherapeutic), 
several analgetics, e.g. pentazocine, ergot and methysergide, bromocriptine, 
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ketobemidone (ketogan) and morphine, neurological drugs, e.g. ethosuximide and 
carbidopa and other agents, e.g. bisoprolol, fosinopril, cocaine and D-penicillamine.
Environmental chemical/toxin exposure associated sclerosis. Polyvinyl 
chloride, epoxyresins and possible silicones used in breast augementation could 
give rise to sclerosis. Environmental accidents have led to scleroderma-like illnesses. 
The Spanish toxic oil scandal began in 1981 following the ingestion of  cooking oil. 
Thirty percent of  the persons developed cutaneous sclerosis, usually involving the 
proximal extremities.29 
Eosinophilia myalgia developed in patients who had ingested L-tryptophan (sold as 
a non-toxic sedative). Some patients developed a pattern of  generalized morphea. 
A pattern resembling eosinophilic fasciitis was most commonly seen.
Traumatic scleroderma, including burns. Repetitive vibrational injury and burns 
can cause sclerosis. 
Metabolic disorders. Porphyria, amyloidosis, Hashimoto thyreoiditis, diabetes 
mellitus and POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, 
M protein, and Skin changes) can give rise to the formation of  sclerotic skin.
Genetic. Several genodermatosis like Progeria, Werner’s syndrome, Rothmund-
Thompson syndrome can lead to sclerosis of  the skin.
Mucinosis, Scleredema of  Buschke. The ﬁ rst description of  the condition 
now known as scleredema adultorum of  Buschke has been attributed to Curzio in 
1752 by Touraine and co-workers34 in their 1936 review of  the disease. It was not 
until 1902 when Abraham Buschke35 described a 46-year-old carriage painter who 
developed ﬁ rm, non pitting edema in the neck and which spread to involve all parts 
of  his body except those distal to the palms and thighs.36
Scleredema can be categorized into 3 subgroups:
Type I: also called the classic type described by Buschke in 1902. All of  these • 
patients have a preceding febrile illness and the lesion will disappear in several 
months to 2 years. This type makes up about 55% of  the cases of  scleredema 
adultorum37.
Type II: These patients do not have a history of  an infection or diabetes. This • 
type tends to follow a slow progressive course and the lesions will persist. Type 
II makes up about 25% of  patients. 
Type III has been termed scleredema diabeticorum. This type is a slowly • 
progressive, non-resolving scleredema that occurs in diabetic patients. This type 
makes up about 20% of  cases.37
Unlike the other subgroups, there is a predominance of  male patients in Type III. 
Scleredema diabeticorum presents itself  as a ﬁ rm, stiff  indurated skin especially 
in the neck and back, but occasionally peripherally. The hardening of  the skin 
is due to broadening of  collagen bundles together with mucin deposition in the 
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Figure 1A
Figure 1C
Figure 1B
Figure 1A and B: Clinical picture of two patients with generalized morphea. 
Figure 1C: Clinical picture of a patient with a linear morphea, ‘en coup de sabre’.
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reticular dermis. The pathogenetic mechanism of  the indurated skin is not revealed. 
It is postulated that hyperglycemia leads to glycolisation of  the collagen. This 
glycation process can divide into 3 stages: The formation of  the Amadori product, 
an irreversible product signiﬁ cantly increased in diabetic patients, then spreading 
with glycol-oxidation reactions and ﬁ nally the formation of  advanced glycation 
end products.38 This action causes for example an impaired collagen resorption, 
rendering the collagen ﬁ bres resistant to degradation by collagenase. With levels of  
hyperglycemia in vivo, the process of  glycation probably takes several months or 
years to become biochemically important. 
Mucinosis, Scleromyxedema. Scleromyxedema was ﬁ rst decribed by Gottron 
in 1954.39 This disease is also known by the name papular mucinosis or lichen 
myxedematosus. Scleromyxedema is a rare connective tissue disorder characterized 
by increased deposition of  mucopolysaccharides and ﬁ brocytes in the skin, 
plasmacytosis of  the bone marrow and frequently a paraproteinemia. The skin 
changes consist of  yellow-red papules on the head, neck, arms, and upper trunk, 
commonly occurring over thickened, indurated skin. The face and arms are the 
most affected areas.40
The disease is chronic and progressive. The face becomes a mask, with thick 
skinfolds and lichenoid papules more prominent around the eyes. Deep glabellar 
folds and ﬁ ssures resemble leonine facies of  leprosy. Scleredema is almost always 
associated with a gammopathy, mainly of  the IgG lambda type. The exact role of  
this paraprotein in the development of  skin changes is not clear.
Malignancy. Several malignancies, like carcinoid syndrome, breast carcinoma 
(carcinoma en cuirasse) could give rise to sclerosis in the skin. 
Radiation exposure. Radiation therapy could give sclerosis of  the skin. After 
radiotherapy a hardening of  the skin could be seen. After the nuclear accident in 
Chernobyl more patients were seen with a hardening of  the skin.
Neurological. Dermal sclerosis after a spinal injury is seen. After limb 
immobilization the skin can show hardening.
Post-infections, e.g. acrodermatitis chronica atrophicans. Lyme disease is 
caused by an infection of  Borrelia burgdorferi. The bacteria are transmitted when a 
tick bites. Acrodermatitis chronica atrophicans, almost exclusively seen in Europe, 
can include ﬁ brous nodules, ulnar bands, and pseudosclerodermatous changes.
Additional to the classifi cation of  Tuffanelli:29 
Lichen sclerosis/sclerosus (et atrophicans), LSA, refers to a chronic, progressive 
dermatologic condition characterized by epithelial thinning, marked inﬂ ammation, 
and distinctive sclerotic or atrophic dermal changes accompanied by symptoms 
of  pruritus and pain. It is still a debate if  LSA belongs to the pseudoscleroderma 
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group, as mentioned earlier. LSA is a chronic inﬂ ammatory skin disorder that 
typically affects the vulva (or penis) and anus. Occasionally, LSA is seen on other 
parts of  the body, especially the upper body, breasts, and upper arms and is 
referred to as extragenital lichen sclerosus. This condition is most common in 
women. 
Nephrogenic systemic fi brosis (NSF). NSF was ﬁ rst observed in 1997 and 
the initial case series were published in 2000.41 The condition was originally 
known as ‘Nephrogenic ﬁ brosing dermopathy’. The name of  the disorder was 
changed to NSF in 2005.42 Nephrogenic ﬁ brosing dermopathy is characterized 
by induration, thickening, and hardening of  the skin with hyper-pigmentation, 
sometimes accompanied by papules and subcutaneous nodules. The skin can have a 
peau d’orange or shiny appearance. The extremities are the most common areas of  
involvement, followed by the trunk. The face is almost never affected.43-46 
NSF almost always occurs in patients with renal insufﬁ ciency who have had 
imaging studies (e.g. magnetic resonance angiography) with gadolinium, a contrast 
agent used in imaging studies. Gadolinium can be found in tissue samples of  NSF. 
The mechanism by which this occurs is clearly linked to the combination of  linear 
chelates of  gadolinium and decreased renal function. 
Necrobiosis lipoidica. Necrobiosis lipoidica is a skin disease that most commonly 
affects the shins. Typically several indurated shiny red-brown plaques appear. The 
earliest lesions are red papules, which enlarge radially to become plaques with 
an atrophic, slightly depressed, yellow-brown center and a well demarcated red/
purple border. Some lesions resolve spontaneously, but many are persistant with 
development of  ulcerations.47 There is discussion if  necrobiosis lipoidica belongs 
to the pseudosclerotic skin diseases category.
Necrobiotic xanthogranuloma. Necrobiotic xanthogranuloma is a rare chronic 
disorder, characterized by the presence of  multiple sharply demarcated nodules 
and plaques.48 A solitary variant is described.49 There is discussion as to whether 
necrobiotic xanthogranuloma belongs to the pseudosclerotic skin diseases category. 
Predeliction sites of  a necrobiotic xanthogranuloma are periobital, but other areas 
of  the face, as well as the trunk and limbs can be involved. Clinically violaceous 
to red lesions are visible with a xanthomatous hue. Development of  ulcerations, 
teleangectasia and central atrophy are possible. This condition is associated with 
paraproteinemia.
1.1.4  Systemic sclerosis 
Systemic sclerosis, formally called systemic scleroderma, is an auto-immune disease 
of  the connective tissue, characterized by thickening and induration of  the skin, by 
ﬁ brotic degenerative changes in muscles, joints and viscera (esophagus, intestinal 
tract, lungs, heart and kidneys) and by microvascular and larger vessel lesions. 
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Epidemiology
Systemic sclerosis (SSc) is a rare illness. A study performed by Allcock et al.50 in 
2004 found a prevalence of  systemic sclerosis of  8.2 per 100,000 persons. The 
ratio of  women to men was 5.2:1. The median age of  patients was 57.1 years. The 
prevalence has increased as a result of  earlier detection through better diagnosis 
and an increased survival rate.
Aetiology
The cause of  scleroderma remains unknown. Vascular, ﬁ brotic and inﬂ ammatory/
immunologic processes are involved in its pathogenesis. Immune activation, 
vascular damage, and excessive synthesis of  extracellular matrix with deposition 
of  increased amounts of  collagen are all suspected to be important in the 
development of  this illness. Although a great deal is now known about the 
abnormalities in immune, endothelial, and ﬁ broblast cell function in systemic 
sclerosis, the initiation/activation of  these pathogenetic pathways are still unclear. 
Genetic factors appear to predispose patients to the disease.
Clinical presentation
The skin thickening, caused by an increase of  collagen after which the disease 
is named, is symmetrical on both sides of  the body, usually beginning on the 
ﬁ ngertips and moving up the arms. Legs and thighs can also be affected. The 
accumulation of  collagen can also occur in other organs, including the lungs, heart 
and the gastrointestinal tract. 
The following symptoms are possible:
Proximal hardening of  the skin (proximal scleroderma): characterized by • 
symmetric thickening, tightening, and induration of  the skin of  the ﬁ ngers and 
the skin that is proximal to the metacarpophalangeal or metatarsophalangeal 
joints.
Thickening of  the skin of  hands (sclerodactyly). • 
Digital pitting scars or a loss of  substance from the ﬁ nger pad. As a result of  • 
ischemia, depressed areas of  the ﬁ ngertips or a loss of  digital pad tissue occurs. 
Pain and stiffness of  the joints. • 
Joint contractures. • 
Raynaud phenomenon and digital ulceration. • 
Gastrointestinal tract problems (e.g. gastroesophageal reﬂ ux caused by lower • 
esophageal sphincter incompetence and decreased or absent peristalsis in the 
lower two thirds of  the esophagus).
Progressive dyspnoea or a dry persisted cough, due to bibasilar pulmonary • 
ﬁ brosis, this can be detected by chest radiograph: linear shadows or “honey-
comb” reticular appearance most pronounced at the periphery of  the lungs and 
at the bases. 
Facial problems (e.g. perioral ﬁ brosis). • 
Dental problems (change in bite, loosening of  teeth due to collagen deposition • 
increasing the size of  the ligaments around the teeth, tooth sensitivity). 
Fatigue attributable to ﬁ brosis in the heart muscle, or/and lung involvement. • 
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Classifi cation
A subclassiﬁ cation divides systemic sclerosis into limited cutaneous systemic 
sclerosis and diffuse cutaneous systemic sclerosis:
limited cutaneous systemic sclerosis/scleroderma. • The limited form is much milder 
compared to the systemic form. Limited cutaneous sclerosis has a slow onset 
and progression. The skin areas involved are limited, mostly hands, feet, face 
and/or forearms. The internal organ involvement is less severe. A much better 
prognosis is expected compared to the diffuse cutaneous systemic sclerosis. 
Raynaud’s phenomenon normally precedes scleroderma by several years. 
Raynaud’s phenomenon is due to vasoconstriction of  the small peripheral 
arteries exposed to cold – in particular involving the hands and feet. It is 
classically characterised by a triphasic colour change - ﬁ rst white, then blue and 
ﬁ nally red on rewarming;
diffuse cutaneous systemic sclerosis/scleroderma•  can affect the skin at almost any 
body area. Internal organs involvement can include kidneys, lungs, heart, 
gastrointestinal tract, and the vascular system. 
Limited cutaneous SSc is associated with the presence of  anti-centromere 
antibodies; diffuse cutaneous SSc is associated with anti-Scl 70 (anti-topoisomerase) 
antibodies.51 The ratio of  limited cutaneous SSc to diffuse cutaneous SSc is 4.7:1.
The classiﬁ cation according to the American College of  Rheumatology (ACR) 
is commonly used in clinical trials. The criteria for the classiﬁ cation of  systemic 
sclerosis requires one major criterion or two minor criteria.51 
Major criterium
proximal scleroderma
Minor criteria
sclerodactyly
digital pitting scars or loss of  substance ﬁ ngerpad
bibasilar pulmonary sclerosis
Table 3: ACR criteria
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1.2  TREATMENT OPTIONS OF SCLEROTIC SKIN DISEASES
1.2.1  Short synopsis
Different treatment options are postulated to help patients with a sclerotic 
skin. Therapies that have been used are topical tacrolimus, imiquimod, topical, 
intra-lesional and systemic corticosteroids, topical and systemic vitamine D 
analogues, vitamin E, antimalarials, phenytoin, salazopyrin, colchicin, ciclosporin, 
plasmapheresis, phototherapy with UVA light, methotrexate, penicillinamine and 
interferon-y (INF-y).
Tacrolimus ointment for localized morphea has recently been evaluated by Mancuso 
et al.52,53 Two uncontrolled open-labelled studies revealed that topical tacrolimus 
showed a beneﬁ cal effect on localized scleroderma.
Imiquimod induces the production of  interferon-α and interferon-γ, which may 
result in decreased ﬁ broblast collagen production and down-regulation of  TGF-β 
expression. An open study with imiquimod 5% cream showed a beneﬁ cal effect on 
morpea plaques.54
Topical and intralesional corticosteroids are used for discrete lesions in the early 
inﬂ ammatory stage of  morphea. Topical corticosteroids and intralesional 
corticosteroids have been beneﬁ cial, but no controlled studies have been 
performed.2 
Oral corticosteroids have been studied in an open-labelled trial in 17 patients with 
severe morphea and the study revealed an improvement of  the skin lesions.55
Vitamin D analogues has a possible inhibitory effect on ﬁ broblast proliferation and 
collagen synthesis. Open-labelled studies on topical calcipotriol and oral calcitriol 
demonstrated an improvement on the lesions.56,57 However a double-blind, 
placebo controlled study did not give a beneﬁ cial outcome for calcitriol.58 
Vitamin E: Ayres et al.59 described a possible therapeutic value of  vitamin E in 
the management of  a number of  disabling skin diseases of  unknown aetiology, 
including (localized) scleroderma. 
Antimalarials: Brownell et al.60 described a slowed disease progression and 
reversed hair loss after treatment with antimalarials and narrow-band ultraviolet B 
phototherapy in a patient with a linear scleroderma. Several open studies and case 
reports decribed beneﬁ cial effects of  antimalarials in the treatment of  localized 
scleroderma.61-64
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Phenytoin: Phenytoin is decribed as a possible treatment option of  sclerotic skin 
diseases,61,65,66 however Kashiwazaki et al.67 described a case of  scleroderma 
developing during treatment of  diphenylhydantoin.
Salazopyrin: Several case reports and case series decribed beneﬁ cial effects of  
salzopyrin in localized scleroderma.68-72
Colchicin: A study perfomed by Alarcon-Segovia et al. and Frati Munari et al. showed 
improvement after treatment with colchicin.73,74
Ciclosporin: Strauss et al. described a child with linear sclerderma repsonding well to 
ciclosporin. Worle et al. descibed a case with localized scleroderma responding with 
clinical improvement (partial regression of  cutaneous sclerosis and inﬂ ammation) 
after ciclosporin.75,76
Plasmapheresis: Wach et al.77 described three patients with severe, localized 
scleroderma and elevated titres of  antinuclear antibodies, who were treated 
with plasmapheresis in combination with a systemic steroid. The therapeutic 
effectiveness was assessed on the basis of  improvement in cutaneous and joint 
lesions. In all cases, signiﬁ cant improvement occurred after 2 months of  therapy.
Phototherapy: The use of  ultraviolet light has reported to be beneﬁ cal in the 
treatment of  morphea.Ultraviolet irradiation leads to induction of  collagenases.78 
Several studies demonstrated the initial clinical effectiveness of  UVA-1 (Chapter 
3.3-3.5) Furthermore broadband ultraviolet A79-85 treatment with or without 
8-methoxypsoralen (oral or topical) has also resulted in skin softening in several 
studies. The optimal dose, frequency and duration of  phototherapy has to be 
researched further.
Methotrexate: In uncontrolled studies methotrexate has been used succesfully.86 
Open-label studies in children and adults have shown that low-dose methotrexate 
in combination with pulse methylprednisolone (monthly) results in skin softening 
in patients with severe generalized morphea, Parry-Romberg syndrome, and linear 
scleroderma.2,87,88 
D-penicillamine is a sulfhydryl amino acid that may be prepared by hydrolytic 
degradation of  penicillin. The drug affects collagen metabolism by decreasing 
cross-linking of  collagen ﬁ bers and possibly by decreasing total collagen synthesis. 
It also has important anti-inﬂ ammatory and immunomodulating properties. Falanga 
et al.89 described the beniﬁ cial effect of  this drug in patients with a localized 
scleroderma. 
Interferon-y is a potent inhibitor of  ﬁ broblast collagen synthesis, because it is able 
to suppress procollagen mRNA (messenger RNA) levels in normal cultured 
ﬁ broblasts. However, Hunzelmann et al. found no difference in size or ﬁ brosis in a 
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double-blind placebo controlled study with intralesional INF-y in 24 patients with 
localized scleroderma.90
Unfortunately, many of  these studies were uncontrolled and for this reason it has 
been difﬁ cult to judge the results. Many therapies have to be evaluated for their 
efﬁ cacy. 
Since this thesis describes the therapeutic options of  topical tacrolimus, MTX and 
UVA-1 for sclerotic skin diseases, these therapies are described more in detail in 
the following chapters.
1.2.2  Tacrolimus
Tacrolimus, introduced in 1989, was ﬁ rst used as an immunosupressive agent in 
transplant patients receiving it as systemic anti-rejection therapy.91 Tacrolimus is 
produced by Streptomyces tsukubaensis, a Japanese soil fungus. Its compounds 
belong to the group of  hydrophobic macrolide lactones. The name tacrolimus is 
derived by taking the “t” for Mount Tsukuba (where the organism was discovered), 
“acrol” for macrolide and “imus” for immunosuppressant. 
On January 20, 2006, U.S. Food and Drug Administration (FDA) announced the 
approval of  updated labeling for tacrolimus ointment. 
Tacrolimus reduces the immune responsiveness to foreign antigens, by suppressing 
the activation of  the T-lymphocytes. Tacrolimus and cyclosporin suppress the 
immune response through a similar mechanism, but chemically they are not 
comparable. Tacrolimus has a smaller molecular size and the immunosuppressive 
effect is 10-100 fold stronger than cyclosporin.91 Tacrolimus has better 
characteristics as a topical agent.91 
Engagement of  the T-cell receptor (TCR) with a major histocompatibility 
complex (MHC) peptide ligand on an antigen presenting cell is followed by 
aggregation of  several pairs of  TCR/MHC molecules (see ﬁ gure 2). This in 
turn induces stabilization of  the T cell–antigen presenting cell interaction by 
binding of  adhesion molecules on one cell to their ligands on the other cell. 
The co-aggregation of  TCRs activates a series of  tyrosine kinases. Several major 
pathways are activated, including phospolipase C (PLC)-γ3. PLC hydrolyses 
phosphoinositol-containing lipids in the plasma membrane resulting in the release 
of  1,4,5 inositol trisphosphate (IP3). IP3 binds to its receptor and releases calcium 
from the endoplasmic reticulum. This leads to the opening of  a membrane 
calcium channel identiﬁ ed as the calcium release-activated calcium channel. 
Increased intracellular calcium stimulates activation of  the calmodulin-dependent 
serine phosphatase calcineurin. Calcineurin is a heterodimer comprising an A 
subunit (CN-A) and a B subunit (CN-B). Activated calcineurin dephosphorylates 
a relatively narrow set of  substrates, including cytoplasmic NFAT (nuclear factor 
of  activated T cells) proteins. This leads to a change, unmasking of  the nuclear 
import signal and translocation of  NFAT to the nucleus. NFAT has a relatively 
low afﬁ nity for DNA and combination with other transcription factors is required 
to activate promoters such as interleukin (IL)-2 which are required for T-cell 
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activation. Sustained calcium signalling is required to maintain NFAT in the 
nucleus.92 Although T-cell activation is a complex process, intracellular calcium 
plays an essential role.
Tacrolimus binds intracellulary with FK506 binding proteins (FKBPs, see 
ﬁ gure 3).  This complex inhibits calcineurin, which prevents the translocation of  
the cytoplasmic sub-unit of  the nuclear factor activated T-cells (NFATc) into the 
nucleus and the formation of  a transcriptionally active NFAT complex. NFAT-
mediated transcription of  inﬂ ammatory cytokine genes is signiﬁ cantly suppressed 
by tacrolimus. Thus tacrolimus interveres at an early stage of  T-cell activation, 
which, in relation to the whole variety of  cells and mediators involved in immune 
responses, leads to several secondary consequences.91,93,94 Tacrolimus also has 
an effect on mast cells and basophils. De Paulis et al. and Marone et al. reported 
that tacrolimus impairs histamine release from IgE-activated skin mast cells.95,96 
Another study reported that tacrolimus had an effect on IL-3 enhanced histamine 
release from basophils. These ﬁ ndings can explain the antipuritic effect of  the 
drug.91
TCR Complex=T-cell Receptor Complex, IP3=Inositol Trisphosphate, Ca2+=Calcium Ions, 
CaM=Calmodulin, CN-A/CN-B=Calcineurin A and B Complex, P=Phosphate, NFAT(c/n)=Nuclear Factor 
Activated T-cells (c=cellular, n=nuclear), ER= Endoplasmatic reticulum, IL2=Interleukin 2.
Figure 2: Schematic representation of T-cell activation. 
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Side effects 
The adverse effects of  topical tacrolimus are related to systemic absorption 
of  tacrolimus and to local effects on the skin. A major concern of  the use of  
tacrolimus ointment is the systemic absorption of  the drug. Toxic adverse effects, 
like nephrotoxicity, cardiovascular risks and increased incidence of  infections, are 
observed in studies performed with orally administrated tacrolimus.97 
However, short- and long-term (24 months) clinical trials97,98 revealed that there 
was only a minimal systemic absorption of  tacrolimus when applied locally. The 
maximum serum levels were almost always below 1 ng/ml. Since the serum level is 
so low, severe systemic adverse effects that are seen with oral adminisation cannot 
be associated with topically applied tacrolimus. 
In conditions with deceased barrier function, or for skin conditions in which 
absortion has not been investigated, topical macrolides should be used with added 
care. 
The most common adverse events of  topical tacrolimus are related to the 
application site and mainly involve a burning sensation and pruritus. The burning 
sensation decreases when application of  the drug is continued. Decreased 
cutaneous absorption of  the drug can be a reason for the diminution of  this 
TCR Complex=T-cell Receptor Complex, IP3=Inositol Trisphosphate, Ca2+=Calcium Ions, 
CaM=Calmodulin, CN-A/CN-B=Calcineurin A and B Complex, P=Phosphate, 
NFAT(c/n)=Nuclear Factor Activated T-cells (c=cellular, n=nuclear), ER= Endoplasmatic reticulum, 
IL2=Interleukin 2, FKBP-12=12kD Tacrolimus Binding Protein, TAC=Tacrolimus
Figure 3: Schematic representation: Mechanism of action of tacrolimus. 
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adverse effect. Patients normally do not experience this as a severe effect and can 
continue the treatment. 
The most common non-application-site adverse event in controlled and non-
comparative trials was ﬂ u-like symptoms.99-101
Other less common adverse effects were headaches, skin tingling, acne, 
hyperaesthesia, folliculitis and alcohol intolerance which is a localized vascular 
reaction to alcohol involving skin ﬂ ushing with heat sensation conﬁ ned to the 
head and neck region. Futhermore, cases of  rosacea-like eruptions or worsening 
of  rosacea and benigne tumours (skin tags, papillomas) and lentigines have been 
reported.101-104
Topical tacrolimus is not associated with skin atrophy.91,101 Experimental and 
clinical studies that compaired topical corticosteriods and tacrolimus revealed that 
topical tacrolimus was not associated with reduction of  the skin thickness. 
Local immunosuppression with topical tacrolimus is a signiﬁ cant concern. The 
inhibiton of  T-cells can possibly be a cause for the development of  viral infections 
or skin cancer. 
A few reports91-101 revealed that topical corticosteroids, which are very potent 
T-cell inhibitory drugs, increase the susceptibility to local viral infection or skin 
cancer. 
However short and long-term studies with topical tacrolimus did not give 
signiﬁ cant results of  a higher incidence of  viral infection. There have been a 
number of  cases with herpes simplex, varicella, human papilloma virus and 
mollusca contagiosum, but these had the same incidence as in the placebo group. 
On February 2005 the pediatric advisory committee of  the FDA warned about an 
elevated risk of  skin cancer after application of  topical calcineurin inhibitors. For 
tacrolimus, 19 cases of  cancer were reported, involving 16 adults and 3 children 
under the age of  16. The cancers were diagnosed 21–790 days after the initiation 
of  therapy (the median time to diagnosis was 150 days). Nine cases involved 
lymphomas, and 10 involved skin tumours (7 at the site of  the drug application). 
Tumour types included squamous cell carcinoma, cutaneous sarcoma and malignant 
melanoma.
However, the majority of  these cases were single cases reported spontaneously 
without an exact veriﬁ cation of  the causal relationship between calcineurin 
inhibitors and carcinomas. None of  them resulted from any systematic scientiﬁ c 
analysis proving an increased cancer risk.
Upon analyzing the details of  the reported lymphomas, it is worth noting that 
they differ clinically and histologically from eczema. There is a high suspicion that 
these patients may never have had an eczema, but were treated for a pre-existing 
condition mimicking eczema.105
Currently, there is no scientiﬁ c evidence of  an increased incidence of  skin cancer, 
lymphomas or systemic immunosuppression in those patients that use or have used 
topical calcineurin inhibitors.106 Long-term clinical trials of  topical tacrolimus did 
not reveal an increased risk for skin cancer.97 
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1.2.3  Methotrexate
Methotrexate (MTX) resembles folic acid and is an inhibitor of  folate dependent 
enzymes, like dihydrofolate reductase. This enzyme is involved in the pyrimidine 
(DNA) synthesis. 
MTX primarily inhibits dihydrofolate reductase (DHFR, see ﬁ gure 4). This results 
in the depletion of  reduced folates (FH4), which are required for deoxythymidine 
monophosphate (dTMP) synthesis from deoxyuridine monophosphate (dUMP), 
and in accumulation of  dihydrofolates (FH2), which inhibit purine synthesis.  
Thymidine is directly converted to thymidine monophosphate by the enzyme 
thymidine kinase (TK), thereby circumventing blockade of  the de novo pathway 
by MTX.107 This method of  action is the reason why MTX is widely used and 
studied as an anti-cancer agent.
Figure 4: Folate pathway (simplified)
In summary: MTX inhibits dihydrofolate reductase, inhibition of  this enzyme 
leads to depletion of  tertrahydrofolates, that are essential for DNA, RNA and 
protein synthesis.108 In a study by Seyger et al. nine patients with widespread 
morphea were treated with oral methotrexate, and in all patients scleroderma 
scores improved.86 The mechanism through which MTX acts in sclerotic skin 
diseases is not elucidated. Direct inhibition of  extracellular matrix production by 
ﬁ broblasts is unlikely. Van den Hoogen et al. reported that MTX did not reduce, 
but even enhances glycosaminoglycan production by scleroderma ﬁ broblasts in 
culture.109 Most studies in rheumatic arthritis patients treated with MTX, show 
only marginal effects on cellular and humoral immune responses. The response 
with MTX suggests an anti-inﬂ ammatory effect.110 MTX is an antimetabolite 
with anti-inﬂ ammatory and antiproliferative activity. When given at low doses (7.5 
mg/m2/week) MTX has no cytotoxic effects, but immunomodulatory and anti-
inﬂ ammatory properties111 by the release of  adenosine,112 which binds to A2 
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receptors and inhibits the oxidative burst in activated neutrophils and the adhesion 
of  these neutrophils to the endothelial cells. Adenosine also modiﬁ es cytokine 
production by neutrophils, macrophags, monocytes and T-lymphocytes. Thereby 
the TNF-α, IFN-α, IL-6 and IL-8 production decreased whereas the IL-10 and IL-4 
production increased.111-114 Increased levels of  soluble IL-2 receptors are present 
and likely reﬂ ect active disease in localized scleroderma. MTX has been shown to 
reduce these IL-2 receptors, as well as to decrease circulating IL-2, IL-6 and IL-8. 
This could be an explanation for the therapeutic way of  action in sclerotic skin 
diseases.88,115-117 
Side effects 
MTX could give rise to gastrointestinal symptoms (like nausea, diarrhoea, anorexia), 
neurological side-effects (like headache, dizziness), infectious side effects (including 
bacterial/viral pneumonia), pulmonary side effects (like coughing, dyspnoea, 
interstitial pneumonitis), hematologic disorders, bone marrow depression, hepatic 
ﬁ brosis, general side-effects such as fatigue and loss of  condition and dermatologic 
side-effects, including rashes, mouth ulcera/ulcerative stomatitis, hair loss and 
pruritus. 
MTX could induce renal dysfunction, mediated by the precipitation of  MTX and 
its metabolites or via direct toxic effect of  MTX in the renal tubes. A long term 
side effect with the use of  high dosages of  MTX is the chance of  malignancy.118 
MTX should not be administrated before or during pregnancy, since it is known to 
be abortifacient as well as teratogen.119
Nodules appearing on the palms and ﬂ exor sites of  the ﬁ ngers, or even nodules 
of  the larynx, lungs and heart are described during the use of  MTX. Occasionally 
these nodules can ulcerate and become secondary infected.120 Finally, erectile 
dysfunction and gynaecomastia have been reported infrequently.121-123 Several 
drugs have been associated with increases in toxicity when co-administrated with 
MTX. The most signiﬁ cant interactions involve agents that interfere with MTX 
excretion, such as salicylates, probenecid, penicillins, sulﬁ soxazole and nonsteroidal 
anti-inﬂ ammatory agents.107
1.2.4 Introduction to phototherapy
Phototherapy including radiation with different wavelengths has been used in 
medicine for a long period of  time. It also plays an important role in modern 
dermatology.
The electromagnetic spectrum can be divided into radiowaves, infrared waves, 
visible waves, ultraviolet radiation, X-rays and gamma rays (see ﬁ gure 5). Ultraviolet 
(UV) radiation is deﬁ ned as that portion of  the electromagnetic spectrum between 
x-rays and visible light. The sun is our primary natural source of  UV radiation.
The solar spectrum consists of  infrared, UV and visible light. 3-7% of  this solar 
radiation energy that reaches the earth is UV radiation. 
Ultraviolet C (UVC, 200-290 nm) has the shortest wavelenght of  UV and is the 
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Figure 5: Electromagnetic spectrum of light
Figure 6:  Ultraviolet spectrum 
gamma
rays
x-rays ultraviolet infrared radio
Wavelength
0,01 nm 0,1 nm 1 nm 10 nm 100 nm 1 µm 10 µm 100 µm 1 mm 1 cm 10 cm 1 m
10
-11
m 10
-10
m 10
-9
m 10
-8
m 10
-7
m 10
-6
m 10
-5
m 10
-4
m 10
-3
m 10
-2
m 10
-1
m 1
 
m
V
io
le
t
B
lu
e
G
re
en
Y
el
lo
w
O
ra
n
ge
R
ed
Visible light
400 - 700 nm
Cosmic
rays
Gamma 
rays
X-rays Ultraviolet Visible Infrared Radiowaves
Vacuum 
UV
Short 
wave 
UV
UVC
Middle 
wave
UV
UVB
Long 
wave
UV
UVA
V
io
le
t
Visible light R
ed
Wavelength (nm) 100 290        320 400 700
         340         400
UVA-1
most energetic portion of  the UV spectrum. UVC is almost totally absorbed by the 
ozone layer.
UV radiation that reaches the earth consists of  UVB and UVA.
Ultraviolet B (UVB, 290-320 nm) is the most destructive form of  UV radiation 
because it has enough energy to cause photochemical damage to cellular DNA. 
UVB effects can include erythema (sunburn), and skin carcinogenese. It is currently 
thought to generate most of  the photo-damage to skin, though not all. 
Ultraviolet A (UVA, 320-400 nm): Atmospheric ozone absorbs very little of  this 
part of  the UV spectrum. UVA is about 1000 times less damaging to the skin 
than UVB as measured by sunburn or damage to cell DNA. UVA exposure has a 
tanning effect followed by erythema if  the exposure is excessive. UVA is needed 
by humans in the synthesis of  vitamin D. Most tanning cabins contain UVA lamps. 
Because of  the longer wavelengths, UVA penetrates deeper into the skin.
Ultraviolet A-1 is that part of  the UV spectrum which emits photons with a 
wavelength of  340-400 nm. This form of  phototherapy has to been distinguished 
from the other wavelengths of  the UV spectrum for its distinctive therapeutic 
potential.
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1.2.5  UVA-1 phototherapy
In 1981 Mutzhas et al.124 presented an article in the Journal of  Investigative 
Dermatology in which a new apparatus was introduced emitting UV radiation in 
the 340-400 nm range (see ﬁ gure 6). This report included diagnostic techniques, 
like photopatch tests and therapeutic trials where they used this long wave UVA, 
later called UVA-1 in 6 patients with acne and 1 patient with vitiligo. 
Little more was published until 1992, when two studies125,126 showed beneﬁ cial 
effects in atopic dermatitis. Nowadays, much more is published about this long 
wave UV therapy. 
The ﬁ rst report describing the use of  UVA-1 irradiation to treat localized 
scleroderma was published by Kerscher in 1995.127
There are various UVA-1 sources: Fluorescent lamp and metal halide resources. 
The ﬂ uorescent lamp cubicles allow only low dose (LD) (10-30 J/cm²) or 
moderate dose (MD) (40-70 J/cm²). The high output, high dose (HD) metal halide 
sources allow up to 130 J/cm² (high doses).128
Side effects
The main short-term side effects of  UVA-1 therapy are erythema, pruritus, 
xerosis cutis, tanning, and recrudescence of  a herpes simplex infection. 
Generalized itching occasionally appears, but it usually responds well to emollients. 
Polymorphic light eruptions have been described as a possible side effect of  UVA-
1 and other photo therapies. Even bullous pemphigoid is described as a side effect 
of  UVA-1.129 The major long-term risk is photo-aging and skin cancer. Chapter 
3.3 contains a review regarding UVA-1 in sclerotic skin diseases. 
In the studies “Period of  remission after treatment with UVA-1 in sclerotic skin 
diseases” and  “Scleredema Diabeticorum case series: Successful treatment with 
UVA-1”, patients were treated with the Waldmann 7001, which is a medium dose 
UVA-1 device (ﬁ gure 7). 
In the study “Scleredema Diabeticorum case series: Successful treatment with 
UVA-1” one patient was treated with the high dose Waldmann, Sellamed 24000 
UVA (ﬁ gure 8).
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Figure 7: Waldmann 7001, medium-dose UVA-1 
Figure 8: Waldmann, Sellamed 24000, high-dose UVA-1
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1.3  METHODS TO SCORE
1.3.1  Durometer 
The durometer, model 1600-OO; rex Gauge Co, Glenview, III, USA, was used 
in the studies of  chapter 3.1, 3.4 and 3.5 as an objective measurement of  the 
hardness of  the skin. This instrument is the international standard for measuring 
the hardness of  plastic, rubber, and other non-metallic material. Model OO 
(ﬁ gure 9), is designed for soft materials, such as animal or human tissue. 
Measurements with this device were carried out with a constant weight that did 
not allow additional pressure. For measurements, the durometer was used at 
24°C room temperature and rested by gravity against the skin. The durometer is 
ﬁ tted with a calibrated gauge that registers linearly divided units on a scale of  0 
to 100. At the bottom of  the durometer, there is a small, inferior indenter that 
is retractable and is responsible for the measurements registered on the gauge. 
Hardness of  the skin was measured in all studies by one investigator at ten 
locations, distributed evenly on the representative sclerotic skin. Each spot was 
measured 3 times and the average of  the three measurements was summed to give 
the total durometer score. The locations were selected preferably on sites where no 
bony structures were present directly beneath the skin. 
In 1997 Seyger et al. proved the use of  this durometer to be reliable in the 
assessment of  morphea.130
Figure 9: Durometer
Chapter 1 - General Introduction
35
1.3.2  Modifi ed Skin Score (MSS)
In 1994 Zachariae et al.131 described a new scoring system used in 41 patients 
with systemic sclerosis. This simple skin score method measured the degree of  
thickening and pliablity in seven regions together with area involvement in each 
region. Seyger et al.130 validated this skin scoring system for the assessment 
of  morphea and the MSS proved to be a reliable scoring system to assess the 
degree of  skin involvement in morphea. The skin is divided into the following 
regions: Head and neck, arms, hands, ﬁ ngers, trunk, legs and feet. The degree of  
thickening and pliability (T) was assessed as 0=normal skin, 1=palpable thickened 
skin, 2=decreased ability to move the skin, 3= the skin could not be moved or 
pinched. In addition, involvement of  each area (A) was determined by estimation; 
0 means no involvement, 1 means < 33% of  the area is involved, 2 means 33-67% 
of  the area is affected, 3 means > 67% of  the area is affected. Both scores are 
summed up. The MSS is Σ (T+A)R1-R7. The minimum score of  0, represents no 
involvement and 42 represents the maximum score indicating extreme involvement 
in all areas.
1.3.3  Quality of  life (QOL) 
Knowledge of  situations affecting the quality of  life may help doctors pay attention 
to those situations and could improve care. A quality of  life assessment can reﬂ ect 
useful information about the illness and treatment effects; therefore it can be used 
to design better therapy plans needed for the patient. It also improves patient-
physician communication about medical, psychological or social impairments, thus 
beneﬁ ting the patient’s well-being.132,133 The impaired quality of  life of  patients 
with chronic skin disease has negative effects on the results of  dermatological 
therapies, like photochemotherapy.134
To assess the physical and psychosocial well being in the studies of  chapter 2, the 
following scales were used:
1.  The Impact of  chronic Skin disease on Daily Life (chapter 2.1 and 2.2)
2.  Dermatological Life Quality Index (chapter 2.1)
Impact of  chronic Skin diseases on Daily Life
The Impact of  chronic Skin diseases on Daily Life (ISDL) is a multidimensional 
health status instrument developed by Evers et al.135 of  the Radboud University 
Medical Centre Nijmegen, The Netherlands.
Their aim was to create a reliable and valid self-report inventory to gauge the 
impact of  skin conditions on daily life, by assessing generic and dermatology-
speciﬁ c health aspects of  chronic skin diseases.
Based on literature on chronic skin diseases, items of  existing questionnaires for 
the following dermatology-speciﬁ c constructs: skin status (severity of  the skin 
disease), physical symptoms of  itching, pain and fatigue and perceived stimatization 
were used.135-137 To assess the generic aspects of  psychological functioning, the 
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impact of  the disease on daily life, illness cognitions and social support, scales of  
existing self-report questionnaires evaluation other chronic physical conditions 
were used.138,139 The ﬁ nal ISDL questionnaire, consists of  ﬁ ve core categories: 
physical functioning, psychological functioning, stressors, illness cognitions, and 
social support. Each category includes subscales and is scored on a visual analogue 
scale.
Physical functioning
This part consists of  the skin status and the physical symptoms of  itching, pain and 
fatigue.
Skin status. Skin status was assessed measuring the degree of  affect to the different 
parts of  the body using a 9-item scale of  the ISDL.135 Patients had to answer per 
part of  the body (face, head, neck, hands, arms, torso, legs, feet and genitals/anus) 
the degree of  affect. The degree of  affect was assessed on a 4-point Likert scale140 
from 1=not affected to 4= totally affected. A total score for the affected area of  
the body was calculated by summing up the scores of  the nine parts. The minimum 
score is 9, representing no involvement and maximum score is 36 which represents 
totally affected involvement in all nine areas. 
Physical symptoms of  itching, pain and fatigue: The Visual Analog Scale (VAS) was 
used to estimate the mean level of  itching, pain and fatigue over the previous four 
weeks on a scale of  0-100 millimeter (mm). 0 mm represents no itching, pain or 
fatigue and 100 mm represents maximal fatigue, pain or itching ever experienced. 
A VAS score >20 mm was considered an indication that patients experienced the 
symptoms and a VAS score >50 was considered that the patients considered the 
symptom as relatively severe. 
Psychological functioning
Psychological well-being was measured with the anxiety scale (ten items) and the 
negative and positive mood scale (six items per scale) of  the Impact of  Rheumatic 
diseases on General health and Lifestyle (IRGL).138 
Stressors
The impact of  disease on daily life, consisted of  a ten items generic scale and 
measured the effect the condition had on activities of  daily life e.g. work, hobbies, 
sleep, sexuality and relationships. This scale is derived from the IRGL. 
Stigmatization: this six-item subscale measured the extent to which the patient felt 
stigmatized by others because of  the sclerotic disease (item examples: Others are 
staring; Others avoid contact)
Illness cognitions
The illness cognition questionnaire was applied to evaluate three chronic disease-
related conditions: Helplessness (six items), acceptance (six items), and perceived 
beneﬁ ts (six items).
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Social support
Qualitative and quantitative aspects of  social support were charted with the IRGL 
scales perceived support (ﬁ ve items) and social network (one index).
Dermatological Life Quality Index 
The Dermatology Life Quality Index (DLQI), a self-administered general 
dermatology quality of  life instrument, was originally developed by Finlay and 
Khan and published in 1994.141 This is the ﬁ rst dermatology-speciﬁ c health-
related quality of  life questionnaire. The DLQI comprises a ten items scale 
measuring the impact of  skin diseases on several physical, psychological and social 
aspects of  daily life. 
The DLQI questionnaire is a well-known instrument for measuring dermatological 
distress and has been translated into a variety of  languages. The DLQI is a simple, 
validated and widely used instrument and has been used for over 36 different 
skin conditions.142 In particular, there are ten questions concerning symptoms 
and feelings, daily activities, leisure, work and school, personal relationships and 
treatment. Each question has to be answered by ticking a box, “very much”, 
“a lot”, “a little” or “not at all”. Each question is scored from 0 to 3 and the scores 
summed, giving a range from 0 (no impairment of  life quality) up to 30 (maximum 
impairment).142 
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1.4  INVESTIGATIONAL APPROACH
1.4.1 Goal and aims
The overall goal of  this thesis is to elucidate the impact of  sclerotic skin diseases 
and provide more information about the therapeutic treatment options of  patients 
with a sclerotic skin disease. In order to reach this goal the following aims were 
deﬁ ned:
Aim I Understand the physical burden and psychological distress in 
patients with a sclerotic skin disease. 
Questions
Ia What is the prevalence of  physical symptoms of  itching, pain and 
fatigue in patients with localized scleroderma or eosinophilic fasciitis?
Ib What is the level of  psychological distress of  anxiety or depressed 
mood and what are the contributors to this distress in patients with 
localized scleroderma or eosinophilic fasciitis?
Aim II Determine the therapeutic effectiveness and tolerability of  
different classes of  treatment for sclerotic skin diseases. 
Questions
IIa Does topical tacrolimus 0.1% ointment induce clinical improvement in 
patients with active plaque morphea? 
IIb Is MTX an effective, well-tolerated treatment for sclerotic skin diseases 
and additionally does MTX give rise to a long period of  remission?
IIc Is UVA-1 effective in patients with a sclerotic skin disease and what is 
the period of  remission?
IId Does UVA-1 decrease the tightness of  the skin in patients with 
scleredema diabeticorum?
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2
Impact of  sclerotic skin diseases
This chapter is based on the following publications:
Kroft EBM, de Jong EMGJ, Evers AWM. • 
Physical burden of  symptoms in patients with localized scleroderma and 
eosinophilic fasciitis
(accepted in the Arch Dermatol)
Kroft EBM, de Jong EMGJ, Evers AWM. • 
Contibutors to psychological distress in patients with localized scleroderma and 
eosinophilic fasciitis
(submitted)
Chapter 2 - Impact of  sclerotic skin diseases
48
2.1  PHYSICAL BURDEN OF SYMPTOMS IN PATIENTS WITH   
 LOCALIZED SCLERODERMA AND EOSINOPHILIC FASCIITIS
2.1.1 Abstract
Background: Sclerotic skin diseases can cause severe morbidity and functional 
disability, however no literature is known about the prevalence of  physical 
symptoms of  itch, pain and fatigue in patients with sclerotic skin diseases. A better 
understanding of  these factors is essential for supporting physicians in diagnostic 
and treatment options and for improving multi-disciplinary care for the patients 
with this often-mutilating disease.
Objective: The goal of  the present study was to examine the prevalence of  physical 
symptoms of  itch, pain and fatigue in patients with localized scleroderma and 
eosinophilic fasciitis (sclerotic skin disease).
Methods: Validated questionnaires included demographic data, co-morbidity, skin 
status, physical symptoms of  itch, pain and fatigue and disease related quality of  
life were sent to all patients with a sclerotic skin disease seen in the period 1995-
2007 in the outpatients’ clinic at the Dermatology Department of  the Radboud 
University Medical Centre Nijmegen, the Netherlands. Eventually, questionnaires 
from 74 patients were suitable for analysis.
Results: Fatigue was the most reported symptom, 55% of  all patients experienced 
fatigue and pain was experienced in 32% of  all patients. Itch was relative less 
frequently reported (22%). Divided per diagnose, patients with a generalized 
morphea and eosinophilic fasciitis particularly reported a high level of  fatigue. 
Pain and itch were especially noticed in patients with an eosinophilic fasciitis. The 
physical symptoms were related to a lower disease-related quality of  life. Fatique 
and pain were signiﬁ cantly associated to a more extended self-reported disease 
severity. Fatique was related to a shorter duration since diagnosis of  the sclerotic 
skin disease.
Conclusion: Fatigue, pain and, to somewhat lesser extent, itch has a high prevalence 
in patients with a localized sclerotic skin disease. Based on the present ﬁ ndings, 
clinicians should be encouraged to carefully assess the physical symptoms in 
patients with sclerotic skin diseases.
2.1.2 Introduction
Sclerotic skin diseases can cause severe morbidity and functional disability, however 
no literature is known about the physical burden of  symptoms in patients with 
sclerotic skin diseases. While it is acknowledged that skin diseases adversely affect 
quality of  life,1-3 less is known about the prevalence of  physical symptoms among 
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patients with skin diseases and their relationship with other disease-related variables 
such as disease severity. Knowledge of  the presence and severity of  physical 
symptoms experienced by patients is important for developing guidelines for the 
management of  sclerotic skin diseases.3
Localized scleroderma, also known as morphea, can be divided in several sub-
types. Peterson et al.4 distinguished the following main types: generalized morphea, 
plaque morphea, bullous morphea, linear morphea and deep morphea. Generalized 
morphea is described as multiple sclerotic plaques, conﬂ uent or affecting more than 
three sites on the body. Plaque morphea is described as one or more circumscript 
patches of  sclerotic skin in two or less anatomic sites. Bullous morphea presents 
as tense subepidermal bullae in sclerotic plaques. Linear morphea presents as a 
linear band of  sclerotic skin with lesions oriented along an affected limb or on 
the face. Eosinophilic fasciitis is often seen as a deep morphea, however several 
classiﬁ cations noted this disease as a separate entity.5-7 Localized scleroderma can 
cause severe morbidity because of  the appearance of  the skin, joint contractures 
and serious deformities. 
We are not aware of  literature about the physical burden of  symptoms among 
patients with a sclerotic skin disease. A better understanding of  symptoms affecting 
patients is essential for supporting physicians in diagnostic and treatment options 
and for improving multi-disciplinary care for the patients with this often-mutilating 
disease.
Therefore, the authors wanted to assess the prevalence and severity of  the most 
reported physical symptoms of  itch, pain and fatigue and the relationship with 
disease severity and quality of  life in patients with sclerotic skin diseases. 
2.1.3 Methods
Patients and procedures
All patients (n=120) with a sclerotic skin disease (localized scleroderma or 
eosinophilic fasciitis) attending the outpatients’ clinic from from 1995 till 2007 
at the Dermatology Department of  the Radboud University Medical Centre 
Nijmegen, the Netherlands, were enrolled and sent a questionnaire. The diagnoses 
of  the patients were conﬁ rmed during the outpatient visit by dermatologic, 
rheumatologic and if  necessary pathologic and/or laboratory investigation.
Disease sub-types grouped the patients: generalized, plaque, bullous, linear 
morphea (occurring on an extremity or the face) and eosinophilic fasciitis. 
Exclusion criteria consisted of  severe psychiatric or mental disabilities, which 
interfere with the study protocol, patients below 16 years of  age, patients 
with systemic sclerosis according to the criteria of  the American College of  
Rheumatology8 or a pseudosclerosis6 (e.g. sclerodermic graft-versus-host disease, 
scleredema of  Buschke, scleromyxedema, and pseudosclerosis due to genetic 
disorders or traumatic agents).
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Measures
Demographic variables of  age and sex were assessed using the patients’ medical 
records. The education level was measured with the self-reported question using 
seven options that can be classiﬁ ed as primary, secondary and tertiary level of  
education, representing 8, 12 and 17 years of  formal education. 
The time since diagnosis is dedicated, in years. 
Co-morbidity, the presence of  chronic diseases other then the sclerotic disease, was 
measured with a question of  the ISDL9, asking for the presence of  co-morbidity 
and (in the case of  co-morbidity) for a further speciﬁ cation.
Skin status or skin severity was assessed measuring the degree to the different parts 
of  the body using a 9-item scale of  the ISDL (Impact of  chronic Skin diseases 
on Daily Life).9 Patients had to answer per part of  the body (face, head, neck, 
hands, arms, torso, legs, feet and genital/anus) the degree of  affection. The degree 
of  affection was assessed on a 4-point Likert scale10 from 1=not affected till 4= 
totally affected. A total score for the affected area of  the body was calculated by 
summing up the scores of  the nine parts (range 9-36). 
Physical symptoms of  itch, pain and fatigue: The Visual Analog Scale (VAS) of  the ISDL9 
was used to estimate the mean level of  itch, pain and fatigue over the previous 
four weeks on a scale of  0-100 millimeters (mm). 0 mm represents no itch, pain 
or fatigue and 100 mm represents maximal fatigue, pain or itch ever experienced. 
A VAS score >20 mm was considered an indication that patients experienced the 
symptoms and a VAS score >50 mm was considered that the patients experienced 
the symptom as relatively severe.
Disease related quality of  life was measured by the Dermatological Life Quality Index 
(DLQI), a 10-item scale measuring the impact of  skin diseases on several physical, 
psychological and social aspects of  daily life.11
2.1.4 Statistical analyses
Statistical analysis was performed using SPSS program (version 14). 
In addition to assessing the level of  physical symptoms by the previously deﬁ ned 
cut-off  scores (see measures), means and SDs were calculated for the different 
physical symptoms of  itch, pain, and fatigue for the whole groups as well as the 
four different diagnostic categories. The relationship of  physical symptoms to age, 
co-morbidity, duration of  disease, skin severity and quality of  life was explored for 
all patients by calculating Pearson correlation coefﬁ cients or binary correlations in 
case of  sex, using p < 0.05 as the level of  signiﬁ cance (2-sided). 
2.1.5 Results
Sample characteristics
Of  the 120 questionnaires sent to the patients, 81 (67.5%) were returned. Due 
to missing answers, 74 questionnaires were suitable for analysis. No signiﬁ cant 
differences could found with regard to sex, age and duration of  disease and 
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morphea sub-type between responders and non-responders. No patients with a 
bullous morphea were seen in the period 1995 to 2007. 
The mean age of  all patients under study was 47.0 years ± 19.2 (SD). Fifty-six 
patients were female and 5.6%, 74.7% and 19.7% of  the patients had a primary, 
secondary and tertiary level of  education, respectively. Mean disease duration 
was 11.0 years ± 8.1 (SD). The demographic data and levels of  skin severity per 
diagnose are shown in Table 1. Twenty-two of  all patients (29.7%) reported co-
morbidity. Respectively 13 (17.6%), 7 (9.5%), 2 (2.7%) of  the patients reported 
to have one, two or three other co-morbidities besides the skin disease (cardial, 
pulmonary, gastrointestinal, urogenital, endocrine, blood, neurological diseases or 
joint problems). In detail, 4 patients suffered from cardial problems, 
5 patients had pulmonary diseases, 3 patients were diagnosed with gastrointestinal 
diseases, 1 patient had an urogenital disease, 2 patients suffered from endocrine 
disorders, 2 patients had blood disorders, 9 patients experienced neurological 
problems and 6 patients had problems with the joints. Finally one patient was 
diagnosed with an alopecia areata. 
Physical symptoms of  itch, pain and fatigue
Fatigue was the most frequently experienced symptom (Table 1). Fifty-ﬁ ve percent 
of  all patients experienced fatigue, 32.4% experienced pain and 21.6% of  all 
patients experienced itch (VAS>20). There were 46 patients (62.2%) who reported 
experiencing at least one of  the three symptoms (VAS>20). Twenty-seven patients 
under study (37.5%) reported at least one of  these three symptoms as severe 
(VAS>50). 
Descriptive views of  differences between diagnoses showed most patients with 
Characteristics total 
population 
(n=74)
generalized 
morphea 
(n=16)
plaque 
morphea    
(n=36)
linear 
morphea    
(n=10)
eosinophilic 
fasciitis 
(n=12)
Women, No. (%) 56 (75.7) 15 (93.8) 11 (30.6) 8 (80) 8 (66.7)
Men, No. (%) 18 (24.3) 1 (6.3) 25 (69.4) 2 (20) 4 (33.3)
Age, mean (SD), y 47.0 (19.2) 45.8 (19.4) 49.7 (18.1) 24.9 (8.9) 59.1 (14.4)
Time since diagnosis, mean (SD), y 11.0 (8.1) 7.2 (5.1) 12.2 (8.1) 12.6 (4.6) 11.5 (12.0)
Skin severity, mean (SD) 12.6 (3.2) 13.3 (2.4) 12.1 (1.7) 11.9 (2.0) 13.9 (6.8)
DLQI, mean (SD) 4.2 (5.1) 5.8 (5.9) 2.8 (3.8) 2.0 (1.8) 9.3 (6.6)
Symptoms
Itch, mean (SD) 15.4 (22.2) 18.9 (23.5) 13.7 (22.2) 3.5 (6.3) 25.4 (25.4)
% patients with itch VAS>20 21.6 31.3 13.9 0 50.0
% patients with itch VAS>50 9.5 12.5 8.3 0 16.7
Pain, mean (SD) 19.0 (24.4) 20.3 (17.4) 13.8 (22.2) 12.5 (21.0) 38.3 (32.8)
% patients with pain VAS>20 32.4 43.8 22.2 10 58.3
% patients with pain VAS>50 14.9 12.5 8.3 10 41.7
Fatigue, mean (SD) 30.6 (27.0) 48.5 (19.4) 20.4 (23.9) 24.1 (30.6) 41.4 (27.1)
% patients with fatigue VAS>20 55.4 93.8 38.9 40 75.0
% patients with fatigue VAS>50 29.7 50.0 19.4 20 41.7
No. = Number, y = years
Table 1: Demographic data, time since diagnosis, disease severity, DLQI and 
prevalences of itch, pain and fatigue
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Itch Pain Fatique
Demographic variables
Higher age 0.08 0.10 0.12
Female sex 0.17 0.14 0.10
More co-morbidity 0.04 0.22 0.23
Skin related variables
Longer duration of  the disease▲ 0.04 0.08 -0.27*
More skin severity 0.16 0.37** 0.39**
Reduced disease-related quality of  life (DLQI) 0.44** 0.43** 0.62**
 * p < 0.05; ** p < 0.01; ▲ Fatigue is related to a shorter duration of  disease.
Table 2: The correlates of itch, pain and fatigue
a generalized morphea (93.8%) and 75.0% of  the patients with an eosinophilic 
fasciitis reported fatigue (VAS>20). Pain and itch were experienced most often by 
patients with eosinophilic fasciitis (58.3% and 50% respectively).
Correlations of  itch, pain and fatigue
Pearson correlation coefﬁ cients indicated that fatigue, itch and pain were 
signiﬁ cantly related to a lower disease related quality of  life (r = 0.62, r = 0.44, 
r = 0.43 respectively) (p < 0.01). Fatigue and pain, but not itch were signiﬁ cantly 
associated with a greater self-reported skin severity (r = 0.39 and r = 0.37 
respectively) (p < 0.01). Fatigue was related to a shorter duration since diagnosis of  
the sclerotic disease (r = 0.27) (p < 0.05) (see Table 2).
2.1.6 Discussion
The present study shows that a substantial proportion of  the patients with a 
sclerotic skin disease experienced physical symptoms. Fatigue, pain or itch was 
experienced in approximately 62% of  all patients. Fatigue was the most commonly 
reported symptom, 55% of  all patients experienced fatigue and more then half  
of  these patients experienced severe fatigue. Pain and itch was reported in at least 
20% of  all patients. The severity of  physical symptoms were relatively strongly 
correlated with a lower disease related quality of  life and pain and fatigue were 
highly signiﬁ cantly related to a more extended self-reported skin severity, which 
suggests that the physical symptoms were consequences of  the skin disease. 
Most patients with a generalized morphea and eosinophilic fasciitis reported fatigue 
and a relatively large number of  patients (46.4%) also severe fatigue. With regard 
to physical symptoms of  pain, particularly patients with an eosinophilic fasciitis 
reported pain. In eosinophilic fasciitis, sclerosis is extended into the deep fascia and 
lower sub-cutis and sometimes even affecting the muscle. The sclerosis is therefore 
extensive and deep; this could be the reason why these patients experienced more 
pain. Also itch was experienced most in patients with an eosinophilic fasciitis. Early 
in the course of  this disease, the deep fascia and lower sub-cutis are edematous 
and inﬁ ltrated with lymphocytes, plasma cells, histiocytes, and eosinophils; these 
features are generally associated with an impressive peripheral eosinophilia and 
later by collagenous thickening of  the dermis and subcutaneous fascia occurs. 
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The dermis becomes thickened and sclerotic. Eosinophilia is a prominent 
laboratory ﬁ nding and eosinophilia is related with itch. Several reports have been 
published about the positive effects of  antihistamines in patients with eosinophilic 
fasciitis.12,13
The study has several limitations, such as absence of  a control group and small 
sample sizes, thus limiting comparison possibilities. The severity of  the disease was 
based on patient assessment rather than physician assessment. In addition, although 
results clearly suggests that the physical symptoms are consequences of  the 
disease process and that co-morbidities did not severely affect the level of  physical 
symptoms in these patients, the explorative assessments of  co-morbidities and 
medication need to be explored in future research. Moreover, when interpreting 
these ﬁ ndings, it is important to realize, that the questionnaires were administered 
at various points in the duration of  the patient’s disease course, thus the present 
study might have been underestimated the presence and severity of  these physical 
symptoms.3 
This study is the ﬁ rst study describing prevalences of  the physical burden of  
symptoms in patients with a sclerotic skin disease, showing a high impact of  
particularly fatigue and pain and to a lesser extent of  itch in these patient groups. 
Assessment of  these physical symptoms can give useful information and can be 
used to make better therapy plans needed for the patient. Knowledge about these 
factors by dermatologists might also improves patient-physician communication 
about medical, psychological or social impairments, to the beneﬁ t of  the patients’ 
well being. Based on the present ﬁ ndings, clinicians should be encouraged to 
carefully assess the physical ﬁ ndings in patients with sclerotic skin diseases and 
provide patients with information about the consequences of  the disease, regarding 
fatigue, pain and itch.
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2.2  CONTIBUTORS TO PSYCHOLOGICAL DISTRESS IN PATIENTS  
 WITH LOCALIZED SCLERODERMA AND EOSINOPHILIC   
 FASCIITIS
2.2.1 Abstract
Background: Although most chronic skin diseases, like atopic eczema and psoriasis, 
are known to affect quality of  life, there is no known literature about the quality of  
life of  adult patients with localized scleroderma (morphea). A better understanding 
of  the factors affecting patients’ psychological adjustment is essential to support 
physicians in diagnostic and treatment options for patients with this often-
mutilating disease. 
Objective: The goal of  the present study was to examine the level of  psychological 
distress and its contributors in patients with a localized scleroderma or eosinophilic 
fasciitis (sclerotic skin disease).
Methods: All patients (n=120) with morphea or eosinophilic fasciitis diagnosed 
between 1995 and 2007 were enrolled and sent a questionnaire. This validated 
‘Impact of  chronic Skin diseases on Daily Life’ (ISDL) questionnaire, includes 
physical, psychological and social health aspects. 
Exclusion criteria consisted of  severe psychiatric/mental disabilities, age younger 
than 16 years, patients with systemic sclerosis/pseudoscleroderma. 
Results: Psychological distress was generally impaired in patients with a sclerotic 
skin disease, particularly in patients with a generalized morphea and eosinophilic 
fasciitis, with thirty-eight percent of  all patients scoring as being psychologically 
at risk. Higher levels of  psychological distress were signiﬁ cantly related to a more 
extended skin status, more pain and fatigue and a higher impact of  the disease on 
daily life, more stigmatization, illness cognitions of  greater helplessness and less 
acceptance and less perceived social support. Illness cognition of  less acceptance 
most conveniently predicted psychological distress in patients with a sclerotic skin 
disease.
Conclusion: Results demonstrated that physical and psycho-social aspects play 
a substantial role in patients with sclerotic skin diseases. Clinicians should be 
encouraged to carefully assess the physical and psycho-social factors in patients 
with sclerotic skin diseases. This approach could greatly improve quality of  life, 
which could ultimately lead to improved dermatological treatment outcomes.
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2.2.2 Introduction
Attention of  research into chronic skin diseases is increasingly being directed 
towards the consequences of  the disease on a patients’ quality of  life.1 It is well 
known that most chronic skin diseases negatively affect a patients’ quality of  
life.2-7 However, past research has largely focused on prevalent skin diseases (e.g. 
psoriasis and atopic dermatitis), whilst there is a lack of  knowledge about the 
psycho-social functioning in adult patients with localized scleroderma. 
Localized scleroderma is a primary cutaneous sclerosis and can be classiﬁ ed 
into the following main groups: Plaque morphea, generalized morphea, bullous 
morphea, linear morphea and deep morphea. Eosinophilic fasciitis is often seen 
as a deep morphea, but several classiﬁ cations have noted this disease as a separate 
entity.8-10
Sclerotic skin diseases can cause severe morbidity because of  the appearance 
and reduced mobility of  the skin and subcutaneous tissue, joint contractures 
and serious deformities of  the face and extremities. All these changes can affect 
almost every aspect of  a person’s life, from relationships to holding a job. A better 
understanding of  the level of  psychological distress in patients with sclerotic skin 
diseases is essential to support physicians in treatment options, and to improve 
multidisciplinary care for patients’ who are psychologically at risk.
In recent decades, the role of  physical and psycho-social factors has been 
repeatedly proposed in chronic diseases, such as psoriasis and rheumatoid arthritis. 
In line with the stress-vulnerability-models11,12 various physical, psychological 
and social factors have been suggested to inﬂ uence the course of  chronic diseases. 
In addition to the clinical status of  skin severity, physical symptoms of  pain, 
fatigue and itch can be considered as severe chronic stressors in sclerotic skin 
diseases, resulting in heigthened levels of  psychological distress.13 In addition, the 
consequences of  the diseases on daily life and perceived stigmatization have shown 
to be possible stressors and contribute to psychological distress in chronic skin 
diseases.11,13,14 With regard to individual vulnerability factors, particularly illness 
cognitions have been shown to be an important predictor of  psychological well-
being in chronic skin diseases and other chronic conditions.11,13,14 Speciﬁ cally, 
patients who report high levels of  helplessness and lower levels of  acceptance 
with regard to their disease, emphasize the negative aspects of  their condition and 
generalize them to all facets of  daily life. Additionally, they are known to suffer 
worse physical and psychological functioning.11,13,14 Finally, social factors are 
known to be important in patients with chronic disease. The number of  people in 
the social network and the qualitative aspects of  this support15,16 can be expected 
to have a protective effect against the development of  psychological distress in 
patients with chronic skin disease. Increasing knowledge about the factors affecting 
the psychological distress could improve multidisciplinary care for patients with this 
often-mutilating disease. 
In this study, the level of  a patients’ psychological distress was examined. Multiple 
regression analyses were performed to examine the relative contribution of  skin 
status and physical symptoms of  itch, pain and fatigue and the psychological and 
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social factors of  the disease. This included the disease related impact on daily 
life, perceived stigmatization, illness cognition of  helplessness, acceptance and 
perceived beneﬁ ts, and social support to psychological distress in patients with a 
sclerotic skin disease. It was hypothesized that psychological distress in patients 
with a sclerotic skin disease would be predicted primarily by more physical 
symptoms of  itching, pain and fatigue, greater disease impact on daily life, lower 
disease related quality of  life, illness cognitions of  greater helplessness, fewer 
acceptance and perceived beneﬁ ts of  the disease and less social support.11 
2.2.3 Methods
Patients and procedures
All patients (n=120) with a localized sclerotic skin disease (localized scleroderma 
or eosinophilic fasciitis) attending the outpatients’ clinic of  the Dermatology 
Department at Radboud University Medical Centre Nijmegen, the Netherlands 
between 1995 and 2007 were enrolled and sent a questionnaire. The diagnosis 
of  the patients was conﬁ rmed by dermatologic, rheumatologic and if  necessary 
pathologic and/or laboratory investigation. The Medical Ethics Committee of  
the Radboud University Medical Centre Nijmegen determined that this study was 
exempt from further review.
Exclusion criteria consisted of  severe psychiatric or mental disabilities that could 
severely interfere with adherence to the study protocol, age younger than 16 
years, systemic sclerosis according to the American College of  Rheumatology or 
pseudoscleroderma (pseudosclerosis) (e.g. sclerodermic graft-versus-host disease, 
scleredema of  Buschke, scleromyxedema, pseudosclerosis due to genetic disorders 
or traumatic agents). Given the above exclusions, data was thus available for the 
following number of  patients per disease sub-type: plaque type morphea (n=36), 
linear morphea (occurring on a extremity or the face) (n=10), generalized (also 
called disseminated) morphea (n=16) and eosinophilic fasciitis (n=12). No patients 
with  a bullous morphea were seen between 1995-2007. Generalized morphea 
was described as multiple sclerotic plaques, conﬂ uent or affecting more then three 
places on the body. Plaque morphea was described as one or more circumscript 
patches of  sclerotic skin in two or less anatomic sites. 
2.2.4 Measures
General characteristics
The demographic variables of  age and sex were determined form the medical 
records. The education level was measured using seven possible responses 
that could be classiﬁ ed as primary, secondary and tertiary level of  education, 
representing 8, 12 and 17 years of  formal education. The time since diagnosis was 
measured in years. Co-morbidity, the presence of  chronic diseases other than the 
sclerotic disease, was measured with the Impact of  chronic Skin diseases on Daily 
Life scale (ISDL)1 The questionnaire enquired as to the presence of  co-morbidity 
and (in the case of  co-morbidity) requested further speciﬁ cation. Psychological 
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well-being was measured using the anxiety scale (10 items) and the negative/
depressed mood scale (6 items) which both reference the ISDL scale.1 
Physical functioning 
Skin status or skin severity was assessed by measuring the degree to which different 
parts of  the body were affected by referencing the ISDL1 9-item scale. Patients had 
to state the degree to which 9 speciﬁ c parts of  the body were affected (face, head, 
neck, hands, arms, torso, legs, feet and genitals/anus). This was then assessed on 
a 4-point Likert scale11 from 1=not affected to 4= totally affected. A total score 
for the affected areas of  the body was then calculated by summing up the 4 point 
scores for each of  the nine body parts. The minimum score of  9 represented no 
involvement and the maximum score of  36 indicated that all 9 body parts were 
totally affected. 
Physical symptoms of  itching, pain and fatigue: The Visual Analog Scales (VAS) of  the 
ISDL1,13 were used to estimate the mean level of  itching, pain and fatigue over the 
previous four weeks on a scale of  0-100 millimeters (mm). 0 mm represented no 
itching, pain or fatigue and 100 mm represented maximal fatigue, pain or itching 
ever experienced. 
Stressors: The impact of  the disease on daily life was measured using the ISDL1 10 
item generic scale. It measures the effect the condition has on day to day activities 
e.g. work, hobbies, sleep, sexuality and relationships. The stigmatization (6 items) 
scale of  the ISDL1 measured the extent to which the patients’ felt stigmatised by 
others as a result of  the sclerotic disease.
Illness cognitions were measured using the ISDL illness cognitions of  helplessness 
(6 items), acceptance (6 items), and perceived beneﬁ ts (6 items).1,11,14 
Helplessness was deﬁ ned as focusing on the negative consequences of  the 
disease and generalizing them to functions in daily life. Acceptance was deﬁ ned 
as acknowledging being chronically ill and perceiving the ability to manage the 
negative consequences of  the disease. Perceived beneﬁ ts were deﬁ ned as perceiving 
positive, long-term consequences of  the disease (e.g. to become a stronger 
person).1 
Finally the social support was measured by reﬂ ecting on qualitative and quantative 
aspects of  social support of  the ISDL1 in the past 6 months. The quantative aspect 
was assessed by the size of  the social network. Patients were asked to ﬁ ll in the 
number of  friends or family members with whom patients associated. The quality 
aspect was measured with a perceived support scale (5 items), measuring perceived 
availability of  emotional and instrumental support. 
2.2.5 Statistical analyses
Square root transformation was applied due to skewed distributions of  scores 
in depressed mood. Social network scores were categorized according to norm 
classes.17 
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The mean and SEM of  the psychological distress scores (anxiety and depressed 
mood) of  the patients with morphea and eosinophilic fasciitis were compared to 
representative Dutch norm groups of  healthy persons from the manual of  the 
validated questionnaires for anxiety and depressed mood of  the ISDL.18,19 
To assess risk groups for psychological distress, the number of  patients with scores 
on ‘anxiety’ and ‘depressed mood’ equal to, or higher than the mean scores of  
psychiatric outpatients was determined by comparing their scores with mean scores 
of  representative norm Dutch groups of  psychiatric outpatients from the manual 
of  the validated questionnaires for anxiety and depressed mood of  the ISDL18,19
The mean ± SEM scores for ‘depressed mood’ of  the Dutch norm groups are for 
healthy persons 1.6 ± 0.4 and for psychiatric outpatients 4.4 ± 0.7. 18,19
The mean ± SEM scores for ‘anxiety’ of  the Dutch norm groups are for healthy 
persons 16.5 ± 0.3 and for psychiatric outpatients 23.1 ± 0.7. 18,19 
The relationship between the predictors (skin status/severity, physical symptoms, 
disease impact on daily life, illness cognitions, social support, in addition to 
demographic variables and time since diagnose) and psychological distress (anxiety 
and depressed mood) was explored by calculating Pearson correlation coefﬁ cients 
for all patients with a sclerotic skin disease. 
Sequential regression analyses were performed to study the relative contribution 
of  the physical and psycho-social factors to psychological distress. Anxiety and 
depressed mood were used as indicators of  psychological distress and were 
the dependent variables. The different predictors were entered in consecutive 
steps in the regression analyses to test their additional contribution in terms of  
signiﬁ cant F-change, after having taken into account the variance explained by 
the other predictors. The grouping of  variables in a step as well as the entry order 
of  the steps was determined ‘a priori’ by the stress-vulnerability model by ﬁ rstly 
entering disease-related predictors ﬁ rst (e.g. indicators of  skin severity and physical 
symptoms were entered before psycho-social factors of  disease-related stressors, 
illness cognitions and social support).The strength of  the beta (standardized 
regression coefﬁ cients) and the accompanying t-test were used as an indicator 
for the relative contribution of  a predictor in comparison to all other predictors 
that were tested in the model, independent of  entry order. Statistical analysis was 
performed using a SPSS program (version 14).
2.2.6 Results
Sample characteristics
Of  the 120 questionnaires sent to the patients, 81 (67.5%) were returned. Due to 
missing answers 74 questionnaires (61.7%) were suitable for analysis. No signiﬁ cant 
differences were found between responders and non-responders with regard to sex, 
age, educational level, time since diagnose, and morphea sub-type. The mean age 
of  all patients was 47.0 years ± 2.2 (SEM). Fifty-six patients were female and 5.6%, 
74.7% and 19.7% of  the patients respectively had a primary, secondary and tertiary 
level of  education.  
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Twenty-two of  the 74 patients (29.7%) experienced co-morbidity. Respectively, 13 
(17.6%), 7 (9.5%), and 2 (2.7%) of  the patients reported to have one, two or three 
other co-morbidities besides the skin disease (cardial, pulmonary, gastrointestinal, 
urogenital, endocrine, blood, neurological diseases or joint problems). More 
speciﬁ cally, 4 patients suffered from cardiac problems, 5 patients had pulmonary 
diseases, 3 patients were diagnosed with gastrointestinal diseases, 1 patient had an 
urogenital disease, 2 patients suffered from endocrine disorders, 2 patients had 
Characteristics total 
population 
(n=74)
generalized 
morphea 
(n=16)
plaque 
morphea    
(n=36)
linear 
morphea    
(n=10)
eosinophilic 
fasciitis 
(n=12)
Women, No. (%) 56 (75.7) 15 (93.8) 11 (30.6) 8 (80) 8 (66.7)
Men, No. (%) 18 (24.3) 1 (6.3) 25 (69.4) 2 (20) 4 (33.3)
Highest Educationlevel 
Primary (%) 5.6 0 8.3 0 9.1
Secondary (%) 74.7 80.0 75.0 66.6 72.8
Tertiary (%) 19.7 20.0 16.7 33.3 18.2
Mean age (y) ± SEM 47.0 ± 2.2 45.8 ± 4.9 49.7 ± 3.0 24.9 ± 2.8 59.1 ± 4.2
Mean time since diagnose (y) ± SEM 11.0 ± 1.0 7.2 ± 4.9 12.2 ± 1.4 12.6 ± 1.4 11.5 ± 3.5
Skin severity ± SEM 12.6 ± 0.4 13.3 ± 0.6 12.1 ± 0.3 11.9 ± 0.7 13.9 ± 2.0
Physical symptoms:
Itch ± SEM 15.4 ± 2.6 18.9 ± 5.9 13.7 ± 3.2 3.5 ± 2.0 25.4 ± 7.3
Pain ± SEM 19.0 ± 2.8 20.3 ± 4.4 13.8 ± 3.7 12.5 ± 6.6 38.3 ± 9.5
Fatigue ± SEM 30.6 ± 3.1 48.5 ± 4.9 20.4 ± 4.0 24.1 ± 9.7 41.4 ± 7.8
Stressors:
Impact of  disease ± SEM 14.3 ± 0.8 15.3 ± 1.6 12.8 ± 0.7 12.2 ± 0.9 18.8 ± 2.2
Stigmatization ± SEM 7.2 ± 0.2 7.5 ± 0.6 7.2 ± 0.3 7.3 ± 0.7 6.8 ± 0.3
Illness cognition:
Helpnessless ± SEM 8.1 ± 0.3 8.3 ± 0.8 7.4 ± 0.4 7.3 ± 0.7 11.0 ± 1.1
Acceptance ± SEM 19.3 ± 0.5 17.3 ± 1.4 20.7 ± 0.5 20.2 ± 1.0 17.1 ± 1.5
Perceived beneﬁ ts ± SEM 13.0 ± 0.6 11.3 ± 1.3 13.7 ± 0.8 12.9 ± 1.8 13.7 ± 1.1
Social support:
Perceived support ± SEM 16.8 ±  0.4 14.4 ± 0.8 17.6 ± 0.5 17.3 ± 1.0 17.5 ± 1.1
Social network ± SEM 2.0 ±  0.09 1.9 ± 0.1 2.1 ±  0.1 2.0 ± 0.2 2.1 ± 0.3
Psychological distress:
Anxiety ± SEM 17.4 ± 0.8 21.6 ± 1.8 15.4 ± 0.8 16.0 ± 2.4 19.4 ± 2.0
Depressed mood ± SEM 3.2 ± 0.5 4.7 ± 1.1 2.1 ± 0.5 3.7 ± 1.9 4.3 ± 1.6
Patients at risk:
Anxiety (%) 22 50 8 10 33
Depressed mood (%) 32 38 25 30 50
Riskgroup (anxiety or depressed 
mood) (%) *
38 50 28 30 58
*The number of  patients with scores on Anxiety and Depressed Mood equal to or higher than the 
mean scores of  psychiatric outpatients was determined by comparing their scores with mean scores of  
representative norm groups in Dutch populations.
18;19
Table 1: Mean ± SEM of demographic data of patients with sclerotic disease sub-
types, skin severity, physical symptoms, stressors, illness cognition, social support, level 
of anxiety and depressed mood and patients at risk for psychological distress. 
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blood disorders, 9 patients experienced neurological problems and 6 patients had 
joint complaints. Finally one patient was diagnosed with an alopecia areata. 
Level of  psychological distress
Table 1 shows the mean ± SEM of  demographic data, skin severity, physical 
symptoms, the mean scores of  skin severity, physical symptoms, stressors, illness 
cognition and social support level of  psychological distress and patients at risk 
for psychological distress of  the morphea and eosinophilic fasciitis patients in all 
categories. 
In general, means scores of  anxiety and depressed mood of  all patient categories 
with sclerotic skin diseases were higher than mean scores of  Dutch healthy norms 
groups. 
Descriptive views of  differences between diagnoses showed that patients with 
eosinophilic fasciitis and generalized morphea reported the highest degree of  
psychological distress (table 1). 
Finally, with regard to risk groups for psychological distress, 38% of  all patients 
with a localized sclerotic skin disease had scores comparable to mean scores of  
psychiatric outpatients and could be considered as psychologically at risk (scored 
on ‘anxiety’ or ‘depressed mood’ equal to, or higher than the mean scores of  
psychiatric outpatients).
Predictors of  psychological distress
Correlation between the predictors (skin severity, physical symptoms, stressors, 
illness cognitions and social support) and psychological distress (depressed mood 
depressed mood anxiety
Physical functioning:
Skin status 0.26*  0.27*  
Physical symptoms: 
Itch 0.44   0.15    
Pain 0.24*  0.25*  
Fatigue 0.38** 0.44** 
Stressors:
Impact of  disease 0.41** 0.32** 
Stigmatization 0.48** 0.40** 
Illness cognition:
Helpnessless 0.49** 0.40** 
Acceptance -0.64**  -0.67**  
Perceived beneﬁ ts -0.17    -0.29*   
Social support:
Perceived support -0.35** -0.55**  
Social network -0.36** -0.27*    
A positive correlation indicated that anxiety or depressed mood is related to a more extended skin disease, 
more itch, pain or fatigue, higher impact of  the disease on daily life or stigmatization, more helplessness, 
acceptance or perceived beneﬁ ts and more social support. * p < 0.05, ** p < 0.01
 
 Table 2: Correlations of depressed mood and anxiety with skin status, physical 
symptoms, stressors, illness cognition and social support.
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and anxiety) are presented in table 2. As expected, there was a strong correlation 
between higher levels of  psychological distress and a more extended skin severity, 
more pain and fatigue and a higher impact of  the disease on daily life, more 
stigmatization, illness cognitions of  greater helplessness and less acceptance and 
less social support. Anxiety was also related to less perceived beneﬁ ts.
Demographic variables (age and sex), education level, co-morbidity, duration of  the 
sclerotic disease and physical symptoms of  itching were not signiﬁ cantly related to 
psychological distress.
Multiple regression analyses were performed to examine the relative contribution 
of  the study variables (skin severity, physical symptoms, stressors, illness cognition 
and social support) to psychological distress (depressed mood and anxiety) in all 
patients being studied (table 3). In the ﬁ rst step, the skin severity (degree to which 
different parts of  the body were affected) did signiﬁ cantly explain 7% of  the 
variance and physical symptoms of  itching, pain and fatigue in step 2 signiﬁ cantly 
explained 15% variance in anxiety (F-change= 3.39, p < 0.05). In step 3, the impact 
of  the disease on daily life and stigmatization did signiﬁ cantly explain 31% of  the 
variance in depressed mood (F-change= 14.18, p < 0.001) and 16% of  the variance 
in anxiety (F-change= 6.29, p < 0.01). Illness cognitions in step 4 added another 
8% variance in depressed mood (F-change= 2.87, p < 0.05) and 14% in anxiety 
(F-change= 4.74, p < 0.01). Finally, social support in step 5 did signiﬁ cantly explain 
the 14% variance in anxiety (F-change= 9.24, p < 0.001).
When the relative contribution of  predictors was compared, β-coefﬁ cients for the 
entire model indicated partly corresponding predictors for depressed mood and 
anxiety, i.e. illness cognition of  less acceptance signiﬁ cantly predicted psychological 
depressed mood anxiety
β 
(a)
 R square 
(b)
β 
(a)
R square 
(b)
Physical functioning:
Skin status -0.01 0.06    0.05    0.07*  
Physical symptoms: 0.08    0.15*  
Itch -0.30* -0.12    
Pain 0.17 0.12   
Fatigue -0.10  0.03   
Stressors: 0.31*** 0.16**  
Impact of  disease -0.15  -0.46*   
Stigmatization 0.31* 0.12   
Illness cognition: 0.08*    0.14**  
Helpnessless 0.34  0.46*  
Acceptance -0.38* -0.42*   
Perceived beneﬁ ts 0.40 -0.01     
Social support: 0.04    0.14***
Perceived support -0.21       -0.43***
Social network -0.11  -0.06    
total R square 0.57*** 0.66***
(a)
 Probability level of  t-test, 
(b)
 Probability level of  F-change, *p < 0.05, **p < 0.01, *** p < 0.001
Table 3: Multiple regression analysis predicting psychological distress in patients with 
a sclerotic skin disease.
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distress in patients with a sclerotic skin disease (acceptance: t= -2.09, p < 0.05 for 
depressed mood and t= -2.60, p < 0.05). In addition, the physical symptoms of  
more itching and more stigmatization also predicted greater depressed mood 
(t= -2.09, p < 0.05 and t= 2.14, p < 0.05), while a higher impact of  the disease 
on daily life and more helplessness, as well as less perceived support, additionally 
predicted more anxiety in patients with sclerotic skin disease (t= -2.18, p < 0.05, 
t= 2.09, p < 0.05 and t= -4.26, p < 0.001).
2.2.7 Discussion
In the present study, psychological distress and factors contributing to 
psychological distress were examined in adult patients with localized scleroderma 
(morphea) including eosinophilic fasciitis. Thirty-eight percent of  all patients with a 
localized sclerotic skin disease scored at levels comparable to psychiatric outpatients 
with anxiety or depressed mood and could be considered as psychologically at risk. 
Of  all patients, those with a generalized morphea and eosinophilic fasciitis reported 
the highest degree of  distress and suffered from heightened levels of  anxiety and 
depressed mood.18,19
Higher levels of  psychological distress (depressed mood and anxiety) were 
signiﬁ cantly related to a more extended skin severity, more pain and fatigue 
and a higher impact of  the disease on daily life, more stigmatization, more 
helplessness and less acceptance and less social support. When comparing the 
relative contributors of  different predictors, illness cognition of  less acceptance 
most conveniently predicted psychological distress in patients with a sclerotic skin 
disease. In addition, the physical symptom of  more itching and more stigmatization 
also predicted greater depressed mood. Finally a higher impact of  the disease 
on daily life, more helplessness and lower perceived support also predicted more 
anxiety in patients with sclerotic skin disease.
A comprehensive set of  physical, psychological and social factors was found to 
be relevant to psychological distress in patients with a sclerotic skin disease. In 
interpreting these ﬁ ndings, it is important to realize that the questionnaires were 
distributed at a random point in time and only a few patients were actively being 
treated for the disease. This may imply that in general, the present study might 
have been underestimated the presence and severity of  psychological distress.13 
Several limitations of  the study have to be mentioned, such as absence of  control 
group and small sample sizes, thus limiting comparison possibilities. In addition, 
explorative assessments of  co-morbidities indicate the need for further research. 
The severity of  the disease was based on patient assessment rather than physician 
assessment. Other psychological factors shown to be possibly relevant in patients 
with a chronic disease in general, such as coping strategies and personality 
characteristics14,20-23 should be taken into account in any further studies. 
However, this study is the ﬁ rst to describe the level of  psychological distress and its 
contributors in patients with a localized sclerotic skin disease. 
The ISDL is a validated self-report instrument for patients with atopic dermatitis 
and psoriasis and most of  the scales have also previously been validated in other 
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chronic diseases, e.g. rheumatic conditions or multiple sclerosis.1,11,14 However, 
in the present study, these factors were for the ﬁ rst time studied in patients with 
sclerotic skin diseases, showing similar ﬁ ndings to those previously found for 
other chronic skin diseases and other chronic conditions and demonstrating that 
corresponding mechanisms might play a role for these types of  skin disease.1,11
Up to now no information was systematically available regarding the quality of  life 
in patients with a morphea or eosinophilic fasciitis. For clinicians, it is important 
to realize, that more than a third of  patients with a localized sclerotic skin disease 
(localized scleroderma or eosinophilic fasciitis) scored at levels comparable to 
psychiatric outpatients with anxiety or depressed mood and could be considered as 
psychologically at risk. While knowledge about the quality of  life is important, since 
an impaired quality of  life has been shown to have an unfavourable effect on the 
outcome of  dermatological therapies, and therefore on patients skin severity24 in 
patients with chronic skin diseases.20 Consequently, it is important to know which 
contributors most conveniently predict psychological distress.
Assessment of  the physical symptoms of  fatigue and pain, impact of  the disease 
on daily life, the illness cognitions helplessness and acceptance and social support 
can give additional information about the patients at risk of  psychological distress. 
Therefore it can be used to design better therapeutic schedules for those patients. 
In practice, patients with a sclerotic skin disease could potentially beneﬁ t from 
multidisciplinary treatment options that focus on fatigue and pain reduction (e.g. 
focusing on sleep disturbances, rest-activity balance and providing patients with 
adequate medication against the pain), changing the perceived stigmatization 
and helpless attitudes about their disease (e.g. social anxiety training, cognitive 
restructuring of  depressogenic cognitions) and promoting social support (e.g. 
mobilizing social support from signiﬁ cant others). Based on the present ﬁ ndings, 
clinicians should be encouraged to carefully assess these factors in patients 
with sclerotic skin diseases (using questionnaires or interviews). This approach 
could greatly improve the quality of  life, which could ﬁ nally lead to improved 
dermatological treatment outcomes.
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sclerotic skin diseases
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3.1  EMOLLIENT-CONTROLLED, RANDOMIZED, DOUBLE 
 BLIND PILOTSTUDY TO ASSESS EFFICACY OF TOPICAL 
 TACROLIMUS 0.1% IN ACTIVE PLAQUE MORPHEA
3.1.1 Abstract
Background: Tacrolimus, a calcineurin inhibitor is an immunomodulating and anti-
inﬂ ammatory drug, which inhibits T-cell activation and production of  cytokines. 
The elevated level of  cytokines in morphea causes ﬁ broblast proliferation and 
subsequently overproduction of  collagen. Theoretically, tacrolimus could inhibit 
the pathophysiological process of  morphea. 
Objective: To assess whether tacrolimus 0.1% ointment is an effective treatment for 
plaque morphea in a double blind emollient-controlled pilotstudy.
Methods: Ten patients with active plaque morphea were included. All patients were 
treated with tacrolimus 0.1% ointment and with an emollient (petrolatum) on 
two selected morphea plaques, applied twice daily for 12 weeks. Initial and ﬁ nal 
assessment included surface area measurements, photography, durometer scores 
and clinical feature scores. Adverse reactions were recorded.
Results: The scleroderma plaques treated with topical tacrolimus 0.1% improved, 
resulting in a signiﬁ cant reduction of  the durometer scores and clinical feature 
scores. Overall a signiﬁ cant difference could be found between topical tacrolimus 
and petrolatum with regard to the durometer score (p < .005) and the clinical 
feature score (p = .019). 
Conclusion: This is the ﬁ rst double blind, controlled pilotstudy comparing tacrolimus 
0.1% ointment with petrolatum in plaque morphea, which shows that tacrolimus 
0.1% ointment is an effective treatment for active plaque morphea.
3.1.2 Introduction
Tacrolimus, a calcineurin inhibitor is an immunomodulating and anti-inﬂ ammatory 
drug, which inhibits T-cell activation and production of  cytokines.1 Tacrolimus 
ointment showed beneﬁ cial effects in common inﬂ ammatory skin diseases such as 
atopic dermatitis and facial and intertriginous psoriasis.1 Skin disorders in which 
T-cell activation plays an important pathogenic role, like localized scleroderma, can 
be regarded as potential targets for treatment with tacrolimus ointment.
Although the cause of  localized scleroderma, also known as morphea, is unknown, 
an autoimmune mechanism is suspected.2 Morphea patients have shown elevated 
serum levels of  cytokines (interleukin (IL)-1, IL-2, IL-4, IL-6, IL-8, IL-13 and 
tumor necrosis factor α).3-6
The elevated level of  cytokines causes ﬁ broblast proliferation and subsequently 
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overproduction of  collagen.7 Theoretically, tacrolimus could be able to inhibit the 
pathophysiological process of  morphea.
No completely satisfying treatment for morphea is available. Numerous modalities 
including corticosteroids,8 calcipotriol,7 imiquimod,9 and PUVA10  phototherapy, 
methotrexate,11-13 penicillamin14 and interferon gamma15 have been used. The 
few open studies and case series did not reveal a signiﬁ cant effect for the treatment 
of  morphea. A randomized controlled study performed by Kreuter et al.16 shows 
that UVA-1 is effective in the treatment of  morphea. UVA-1 is a time consuming 
treatment which is not widely available.
Morphea can be divided in several subtypes. Peterson et al.17 distinguished the 
following main types: plaque morphea, generalized morphea, bullous morphea, 
linear morphea and deep morphea. The current study was focused on patients with 
plaque morphea. 
In 2005 the ﬁ rst case reports of  successful topical tacrolimus therapy in patients 
with morphea was published by Mancuso et al.18,19 Seven patients with active and 
non-active morphea were treated with tacrolimus ointment twice daily for three 
months. Histopathological evaluation of  biopsy specimens showed a reduction of  
the sclerosis after treatment. Unfortunately, this was an open-labelled trial study. 
The purpose of  the current study is to evaluate the efﬁ cacy of  tacrolimus 0.1% 
ointment versus petrolatum on active plaque morphea using a within patient double 
blind comparison. 
3.1.3 Methods 
After approval of  the ethical committee, ten patients were enrolled in this 
prospective randomized, double blind trial. Informed consent was obtained from 
each patient prior to participation. Patients were recruited from the outpatients’ 
clinic from the Dermatology Department of  the Radboud University Medical 
Centre Nijmegen, the Netherlands. The diagnosis was established by two 
dermatologists, in combination with histological and/or laboratory examinations 
when necessary. Ten adult patients (aged ≥ 18 years) with the diagnosis of  an active 
plaque morphea were included in this study. An active morphea plaque was deﬁ ned 
as a sclerotic plaque with erythematous border. 
Inclusion criteria consisted of  two or more active morphea plaques separated by at 
least 15 centimetres, no concomitant topical treatment for at least three weeks and 
no systemic immunosuppressives, penicillamin, interferon gamma or phototherapy 
for at least three months. 
Exclusion criteria consisted of  systemic sclerosis20 and  pseudosclerosis,21 proved 
adverse reactions to tacrolimus in the past (e.g. hypersensitivity/intolerance), 
females who were pregnant, nursing or planning to become pregnant during the 
study, an active skin infection at the morphea plaque and a recent vaccination 
(from 28 days before start of  this study). Serologic evidence of  Borrelia Burgdorferi 
infection was excluded.
The study would be discontinued in case of  an active skin infection, pregnancy, 
initiation of  prohibited medication during study, serious adverse events and failure 
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to comply applications, evaluations, or other study requirements. Patients had to 
avoid the sun during study.
During the ﬁ rst visit, two separate active morphea plaques were selected. To 
measure the surface area of  the two plaques an adhesive transparent ﬁ lm 
(ColoplastTM, 3M Health Care) pre-printed with squared centimetres was used. 
The ﬁ lm was applied on the skin of  the patient and the borders of  the indurate 
lesions were marked with permanent colour. 
The extensiveness of  the plaque morphea was measured once at the ﬁ rst visit by 
using the modiﬁ ed skin score (MSS), according to Zachariae.22 In this scoring 
system, the skin is divided in seven regions: the head and neck region, arms, hands, 
ﬁ ngers, trunk, legs, and feet. The degree of  thickening and pliability was assessed 
on a 0 to 3 scale: 0 = normal skin, 1 = palpable thickened skin, 2 = decreased 
ability to pinch or move the skin and 3 = the skin could not be moved or pinched. 
In addition, involvement of  each area was determined by estimation and given the 
following scores: 0 = no involvement, 1 = < 33% of  the area is affected, 
2 = 33-67% of  the area is affected, 3 = > 67% of  the area is affected. The sum of  
the scores of  both thickness and affected area is the MSS, with a minimum score 
of  0 for not affected skin and 42 representing the maximum score of  extreme 
involvement in all areas.22
Tacrolimus 0.1% ointment and petrolatum were randomly assigned to the two 
plaques and the ointments were blinded for patient and investigator.
Topical tacrolimus had to be applied twice daily for a period of  12 weeks on one, 
and petrolatum bid for 12 weeks on the other selected plaque, which served as 
control. Follow-up visits were performed every four weeks to evaluate the clinical 
outcomes. Adverse reactions of  the applied ointments were recorded and the 
amount of  application was weighed. 
Initial and ﬁ nal assessment of  both morphea plaques included measurement of  the 
surface area, photography, durometer score and clinical feature score. 
3.1.4 Evaluation of  the outcomes
Durometer score
Objective measurements of  the hardness of  the skin were performed by 
a durometer (model 1600-OO; rex Gauge Co, Glenview, III, USA). For 
measurements, the durometer was used at 24°C and rested by gravity against the 
skin with a constant weight that did not allow additional pressure. The durometer 
is ﬁ tted with a calibrated gauge that registers linearly divided units on a scale of  0 
to 100. At the bottom of  the apparatus, there is a small, inferior indenter that is 
retractable and is responsible for the measurements registered on the gauge. The 
hardness of  the skin was measured by one investigator at ten locations, distributed 
equally on the morphea plaque. Each spot was measured three times and the 
score was averaged. The averages of  the ten points were summed up to give the 
total durometer score for one plaque (in theory the total durometer score range 
varies from 0 until 1000). The locations were selected preferably on sites where no 
bony structures were present directly beneath the skin.23,24 During the ﬁ rst visit 
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the measure points were photographed to guarantee measurements at the same 
location each visit. 
Clinical feature score
The clinical features of  each plaque were evaluated using the ‘modiﬁ ed DIET’ 
score: Dyspigmentation (D), Induration (I), Erythema (E), Telangiectasia (T) and 
additional Atrophy (A). Each clinical feature was rated on a scale of  0 (none), 1 
(mild), 2 (moderate) and 3 (severe). The total score of  each plaque was provided by 
the sum of  the separate features: SUM(D+I+E+T+A) with a minimum score of  0 
and a maximum score of  15.25
 
3.1.5 Statistical analyses
Statistical analysis was performed using SPSS program (version 14). Null hypothesis 
was based on the assumption that there was no difference in efﬁ cacy between 
petrolatum and tacrolimus 0.1% ointment. 
Comparisons of  the data of  the durometer scores and clinical feature scores 
were assessed by means of  2-sided paired t-tests. The mean differences, SEMs, 
SDs and ranges were calculated. Analysis of  data distribution was assessed by 
visual inspection due to the small population size. Differences were considered 
statistically signiﬁ cant as p < .05 and highly signiﬁ cant as p < .01. 
3.1.6 Results
The mean age of  the 10 patients (7 females and 3 males) was 44.3 years ± 22.1 
(SD). Nine patients were Caucasians and one patient was an Indonesian Creole. 
The mean duration of  active disease was 3.4 years ± 2.8 (SD). The extensiveness 
of  the plaque morphea (MSS) was 4.1 ± 1.9 (SD) and all patients had at least two 
active morphea plaques. Location of  the plaques were situated at the trunk (12) 
and arms (8). Prior treatments consisted of  topical steroids (9), oral steroids (1), 
penicillin (1), penicillamine (1), UVB-TL01 phototherapy (2), PUVA phototherapy 
(1) and methotrexate (6). All patients completed the study. The results are 
summarized in Table 1.
Surface measurements of  the plaques
Measurements of  the surface area of  the plaques treated with topical tacrolimus 
revealed a decrease (5), increase (1) or no difference in size (4). The mean surface 
area of  the plaques applied with topical tacrolimus before treatment was 
87.1 cm2 ± 17.7 (SEM) and after treatment 81.8 cm2 ± 15.7 (SEM). The mean 
decrease in plaque size after treatment was 5.3 cm2 ± 3.3 (SEM), p = .143. 
Measurements of  the surface area of  the plaques treated with petrolatum revealed 
a decrease (2), increase (3) or unchanged surface of  the plaque (5). The mean 
surface area before treatment with petrolatum was 80.0 cm2 ± 14.0 (SEM) and 
after treatment 81.3 cm2 ± 12.1 (SEM). No signiﬁ cant increase of  plaque size after 
treatment with petrolatum could be found (1.3 cm2 ± 3.2 (SEM), p = .707). 
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Comparing the differences of  plaque size before and after treatment of  the two 
plaques, improvement in size due to tacrolimus 0.1% ointment did not show 
signiﬁ cance (p = .132). The mean applied dose of  topical tacrolimus was 
0.47 grams/cm2 and 0.54 grams/cm2 for petrolatum.  
Durometer score
All durometer scores of  the plaques applied with tacrolimus 0.1% ointment 
decreased. Before treatment the mean score was 509.0 ± 35.8 (SEM) and after 
treatment 459.5 ± 32.2 (SEM). The mean decrease was 49.5 ± 6.3 (SEM), which is 
a highly signiﬁ cant improvement (p < .005). 
The plaques applied with petrolatum showed no signiﬁ cant change of  durometer 
scores. The mean durometer score before treatment was 510.7 ± 30.4 (SEM) and 
after treatment 506.7 ± 26.6 (SEM), the difference was not signiﬁ cant (p = .529). 
Comparing the differences in durometer scores before and after treatment between 
the two ointments, a highly signiﬁ cant reduction of  the durometer score with 
regard to topical tacrolimus could be found (p < .005). Figure 1 shows the mean 
durometer scores, ± 95% conﬁ dence interval (CI), of  all patients before and after 
treatment with petrolatum or topical tacrolimus 0.1%. 
topical tacrolimus 
0.1%
petrolatum difference between 
ointments
Surface measurement plaques 
Before Tx mean 87.1 80.0
SD 55.9 44.4
Range 10-200 29-162
After Tx mean 81.8 81.3
SD 49.7 38.2
Range 12-166 41-162
P-value .143 .707 .132
Durometer score 
Before Tx mean 509.0 510.7
SD 113.3 96.0
Range 355-696 372-653
After Tx mean 459.5 506.7
SD 101.9 84.2
Range 331-617 378-634
P-value <.005 .529 <.005
Clinical feature score
Before Tx mean 8 7.5
SD 1.8 1.5
Range 4-10 5-10
After Tx mean 5.2 6.9
SD 1.8 1.4
Range 2-8 4-9
P-value .003 .024 .019
Table 1: Surface measurements, durometer scores and clinical feature scores of both 
morphea plaques
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Figure 1: The mean durometer scores of all patients +/- CI 95 %. 
The baseline mean durometerscore is defined as 100%.
Clinical feature score
The clinical feature scores of  the plaques applied with tacrolimus ointment 
decreased in eight patients and remained unchanged in two patients. The mean 
score before treatment with topical tacrolimus was 8.0 ± 0.6 (SEM) and after 
treatment 5.2 ± 0.6 (SEM). The mean decrease after treatment was 2.8 ± 0.7 (SEM) 
and shows a signiﬁ cant improvement of  the clinical feature score (p = .003). 
The clinical feature scores of  the plaques applied with petrolatum decreased in 
seven patients, remained the same in two patients and increased in one patient. 
The mean clinical feature score before treatment was 7.5 ± 0.5 (SEM) and after 
treatment 6.9 ± 0.5 (SEM). The mean decrease after treatment with petrolatum was 
0.6 ± 0.2 (SEM) and shows a signiﬁ cant improvement as well (p = .024). 
However comparing the differences between both ointments, the decrease of  the 
mean clinical feature scores of  the plaques treated with tacrolimus ointment was 
highly signiﬁ cant (2.2 ± 0.8 (SEM), p = .019), compared to petrolatum ointment. 
No difference of  the clinical feature atrophia was found between before and after 
treatment with both topicals. Overall no different response to treatment could be 
found in different body areas. Figure 2 shows clinical pictures of  a morphea plaque 
before and after treatment with topical tacrolimus 0.1%. 
Tolerability
Severe side effects were not observed. One patient complained about a mild 
headache the last two weeks of  the treatment (week 11-12) and one patient 
complained about itch on the plaque where tacrolimus was applied. Furthermore, 
no adverse effects were reported on the application sites of  tacrolimus ointment or 
petrolatum. 
0
0
0
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Figure 2A: Clinical presentation of a patient with active plaque morphea before 
treatment with topical tracrolimus 0.1% 
Figure 2B: Clearance of the erythematous border of the sclerotic plaque after 12 weeks 
of application, twice daily, with tacrolimus ointment 0.1%.
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3.1.7 Discussion
In this double-blind emollient controlled study, topical tacrolimus was found to 
be effective in the treatment of  active plaque morphea. The scleroderma plaques 
treated with topical tacrolimus 0.1% improved, resulting in a signiﬁ cant reduction 
of  durometer and clinical feature scores. A highly signiﬁ cant improvement of  the 
durometer scores of  the plaques applied with tacrolimus 0.1% ointment was found, 
whereas no signiﬁ cant effect could be found in the plaques treated with petrolatum. 
The durometer is a validated objective apparatus that measures the hardness of  the 
skin.23,24 
Another compelling result was the signiﬁ cant improvement of  the clinical feature 
score of  the plaques applied with tacrolimus 0.1% ointment. However the plaques 
treated with petrolatum showed improvement of  the clinical feature score as well. 
An evident signiﬁ cant difference between topical tacrolimus and petrolatum 
(p = .019) in favour of  tacrolimus was found. According to the results tacrolimus 
0.1% ointment shows beneﬁ cial improvement on active morphea plaques.
Tacrolimus was discovered in 1987 by Goto et al.26 Since the introduction of  
tacrolimus ointment, many studies and case reports have been published about 
the off  label use of  this calcineurin inhibitor.18,19,27,28 Several open studies and 
case reports showed  beneﬁ cial effects of  topical tacrolimus on lichen sclerosus, a 
related disease.29-32 
Although the pathogenesis of  morphea is unknown, an auto-immune aectiology is 
suspected. In the inﬂ ammatory stage of  the disease increased levels of  cytokines 
have been observed.33 Morphea patients have shown elevated serum levels of  
cytokines (interleukin (IL) 1, IL-2, IL-4, IL-6, IL-8, IL-13 and tumor necrosis factor 
α). This provides evidence for T-helper 2 activation in the pathogenesis of  the 
disease.3-6
Cytokines and growth factors produced by endothelial and inﬂ ammatory cells 
result in the stimulation of  ﬁ broblasts as well as accumulation of  connective tissue 
matrix.7
Tacrolimus has the ability to suppress the immune response and inﬂ ammatory 
factors, which are observed in the active phase of  morphea, by inhibiting the 
activation of  T-lymphocytes and reducing cytokine production. 
Limitations of  this study include a relatively small sample population and short 
evaluation time. Future investigation is needed to conﬁ rm the results studying 
larger groups of  patients with morphea. Spontaneous remission in plaque morphea 
occured, however this study was performed in only 12 weeks, while all patients had 
an active disease for more then one year. An evident signiﬁ cant difference between 
topical tacrolimus and petrolatum could be found. 
The results of  this study only apply to (limited) plaque morphea. Patients with a 
linear or deep sclerosis (involvement of  the fascia, fat tissue and muscles) would be 
undertreated with topical tacrolimus and require systemic treatment.
Topical tacrolimus proved to be an effective treatment in atopic dermatitis, with 
a low rate of  side effects,28 in the current study one patient experienced mild 
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headache and one patient experienced itch during treatment with topical tacrolimus. 
No serious side effects were observed. 
The most common adverse events are related to the application site and are 
generally a burning sensation and pruritus.34 Studies have shown that the 
systemic absorption of  tacrolimus when applied topically is very low, with blood 
concentrations being below the level of  quantiﬁ cation in most patients.1,28 
Serious adverse effects and increased risk of  cutaneous carcinoma and lymphoma, 
observed with systemic administrated tacrolimus, have not been revealed with the 
use of  topical tacrolimus 0.1%.27
Besides the low rate of  adverse effects, experimental and clinical studies which 
compared topical corticosteroids with tacrolimus ointment revealed that tacrolimus 
was not associated with skin atrophy.35-37 Also in this study, tacrolimus 0.1% 
ointment for 12 weeks did not induce clinical atrophy in morphea. 
This is the ﬁ rst double blind, controlled study in which tacrolimus 0.1% ointment is 
compared to petrolatum, that shows that tacrolimus 0.1% ointment is an effective, 
safe and well tolerated treatment for active plaque morphea.
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3.2  EFFECTIVENESS, SIDE EFFECTS AND PERIOD OF 
 REMISSION AFTER TREATMENT WITH METHOTREXATE IN 
 SCLEROTIC SKIN DISEASES: AN INCEPTION COHORT STUDY
3.2.1 Abstract
Background: Methotrexate (MTX) is frequently used as therapy in sclerotic skin 
diseases, but detailed information is lacking on effectiveness, side effects and 
duration of  remission after discontinuation of  MTX.
Objective: To determine effectiveness, side effects and period of  remission gained by 
use of  MTX in sclerotic skin diseases.
Methods: All patients included in an inception cohort of  our tertiary referral centre 
of  the departments of  Dermatology and Rheumatology, diagnosed with a sclerotic 
skin disease, treated with A: MTX or B: MTX with corticosteroids (CS) between 
1995 and 2007 January 1st were evaluated. Treatment was started in case of  active 
disease, deﬁ ned as: 
1. extensive and/or progressive disease; 
2. sclerotic skin disease leading to a substantial loss of  mobility; 
3. warmth and erythema of  skin lesions. 
Treatment was stopped in case of  good or excellent improvement, stabilisation of  
improvement, progression despite treatment, or severe side effects. Response was 
graded from 1 to 6 (excellent to no improvement). Patients were seen 3-monthly. 
Data collected encompassed: detailed information about MTX and CS treatment, 
effectiveness, side effects, duration of  the remission period, and in case of  a 
relapse, the time between stop and restart of  MTX or MTX + CS. A Mann-
Whitney U and a Fisher exact test were used to compare treatment groups (two-
sided tested, p < 0.05).
Results: Fifty-eight patients (A: n=47, B: n=11) with generalized morphea (A: 25, 
B: 2), localized morphea (A: 7, B: 2), linear morphea (A: 11, B: 2), scleredema 
diabeticorum (A: 2, B: 0), and scleromyxedema (A:2, and B: 0), eosinophilic fasciitis 
(A: 0, B: 5) were evaluated with a maximum follow-up duration of  144 months. 
Median disease duration before start of  treatment was 22 months 
(7-120, percentiles 10-90). Improvement of  sclerotic skin disease was seen in 38 
patients (81%, A) and 11 patients (100%, B). Remission status was reached after 
one treatment course in 51% of  patients (A) and in 73% (B) with a median follow 
up time of  55 (A) and 58 (B) months. Response was seen after relapse in a second 
course and a third course of  treatment. Patients with relapse had received a lower, 
not signiﬁ cant, cumulative dose of  MTX in the ﬁ rst course (443 mg (A); 658 mg, 
(B)) compared to the patients who reached remission status (708 mg (A), 1070 mg 
(B), due to a shorter period of  treatment. The mean dose of  CS was 17 mg/day. In 
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6 (10%) patients serious side effects were seen: infections (2), gastrointestinal side 
effects (2), and eleveated liver enzymes (2). A larger cumulative dose of  MTX and 
a better clinical score were seen in group B compared to group A. Patients showing 
a relapse after one treatment course had a longer, though not signiﬁ cant disease 
duration. Gender, age or diagnosis was not associated with relapse.
Conclusion: This study is the largest published for a series of  patients with sclerotic 
skin diseases treated with MTX showing that both treatment strategies (MTX 
and MTX+CS) are effective and safe treatments with a long median period of  
remission. After relapse, restart of  MTX was still effective. Thus: MTX was 
an effective treatment for various sclerotic skin diseases with a long period of  
remission and relative low toxicity. Patients with a relapse, still responded to a 
second course and even to a third course of  MTX. 
3.2.2 Introduction
The scleroderma skin disorders comprise a heterogeneous group of  conditions 
linked by the presence of  sclerotic skin lesions. Scleroderma can be subdivided 
into three groups: systemic sclerosis (not investigated in this study), localized 
scleroderma, and scleroderma-like disorders, also called pseudoscleroderma. 
Sclerotic skin diseases (hardening or sclerosis of  the skin) can cause severe 
morbidity and functional disability. There is no consensus about the treatment of  
sclerotic skin diseases. Because of  the heterogeneous character of  the sclerotic 
skin diseases and the relative low incidences of  these diseases, no double blind 
controlled trials assessing efﬁ cacy of  any treatment have been performed. Although 
the cause of  localized scleroderma remains unknown, an auto-immune mechanism 
is suspected.1 Hormonal causes, repetitive trauma,2 and infectious agents3,4 have 
been suggested, however no evidence has been found. Localized scleroderma 
can manifest in different forms, and Greenberg and Falanga5 distinguished the 
following main types: morphea, linear morphea and generalized morphea. Plaque 
morphea (in this study referred to as localized morphea) is described as one or 
more circumscript patches of  sclerotic skin in one or two anatomic sites. Linear 
morphea, the most common form of  scleroderma in children, is characterized by 
visible linear bands of  sclerotic skin, along an affected limb, often complicated 
by contractures. Generalized morphea is described as either conﬂ uent plaques 
or multiple plaques, affecting more than three sites on the body. In addition, 
eosinophilic fasciitis can be distinguished,6 characterized in its early phase by limb 
or trunk erythema and oedema, followed by collagenous thickening of  the dermis 
and subcutaneous fascia. Eosinophilia is often a prominent laboratory ﬁ nding. 
Scleroderma is a primary cutaneous sclerosis. Secondary cutaneous sclerosis, also 
called pseudoscleroderma or scleroderma-like disorders, consists of  a wide range 
of  conditions, such as scleredema diabeticorum and scleromyxedema. Scleredema 
diabeticorum, or scleredema of  Buschke III, is a rare condition with unknown 
pathophysiology, characterized by non-pitting skin indurations occasionally with 
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erythema. Though patients suffer from diabetes mellitus, mostly late onset, its’ 
aetiology is unknown. 
Scleromyxedema or lichen myxedematosus is characterized by the formation of  
lichenoid papules forming conﬂ uent sclerotic plaques, usually accompanied by 
paraproteinemia, which is commonly found despite normal serum proteins. 
The therapeutic options for the treatment of  sclerotic skin diseases, based 
on literature, include the use of  corticosteroids,7 vitamin D analogues (e.g. 
calcitriol),7 PUVA (psoralen-UVA),8 UVA-1 (long wave UVA),9 cyclosporine 
A,10 d-penicillamin,7 extracorporeal photopheresis,7 and methotrexate (MTX). In 
the last decade, more literature has become available regarding effectiveness and 
side effects of  these treatments in sclerotic skin diseases.7 The severity, extent, 
localisation and progression of  the lesions determine the choice of  treatment. 
Systemic treatment should be considered in extensive or progressive and linear 
forms of  morphea and in cases with a high risk of  functional impairment. 
Although MTX is commonly used in various sclerotic diseases, including systemic 
sclerosis11 and generalized morphea,12 no information has been provided on its 
effectiveness, or the duration of  its effect, when MTX is discontinued.
MTX resembles folic acid and is an inhibitor of  folate dependent enzymes, 
like dihydrofolate reductase. This enzyme is involved in the pyrimidine (DNA) 
synthesis. Inhibition of  this enzyme leads to depletion of  tetrahydrofolates, that are 
essential for DNA, RNA and protein synthesis.13 Major advantages of  treatment 
with MTX encompass a weekly dosage schedule, low costs and a longstanding 
safety proﬁ le. Disadvantages of  MTX are the potential systemic toxicity, drug 
interactions, and need for frequent blood monitoring. 
The aim of  this study is to investigate the effectiveness and side effects of  MTX in 
an inception cohort of  patients with various sclerotic skin diseases, and in addition, 
to evaluate the duration of  the period of  remission after discontinuation of  MTX. 
3.2.3 Methods
Inception cohort: inclusion of  patients from December 1994 onward with various 
sclerotic skin diseases, except patients with systemic sclerosis, who were treated 
with MTX or MTX with Corticosteroids (MTX+CS). Patients were seen at least 
every three months. Long-term results were recorded till 1 January 2007.
 
Patients
The records of  all patients with sclerotic skin disease, i.e. localized scleroderma, 
eosinophilic fasciitis and pseudoscleroderma who were treated with MTX 
from December 1994 to January 2007 were evaluated. Detailed information for 
all patients was collected regarding the duration of  the disease and previous 
treatments before start of  MTX, dosage and duration of  MTX, concomitant 
immunosuppressive medication and corticosteroids (CS) treatment (Prednisone), 
and in addition to MTX treatment: effectiveness, side effects, duration of  the 
remission period and in case of  a relapse, the time between restart (time between 
stop and restart of  MTX).
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The patients were treated at the combined Dermatology-Rheumatology outpatient 
clinic at the Radboud University Medical Centre Nijmegen, the Netherlands. 
Patients with systemic sclerosis, formally called systemic scleroderma (limited 
cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis) or 
concomitant immunosuppressive treatment (except corticosteroids) were excluded 
after extensive history and physical examination targeted on auto-immune diseases.
Diagnoses were established by a clinical expert team comprising a dermatologist 
and rheumatologist, after extensive serologic, radiologic and/or histological 
examinations when necessary. 
Based on clinical judgment, patients were treated with either MTX (group A) or 
MTX with CS (group B). Within every group, subgroups were deﬁ ned according to 
the number of  treatment courses with MTX or MTX+CS. 
Patients were treated, in case of  (see ﬁ gure 1):
extensive and/or progressive disease, deﬁ ned as an increase in size of  previous • 
lesions or appearance of  new lesions; or
 sclerotic skin disease leading to a substantial loss of  mobility, i.e. lesions that • 
could give loss of  function; or
 signs of  an active disease (warmth or erythema).• 
Schedule: The dosage of  MTX at start was 15 mg weekly, and in case of  a lack of, 
or partial response increased to a maximum of  25 mg weekly. Dosages of  MTX 
were adjusted in patients younger than 18 years. Since the late nineties folic acid 
was added routinely for reduction of  toxicity, based on evidence from literature. 
Patients were treated for at least six months, unless severe side effects appeared. 
A treatment algorithm is provided in ﬁ gure 1.
Treatment was stopped based on judgment of  the clinical expert team, in case of:
 good or excellent improvement;• 
 after stabilisation of  improvement;• 
 lack of  improvement;• 
 in case of  progressive disease, despite maximal MTX dose;• 
 the occurrence of  severe side effects (see monitoring of  treatment).• 
Patients were retreated, when a relapse occurred (restart treatment algorithm, 
ﬁ gure 1). Relapse was deﬁ ned as a worsening of  the sclerosis (degree, extension 
or the appearance of  new lesions) or signs of  an active disease. Based on the 
judgment of  the clinical expert team, MTX treatment was started as previously 
described.
Monitoring of  treatment
Previous to start of  treatment with MTX, evaluation consisted of  laboratory 
examinations: full blood cell counts, kidney and liver function. These tests were 
performed regularly: 2-weekly for the ﬁ rst 3 months of  treatment, and thereafter 
4-weekly in the second 3 months of  treatment and thereafter 3-monthly in case of  
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*Every three months the treatment response was evaluated. Treatment was stopped when no additional 
improvement occured in the last three months. 
Figure 1: Treatment algorithm 
a stable dose and absence of  any toxicity. More frequent monitoring was performed 
when indicated.
Dependent upon the severity of  side effects, treatment could be continued (in 
cases of  mild side effects); the dose of  MTX adjusted or temporarily discontinued/
withdrawn (moderate side effects); or stopped, in cases of  severe side effects, 
deﬁ ned as leukopenia (<2.5 mmol/l), increase of  liver enzymes (>2 times upper 
limit), increase in serum creatinine (>20 mmol/l) or in cases of  severe clinical 
adverse events, e.g. severe infection.
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3.2.4 Evaluation of  the outcomes
Effectiveness: Information on overall disease activity and function was retrieved 
from clinical expert team opinions documented in patients’ medical ﬁ les. If  there 
was missing data in the patient ﬁ les, then the patients were contacted and seen. 
The overall disease activity and function was assessed at the date when MTX was 
stopped and was noted as a semi-quantative score on a six-point treatment scale as 
follows: 
1 = excellent improvement, deﬁ ned as recovered 
2 = good improvement, deﬁ ned as nearly recovered, slight remaining problems 
3 = moderate improvement, deﬁ ned as some recovery, but clear remaining 
problems
4 = mild improvement, deﬁ ned as minor recovery, with evident remaining 
problems
5 = no improvement, deﬁ ned as no improvement in the disease activity/function
6 = worsening, deﬁ ned as a worsening of  the disease activity/function, 
i.e. worsening of  the sclerosis or function
Side effects were evaluated during each visit and were classiﬁ ed as general, 
gastrointestinal, dermatological, neurological, pulmonary, haematological or 
infections. Period of  remission was deﬁ ned as the time interval between stopping 
of  MTX after successful treatment and the censoring date of  1 January 2007 
(deﬁ ned as the end date for following up patients for this study). In addition time 
between restart of  MTX was deﬁ ned as the time between stopping of  MTX 
after successful treatment and the time of  restarting MTX due to a relapse of  the 
disease, deﬁ ned as an active, extensive and/or progressive sclerotic skin disease, as 
observed by the clinical expert team.  
3.2.5 Statistical analyses
Descriptive statistics were used to reproduce study results as percentages, medians 
and p10 and p90 (percentiles 10-90). A Mann-Whitney U and a Fisher exact test 
were used to compare treatment groups (two-sided tested). p < 0.05 was considered 
to be signiﬁ cant. Statistical analysis was performed using SPSS 14 software.
3.2.6 Results
In total 67 patients were included in the inception cohort. Nine patients were 
actively treated at January 1st 2007 and were ﬁ nally excluded from this study. The 
remaining 58 patients (18 males, 40 females, median age 40 (13-67 p10-p90) years), 
were evaluated in this study with January 1st 2007 as the censoring date (see 
ﬁ gure 2). Demographic data and diagnoses are shown in table 1. 
Four of  the 58 patients were contacted and seen in September 2007, due to missing 
data on their medical ﬁ les. These patients have been treated with one course MTX 
and are still in the remission state after discontinuation of  MTX. A statistically 
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Demographic data Total 
population
Group A Group A: 
Second 
course
Group A:     
Third 
course
Group B group B:  
Second 
course
Number 58 47 11 3 11 3
Female 40 34 8 2 6 2
Male 18 13 3 1 5 1
Median age till MTX  (P10-P90) 
in years
40 (13-67) 30 (13-65) 39 (16-74) 46 ± (24-57) 52 (27-74) 45 (16-57)
Median duration disease till start 
MTX ± (P10-P90) in months*
22 (7-120) 25 (9-122) 72 (36-87) 85 ± (70-98) 12 (6-31) 55 (54-72)
Diagnose
Scleredema diabeticorum 2 2 0 0 0 0
Eosinophilic fasciitis** 5 0 0 0 5 1
Localized morphea 9 7 2 1 2 1
Generalized morphea 27 25 4 0 2 0
Linear morphea 13 11 4 2 2 1
Scleromyxedema 2 2 1 0 0 0
* A statistical difference could be found in the duration of  sclerotic disease, patients treated with MTX+CS 
had signiﬁ cantly shorter disease durations.
** Statistical differences could also be found for those diagnosed with eosinophilic fasciitis, most of  whom 
were treated with MTX+CS.
Table 1: Demographic data study population (p10-p90 is referred to percentiles 10-90). 
Patients were treated with MTX (group A) or MTX+CS (group B)
Figure 2: Flow diagram with number of patients treated with MTX. For the two 
patients who stopped the MTX permanently, data were recorded as no clinical effect.
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signiﬁ cant difference could be found in the duration of  sclerotic disease at start 
MTX and for those diagnosed with eosinophilic fasciitis, of  whom most were 
treated with MTX+CS. Patients treated with MTX+CS had a signiﬁ cantly shorter 
disease duration. Five females died during follow up (after the MTX treatment was 
stopped), with no causal relationship to MTX. 
Figure 2 shows the different treatment groups that were analysed. These consist of:
Group A. MTX mono-therapy (n=47, 13 males, 34 females)
Encompassing scleredema diabeticorum (2), localized scleroderma (7), generalized 
morphea (25), linear morphea (11), and scleromyxedema (2). Previous treatment 
consisted of  topical steroids (15), non-steroid ointment (3), triamcinolon acetonide 
injection lesional (1), antibiotics (penicillin) (7), penicillamine (5), isotretinoin (3), 
azathioprine (1), antimalarials (4), and phototherapy (4). In 24 patients a remission 
could be achieved, and 11 (3 males, 8 females) of  the 14 patients who showed 
a relapse were treated for a second time with MTX mono-therapy (localized 
scleroderma (2), generalized morphea (4), linear morphea (4), and scleromyxedema 
(1). Six of  these patients again achieved a remission. One female with no clinical 
improvement died 10 years after termination of  MTX therapy.
Three (1 male, 2 females) patients with, localized scleroderma (1) and linear 
morphea (2) with only mild response, were treated for a third course with MTX as 
mono-therapy, and two of  them achieved a remission.
Three females died after MTX was stopped. The causes of  death were neither 
disease nor treatment related. In two patients no response to MTX was seen and 
one patient died 108 months after discontinuation of  MTX. No exacerbation 
of  skin sclerosis had occurred in this patient during follow up, and this case was 
recorded as remission status till death occurred (follow up till date of  death).
Group B. MTX and Corticosteroids (n=11, 5 males, 6 females): 
Encompassing eosinophilic fasciitis (5), localized scleroderma (2), generalized 
morphea (2) and linear morphea (2). A mean dosage of  17 mg CS (Prednisone) 
per day was given. Previous treatment, topical steroids (1) and antimalarial (1) had 
not resulted in sufﬁ cient improvement. Eight patients reached remission, and three 
(1 male, 2 females) patients had a relapse, encompassing eosinophilic fasciitis (1), 
localized scleroderma (1) and linear morphea (1). These patients were treated again 
with MTX (without CS), and 2 of  them again achieved a remission. One female 
died 92 months after stopping MTX+CS treatment; she was in a remission state till 
death occurred. Her cause of  death was neither disease nor treatment related.
Figure 3 and table 2 show the cumulative dosage of  MTX, duration of  treatment, 
effect of  MTX, time until restart, period of  remission and the side effects in the 
different treatment groups.
Duration of  sclerotic skin disease till start MTX: The median duration of  the disease, 
was 22 (7-120, percentiles 10-90) months, and the median disease duration of  
group A was, 25 (9-122, p10-p90) months and of  group B 12 (6-31, p10-p90) 
months (p=0.02). 
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Figure 3: Flow diagram as Figure 2. MTX=median cumulative dosage (p10-p90). 
Median duration of treatment is referred to in weeks (p10-p90).
Group A Group A
Second course
Group A 
Third course
Group B Group B 
Second course
Number n=47 % n=11 % n=3 % n=11 % n=3 %
Clinical results
Excellent improvement 6 13 0 0 0 0 1 9 0 0
Good improvement 24 51 7 64 2 67 8 73 2 67
Moderate improvement 4 9 2 18 1 33 0 0 0 0
Mild improvement 4 9 0 0 0 0 2 18 0 0
No improvement 9 19 2 18 0 0 0 0 1 33
Worsening 0 0 0 0 0 0 0 0 0 0
Side effects*
Gastrointestinal 20 43 4 36 1 33 4 36 0 0
Neurologic 3 6 0 0 0 0 0 0 0 0
Infectious 4 9 0 0 0 0 1 9 0 0
Pulmonary  0 0 0 0 0 0 0 0 0 0
Haematologic 3 6 0 0 0 0 2 18 0 0
General 7 15 2 18 1 33 2 18 0 0
Dermatologic 6 13 0 0 0 0 0 0 0 0
Remissionperiod 
Remissionstatus 24 51 6 1 2 67 8 73 2 67
Median follow up 
(months) ± P10-P90
55 14-91 41 3-106 21 6-35 58 8-100 19 9-29
Relapse 14 30 3 27 1 33 3 27 0 0
Median time between 
restart (months)
15 16 15
No effect 9 19 2 0 0 0 0 0 1 33
* Number of  side effects (a patient can have several side effects)
Table 2: Clinical results, side effects and period of remission and time between restart 
(in case of a relapse) of the different groups
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Cumulative dosage of  MTX: The patients who were treated with MTX+ CS received a 
signiﬁ cant higher median cumulative dose of  MTX (890 versus 545 mg, p=0.04). 
Patients who showed a relapse after one course of  MTX had received a lower 
median cumulative dose of  MTX in the ﬁ rst course (443 mg group A, 658 mg 
group B) compared to the patients who reached remission status (708 mg (A), 1070 
mg (B) p = not signiﬁ cant (n.s.)). 
Patients with a relapse after one course MTX+CS, received a relative low 
cumulative MTX dose to reach remission the second course (355 mg).
Weekly dosage of  MTX: No difference in the weekly median dose of  MTX could 
be found between patients who were treated with MTX and patients treated with 
MTX+CS (median dose of  15 mg MTX/week (10-22, p10-p90 (A) and 15-24, 
p10-p90 (B)).
No sigiﬁ cant difference in weekly median MTX dose could be found between the 
patients who reached the remission status and patients with a relapse after one 
course of  MTX or MTX+CS. 
Period of  treatment: The median period of  treatment MTX was 46 weeks, and of  
MTX+CS 77 weeks. 
Clinical effect: Clinical assessment revealed that 81% of  the patients who were 
treated with MTX and all patients treated with MTX+CS showed improvement of  
sclerotic skin. 
After two treatment courses MTX still showed beneﬁ t on clinical improvement 
in 82% of  the patients treated with MTX mono-therapy and 67% of  the patients 
treated ﬁ rst with the combination therapy. After three treatment courses, MTX 
showed beneﬁ t in all (n=3) patients. Start of  treatment in an early disease, seems to 
improve the therapeutic outcome. Three of  four patients with a pseudoscleroderma 
didn’t show any improvement during MTX treatment. No worsening of  the 
sclerosis or increase of  functional disability were seen during MTX treatment.
Time between restart: The median time between stop and restart of  MTX was 15 (2-
24, p10-p90) months in the 11 patients treated with a second course (A), and 16 
(10-54, p10-p90) months for the remaining 3 patients ﬁ nally treated with a third 
course, and 15 (6-22, p10-p90) months for patients of  group B.
Period of  remission: After one treatment course of  MTX more than half  of  the 
patients (51%) treated with a MTX (A) and 73% of  the patients with MTX+CS 
(B) reached remission status with a median follow up time of  55 (14-91, p10-p90) 
and 58 (8-100, P10-P90) months, not being statistically signiﬁ cantly different. After 
two courses of  MTX, 55% of  the patients treated with mono-therapy and 67% of  
patients treated with combination therapy reached remission status with a median 
time of  follow up of  (A) 41 (3-106, p10-p90) and (B) 19 (9-29, p10-p90) months. 
After 3 treatment courses of  MTX mono-therapy 67% reached a remission status 
with a median follow up time of  21 (6-35, p10-p90) months.
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In total 68% treated with MTX and 91% of  the patients treated with MTX +CS 
reached remission status.
Side effects: No life threatening side effects occurred. Side effects occurred in 62% 
and 45% of  patients treated with MTX and MTX+CS respectively. MTX treatment 
had to be discontinued in 6 patients (MTX (5), MTX+CS (1) due to severe side 
effects, encompassing infections (2), gastrointestinal side effects (2), and elevated 
liver enzymes (2). MTX could be restarted in four of  these 6 patients, without any 
recurrence of  side effects. 
3.2.7 Discussion
This study is the largest published for a series of  patients with sclerotic skin 
diseases treated with MTX. The patients in this study had a relatively long disease 
duration of  22 (7-120, p10-p90) months before MTX was started. Both treatment 
strategies (MTX and MTX+CS) were effective. No difference in median weekly 
MTX dose could be found between both treatment strategies. Also no difference 
in median weekly MTX dose could be found between patients who showed a 
remission after one course of  MTX or MTX+CS and patients with a relapse after 
one course of  MTX or MTX+CS. 
Patients with a relapse after discontinuation of  MTX, still responded to a second 
course of  MTX and even to a third course of  MTX. Patients who showed a relapse 
had received a lower cumulative dose of  MTX in the ﬁ rst course (443 mg group 
A, 658 mg group B) compared to the patients who reached remission status (708 
mg (A), 1070 mg (B), p=not signiﬁ cant), suggesting a role for the total cumulative 
MTX dose in achieving deﬁ nitive remission.
The median duration of  treatment was 46 and 77 weeks for MTX and MTX+CS, 
respectively. The dose of  MTX was signiﬁ cantly higher in the MTX+CS group 
(p=0.04), however, both groups were not identical, due to actual differences 
by indication based on disease severity and disease duration. Patients with an 
eosinophilic fasciitis were treated with MTX+CS. In these patients corticosteroids 
were added because the extent and speed of  progression required a fast response 
to therapy. In one course of  treatment 81% of  the patients treated with a mono-
therapy and 100% of  the patients treated with a combination therapy showed 
improvement of  the sclerotic skin, although the latter group was small. 
Fifty-one percent of  the patients treated with MTX and 73% of  the patients 
treated MTX+CS reached remission after one treatment course. Sixty-two percent 
of  the patients treated in the ﬁ rst course with MTX experienced side effects in 
contrast to 45% of  the patients treated with MTX+CS. 
The cumulative dose of  MTX was higher in the MTX+CS group, due to a longer 
period of  treatment. These patients, showed a good response to therapy, and better 
clinical scores were found, however, no deﬁ nite conclusions could be drawn, due to 
small sample sizes. 
Additionally, patients with a relapse after one treatment course seemed to have 
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longer disease duration of  the sclerotic disease, though not statistically signiﬁ cant. 
Gender, age or diagnosis seems not to play a role in likelihood of  a relapse. 
MTX proved to be effective in most of  the patients with a sclerotic skin disease. 
Especially patients with localized scleroderma responded well, MTX showed 
beneﬁ t in just one of  four patients with a pseudoscleroderma (scleromyxedema). 
A possible explanation of  the therapeutic way of  action in sclerotic skin 
diseases14-17 is that MTX interferes with several processes involved in the immune 
system. Increased levels of  soluble IL-2 receptors are present and likely reﬂ ect 
active disease in localized scleroderma. MTX has been shown to reduce these IL-2 
receptors, as well as to decrease circulating IL-2, IL-6 and IL-8. 
Limitations of  this study are the absence of  a control group. Large cohort 
trials assessing effectiveness of  MTX will probably be sparse, because of  the 
heterogeneous character of  sclerotic skin diseases and their relative low incidence. 
Another limitation is that both treatment strategies (MTX or MTX+CS) were not 
randomly assigned. In this study no differences between weekly median dose of  
MTX could be found between the patients who reached the remission status and 
patients with a relapse after one course of  MTX or MTX+CS. An unanswered 
question remains as to whether or not patients with a sclerotic skin disease treated 
with high weekly dose of  MTX given in a short time show better clinical outcomes 
compared to those treated with a low weekly dose of  MTX for a longer period.
The results of  this inception cohort study reﬂ ect treatment strategies in daily 
clinical practice. Spontaneous remission of  cutaneous sclerosis can occur, 
however, this is more unlikely in this group. Moreover, when interpreting this 
information, it is important to realize that the patients had relatively long disease 
durations before MTX was started. Treatment occurred, in case of  an active, 
extensive and/or progressive sclerotic skin disease, or lesions that could lead to a 
loss of  function. Many patients noticed improvement of  the sclerosis (function 
or decrease in disease activity) on the second three months of  treatment, which 
makes spontaneous remission or remission due to corticosteroid effect alone, more 
unlikely. Besides this, 29% of  all patients (n=17) had a relapse, suggesting that no 
spontaneous remission occurred in these patients.
In this large inception cohort, MTX showed to be beneﬁ cial in the ﬁ rst course in 
patients with various sclerotic skin diseases, and in patients with a relapse still was 
beneﬁ cial in a second and even a third course of  MTX. Future research would 
be worthwhile to study larger groups of  sclerotic skin diseases. This investigation 
should have been performed, using validated assessments for efﬁ cacy, such as the 
modiﬁ ed skin score according to Zachariae,18,19 durometerscores,18 quality of  life 
scores or ultrasound measurements of  skin thickness.20 Unfortunately, in 1994 no 
validated scoring system for localized scleroderma existed. Hence a semi-quantative 
score was used.25 
The results of  this large cohort study show that MTX is an effective treatment for 
various sclerotic skin diseases, even in patients with a long history of  the hardening 
of  the skin. Side effects were mild. A long period of  remission was achieved in the 
majority of  patients, and restart of  treatment was effective. 
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3.3  ULTRAVIOLET A-1 PHOTOTHERAPY FOR 
 SCLEROTIC SKIN DISEASES, A SYSTEMATIC REVIEW 
3.3.1 Abstract
Background: UVA-1 phototherapy is now available for a variety of  skin diseases. 
Increasingly since 1995, there have been investigations on the effectiveness of  
UVA-1 (340-400 nm) therapy on sclerotic skin diseases. Most studies undertaken 
treated patients suffering from localized scleroderma, but UVA-1 phototherapy is 
nowadays also used for other sclerotic skin diseases. 
Objective: To assess the effectiveness, biological effects and side effects of  UVA-1 
in a variety of  sclerotic skin diseases (localized scleroderma, eosinophilic fasciitis, 
chronic graft-versus-host disease, lichen sclerosus et atrophicus, scleredema 
adultorum, necrobiosis lipoidica, POEMS disease, pansclerotic porphyria cutanea 
tarda and drug-induced scleroderma-like disorders). 
Methods: The authors searched for publications dated between January 1996 and 
November 2007 in the computerized bibliographic database Pub Med. The Pub 
Med was searched using MeSH terms as well as open searches to retrieve the latest 
reports. 
Results: The evidence based on research on these skin diseases and full spectrum 
UVA (320-400 nm) and UVA-1 is still growing, and appears promising. Up to the 
present, good results are shown for all different doses (LD/MD/HD) UVA-1 
and UVA. There is insufﬁ cient data regarding use of  HD UVA-1 and comparative 
studies to make a clear assessment regarding the superiority of  LD, MD or 
HD UVA-1 therapy. Due to a limited availability of  randomized controlled trials 
and large cohort studies, it is difﬁ cult to draw ﬁ rm conclusions on the long-term 
efﬁ cacy, optimum dose and best treatment regimens for UVA-1 therapy in treating 
sclerotic skin disorders. Although UVA-1 has various effects on, e.g. ﬁ broblasts and 
inﬂ ammatory cells, the precise action remians obscure. 
The main short term side effects of  UVA-1 therapy are erythema, pruritus, xerosis 
cutis, tanning, and recrudescence of  a herpes simplex infection. More studies 
are warranted to investigate the potential long-term risk of  photo-aging and skin 
cancer. At present UVA-1 is regarded as being less carcinogenic than PUVA.
Conclusions: Full spectrum UVA and UVA-1 phototherapy seem effective in the 
treatment of  sclerotic skin diseases based on the data retrieved from literature. 
With regard to UVA-1: UVA-1 treatment can shorten the active period of  localized 
scleroderma and pseudoscleroderma and prevent further disease progression, 
including contractures. Further investigations will be needed to determine more 
biological effects of  UVA-1. Although long-term side effects are not yet available, 
UVA-1 might develop into a promising beneﬁ cial and well-tolerated treatment in 
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the poor therapeutic armentarium of  sclerotic skin diseases. Long-term studies in 
large groups of  patients are clearly needed.
3.3.2 Introduction
Phototherapy has been used in medicine for a long period of  time; it also plays an 
important role in modern dermatology. The solar spectrum consists of  infrared, 
UV and visible light. Between 3%-7% of  the solar radiation energy that reaches the 
earth is UV radiation and consists of  UVB and UVA. Ultraviolet B (UVB, 290-320 
nm) is the most destructive form of  UV radiation, because it has enough energy to 
cause photochemical damage to cellular DNA. UVA (320-400 nm) is about 1,000 
times less damaging to the skin than UVB as measured by sunburn or damage to 
cell DNA. UVA penetrates deeper into the skin. 
Ultraviolet A-1 (UVA-1) is that part of  the UV spectrum which emits photons with 
a wavelength of  340-400 nm and was ﬁ rst described by Mutzhas in 1981.1 Longer 
wave-lengths in the UVA region have the capacity to reach the deeper layers of  the 
dermis and possibly the sub cutis. At present, there are two main UVA-1 sources, 
namely ﬂ uorescent lamp and metal halide. The ﬂ uorescent lamp cubicles only allow 
low dose (LD) (10-30 J/cm²) or moderate/medium dose (MD) (40-70 J/cm²). The 
high output, high dose (HD) metal halide sources allow up to 130 J/cm².2 Another 
classiﬁ cation is based on the administered cumulative dose. High dose is then 
deﬁ ned as a cumulative dose of  975-1840 J/cm², medium dose as a cumulative 
dose of  300-975 J/cm² and ﬁ nally low dose as a cumulative dose of  300 J/cm² or 
lower. 
Different types of  UVA-1 phototherapy were introduced as innovative and 
promising therapeutic options for inﬂ ammatory diseases such as atopic dermatitis.3 
Since then, it has shown promising results for a variety of  indications. 
Encouraged by the clinical success and the diversity of  immunomodulatory 
effects achieved by the use of  UVA-1 therapeutic regimens in a wide variety of  
indications, further studies focused on the effectiveness of  UVA-1 phototherapy in 
the treatment of  sclerotic skin diseases. The ﬁ rst report describing the use of  UVA-
1 irradiation to treat localized scleroderma was published by Kerscher in 19954 
and has since then been followed by case reports and studies indicating effective 
treatment of  sclerotic skin diseases using UVA-1.
The scleroderma skin disorders comprise a heterogeneous group of  conditions 
linked by the presence of  sclerotic skin lesions. It can manifest itself  as a small 
indurated plaque to conditions that may cause signiﬁ cant functional and cosmetic 
deformity, with a variety of  extracutaneous features.5 Localized scleroderma is 
a primary cutaneous sclerosis. Examples of  localized scleroderma are plaque 
morphea, linear morphea or deep morphea.6 Scleroderma-like disorders, also called 
secondary cutaneous sclerosis or pseudoscleroderma, are disparate conditions 
mimicking cutaneous localized sclerosis e.g. chronic sclerodermic graft-versus-host 
disease, drug-induced scleroderma-like disorders and mucinosis such as scleredema 
of  Buschke/adultorum and scleromyxedema.7
Therapeutic options for sclerotic skin diseases include topical treatments, 
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e.g. topical steroids8 or vitamin D analogues,8 vitamin E,9 imiquimod10,11 
and systemic treatments e.g. corticosteroids,12 vitamin D analogues,13,14 
ciclosporin,15 d-penicillamin, penicillin G,16,17 extracorporeal photopheresis,18 
methotrexate,19,20 interferon-gamma,21 anti-malarial drugs,22 sulfasalazine23 and 
(P)UVA.24
This review describes the biological effects, side effects and therapeutic use of  
UVA-1 in localized scleroderma, eosinophilic fasciitis and pseudoscleroderma.
3.3.3 Methods
The focus for attention was the use of  UVA-1 (340-400 nm) phototherapy in 
patients with sclerotic skin diseases. Moreover, the use of  full spectrum UVA 
(320-400 nm) in localized scleroderma has also been evaluated. 
Exclusion criteria: The use of  Psoralen-UVA (Psoralen with 320-400 nm UVA) is 
not included in this review and neither is systemic sclerosis/scleroderma (diffuse or 
limited).
The authors searched for publications dated between January 1996 and November 
2007 in the computerized bibliographic database Pub Med. 
Reference lists of  these articles were further retrieved from relevant English, 
Dutch or German original papers, case reports, studies, reviews, letters or articles 
in books. The key terms used were: ultraviolet phototherapy, phototherapy, long 
wave therapy, UVA, UV-A, UVA phototherapy, UVA-1, UVA1, UV-A1, Ultraviolet 
A1, Ultraviolet A, sclerotic, sclerosis, sclerosus, sclerodermic, scleroting, localized 
scleroderma, scleroderma, morphea, morphoea, pseudosclerosis, scleroderma 
like, secondary sclerosis, scleredema diabeticorum, scleredema of  Buschke, 
scleredema adultorum, Graft versus Host, GVHD, lichen sclerosis, lichen sclerosus, 
eosinophilic fasciitis, Shulman disease, pansclerotic, POEMS, medication induced 
scleroderma, mucinosis and necrobiosis lipoidica. The Pub Med was searched using 
MeSH terms as well as open searches to retrieve the latest reports. 
In this review the classiﬁ cation LD, MD or HD is based on the administered dose 
per session. LD UVA-1 is deﬁ ned as a single dose of  10-30 J/cm² per session. 
MD as a single dose of  >30-70 J/cm² and ﬁ nally HD UVA-1 as a single dose of  
>70-130 J/cm².
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3.3.4 Results
UVA-1 in localized scleroderma
The classiﬁ cation of  localized scleroderma according to Peterson et al.6 is based on 
ﬁ ve general types: plaque morphea, generalized morphea, bullous morphea, linear 
morphea and deep morphea. Plaque morphea involves the dermis and is described 
as one or two circumscript patches of  sclerotic skin in two or less anatomic sites. 
Generally, this type of  morphea is located on the trunk.25 Plaque morphea has 
a number ofvariants: guttate, keloidal, atrophoderma of  Pasini and Pierini and 
a plaque morphea, which overlap with lichen sclerosis et atrophicus. Bullous 
morphea presents as tense sub-epidermal bullae in the plaque.6 Generalized 
morphea presents with multiple plaques that affect more than three sites of  the 
body or the individual plaques that become more conﬂ uent. It can progress and 
involve widespread areas of  the body. The multiple plaques eventually become 
indurated and hyperpigmented. 
Linear morphea presents as a single, linear and unilateral band, which involves the 
dermis, and subcutaneous tissue and it may extend to the muscle and bone. Usually 
the localization of  the lesion is an extremity. Linear morphea that affects the face 
or scalp is called ‘coup de sabre’.6 
In addition, eosinophilic fasciitis can be separately distinguished. Table 1 shows 
per study the form of  UVA-1 or UVA, number of  patients, dose, cumulative dose, 
number of  treatments and the evaluation of  outcomes.
Randomized controlled trials
One randomized controlled trial was performed by Kreuter et al.26 in 2006. Sixty 
four patients with localized scleroderma were randomly allocated to three groups 
receiving LD /MD UVA-1 or narrowband UVB phototherapy (NB UVB). Skin 
status (or modiﬁ ed skin score) signiﬁ cantly improved in all three groups, although 
MD UVA-1 seemed to be more effective than NB UVB. There were no signiﬁ cant 
differences between LD and MD UVA-1. Furthermore there was no signiﬁ cant 
difference between LD UVA-1 and NB UVB. The authors suggested that the study 
size (LD UVA-1 n=27, MD UVA-1 n=18, NB UVB n=19) was too small to imply 
signiﬁ cance on this point. The reduction of  the clinical score was accompanied 
by an improvement of  the Visual Analog Scale (VAS) for itching and tightness, 
histological score and skin thickness measured by 20 MHZ ultrasound. Only MD 
UVA-1 showed a signiﬁ cant decrease of  the VAS for tightness and itching, whereas 
LD UVA-1 and NB UVB only showed a signiﬁ cant decrease of  tightness of  the 
sclerotic skin. 
Open studies
Most studies performed were open non-randomized clinical trials. Stege et al.27 
found that HD UVA-1 therapy was superior to LD UVA-1 therapy in patients with 
localized scleroderma in, decreasing thickness of  the sclerotic skin, softening of  
the lesions (palpation) and improving elasticity. Several other studies showed that 
using LD UVA-1 in different treatment regimens was able to produce a remarkably 
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good clinical response in patients with localized scleroderma.4,26-30 An open 
study showed a decrease of  clinical assessment of  induration and a signiﬁ cant 
improvement of  elasticity after MD UVA-1 irradiation.31 So far, LD, MD as well 
as HD UVA-1 phototherapy seem to be effective in the treatment of  localized 
scleroderma. Kreuter et al.32 treated 19 children with LD UVA-1 and calcipotriol 
ointment. All patients showed softening of  the sclerosis, ultrasound showed a 
decreased dermal thickness. El-Mofty et al.33 performed an open study in 2000, 
whereby 12 patients with morphea were treated with 320-400 nm UVA. All patients 
showed signiﬁ cant softening of  the sclerosis in this intra-individual controlled 
study. The covered plaques show no signiﬁ cant reduction of  the concentrate 
collagen per surface area, measured by an image analyzer. Two more studies 
performed by El-Mofty et al. showed a remarkable softening of  the sclerosis using 
320-400 nm UVA in different treatment regimes.34,35
Case reports
Four patients with morphea were treated with broadband UVA (320-400 nm 
UVA). In three patients, the skin thickness of  the sclerotic lesions improved, 
whereas in the other patients no improvement occurred.36 Ten patients with 
localized scleroderma (morphea n=7, pansclerotic localized scleroderma n=2, 
overlap morphea and extragenital lichen sclerosis n=1) were described in 5 case 
studies.28,36-39 Six patients (morphea n=3, pansclerotic localized scleroderma 
n=2, overlap morphea and extragenital lichen sclerosis n=1) were treated with 
LD UVA-1 phototherapy, with good clinical responses, e.g. resolving of  sclerotic 
plaques.28,37-39
UVA-1 in eosinophilic fasciitis
Eosinophilic fasciitis (also called Shulman’s syndrome or diffuse fasciitis with 
eosinophilia) is an uncommon disorder of  unknown aetiology, characterized in 
its early phase by limb or trunk erythema and oedema, and later by collagenous 
thickening of  the dermis and subcutaneous fascia. Eosinophilia is often a 
prominent laboratory ﬁ nding. One case report written by Breuckmann et al. in 
2001,40 showed beneﬁ cial effect of  UVA-1 photoherapy in one patient with 
eosinophilic fasciitis, unfortunately there was no additional information on what 
was precisely meant by ‘beneﬁ cial effect’. 
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Therapy 
Localized 
scleroderma
Number  
of  
patients
Dose      
(J/cm²)
Cumulative 
dose 
(J/cm²)
Number 
of  
treatments
Evalution 
of  
outcomes
MD UVA-1               
versus LD UVA-1                    
and NB-UVB                 
MD UVA-1
LD UVA-1
NB UVB
18
27
19
50
20
different
2000
800
different
40
40
40
C, VAS, H, U
LD UVA-1 10 20 480 24 C, H, U
LD UVA-1                         20 20 600 30 C, H, U
UVA                   12 20 400 20 C, H
Different low doses                 
of   UVA  
16
21
26
5
10
20
100
200
400
20
20
20
C, H
LD UVA-1                       5 20 480 24 C, H, ISH, IHC
UVA               12
9
20
10
400
200
20
20
C, PCR
LD UVA-1                 7 30 900 30 C, H
MD UVA-1                 8 48 960 20 C, E, FFT
HD UVA-1               
versus LD UVA-1             
HD UVA-1
LD UVA-1
10
7
130
20
3900
600
30
30
C, U, PCR 
(only 4 of  10 patients treated 
with HD UVA-1)
LD UVA-1 19        
children
20 800 40 C, U 
(just 4 patients)
LD UVA-1                         1 20 600 30 C
LD UVA-1                        1 20 640 32 C, H, U
LD UVA-1                         2
1
20
20
600
660
30
32
C, H
C, H
LD UVA-1 1 20 480 24 C
UVA             1 15-20 900-1200 60 C, H
1 15-20 450-600 30 H
1 15-20 450-600 30 H
1 15-20 600-800 40 H
C=clinical criteria, H=histopathology, U=ultrasound, E=elastometry/cutometry, ISH=immunochemistry, 
ISH=in situ hybridisation, VAS=visual analog scale, PCR=polymerase chain reaction, FFT=fast Fourier transform method
Table 1: UVA-1 phototherapy in localized scleroderma 
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Results Author, year 
of  publication 
(reference 
number)
Skin status signiﬁ cantly improved in all patients, resulting in a signﬁ cant reduction in clinical score. MD 
UVA-1 was signiﬁ cant more effective than NB-UVB. No signiﬁ cant difference could be found between MD 
UVA-1 and LD UVA-1.VAS for tightness and itching signiﬁ cantly decreased in MD UVA-1, whereas the VAS 
tightness decreased in LD UVA-1 and NB-UVB. The histological score (decreased thickness, decreased elastic 
ﬁ bers, decreased inﬁ ltrate) was only signiﬁ cant for NB-UVB. Ultrasound: Corium thickness was signiﬁ cantly 
decreased after MD UVA-1 treatment.
Kreuter et al., 
2006 (26)
After 24 treatments, more than 80% of  lesions were completely cleared, ultrasound and histopathology 
revealed a nearly normal skin thickness.
Kerscher et al., 
1995 (4)
After 24 sessions more than 80% of  lesions were completely cleared (clinical improvement), ultrasound 
revealed normal skin thickness. Histopathologically, the structure of  dermal collagen returned to normal 
human dermis.
Kerscher et al., 
1998 (29)
Intraindividual control study: In all patients remarkable softening of  the sclerosis, signiﬁ cant reduction of  
mean concentrate of  collagen per surface area in exposed plaques were detected also the thickness of  dermis 
was reduced. The covered plaques, shows no signiﬁ cant reduction of  the concentrate collagen per surface 
area.
El-Mofty et al., 
2000 (33)
All three groups showed remarkably softening of  lesions. There was no signiﬁ cant difference in the session 
number of  ﬁ rst seen improvement or the degree of  softening. Late, ﬁ brotic white plaques showed fair to poor 
responses, whereas early indurated lesions responded well. Collagen bundles appeared thinner in the 10 and 
20 J/cm2 group, but no signiﬁ cant difference could be found between the three groups in this point. 
El-Mofty et al., 
2004 (35)
In 3 of  5 patients complete clearance after UVA-1 was found. Two of  5 patients noticed a softening of  
sclerotic plaques. In all patients increased expression of  collagenase in ﬁ broblasts after irradiation was found 
with nearly normal dermal collagen thickness.
Gruss et al., 
1997 (28)
In 18 patients remarkebly softening of  lesions was noticed. Signiﬁ cant decrease in histopathological sections 
of  collagen I, III and TGF-β, and an increase in collagenase and IFN-γ (signifcant higher in the group 
receiving 20 J/cm2). The relative increase was greatest in collagenase, IFN-γ and TGF-β.  No signiﬁ cant 
difference between the two groups in clinical response.
El-Mofty et al., 
2004 (34)
All 7 patients noticed a decrease of  induration and 1 of  7 patients noticed an increased mobility of  the elbow. 
A signiﬁ cant increase of  CD34+ cells was found. Atrophic lesions remained unchanged.
Camacho et al, 
2001 (30)
Intraindividual control study: All patients showed softening of  affected areas and improved elasticity of  the 
skin measured by a cutometer. After 12 weeks, 7 weeks after the therapy, the improved elasticity did not last 
and was the same as before therapy. The FFT technique did not reveal a change in bundle orientation ratio or 
bundle spacing.
De Rie et al., 
2003 (31)
5 of  10 patients: intraindividual control: HD UVA-1: all patients showed softening of  lesions, 4 of  10 patiens 
showed complete clearance and 1 patient revealed improved joint mobility, skin thickness and skin elasticity 
signiﬁ cantly improved. These changes could not be detected in unirradiated control plaques. LD UVA-1: 2 of  
7 patients showed a reduction and softening of  lesions, no patients showed complete clearance. HD UVA-1 
was superior to LD UVA-1 for all factors examined.
Stege et al., 
1997 (27)
LD UVA-1 and Calcipotriol Ointment: All patients showed softening and repigmentation of  sclerotic lesions, 
ultrasound showed decreased dermal thickness. UVA-1 therapy increased collagenase expression about 20-
fold. No control group of  UVA-1 only.
Kreuter et al. 
2001 (32)
Morphea of  eyelid lesion softened, eye lid retraction resolved. Steger and 
Matthews, 
1999 (38)
Resolution of  lesions, healing of  limb ulcer and improvement of  joint mobility. Overall thickness of  the 
dermis was signiﬁ cantly less than before treatment.
Gruss et al., 
1997 (28)
All patients showed complete clearance, of  whom one with non-active lesions. Dermal thickness was 
signiﬁ cantly less. Patient with overlying LSA, complete clearance after therapy, histopathological changes of  
sclerosis disappeared.                       
Gruss et al., 
2001 (37)
Softening of  the skin and repigmentation. Yildirim et al., 
2003 (39)
Dermal thickness decreased from 1.9 to 1.1 mm and skin became thinner and softer. Oikarinen and 
Knuutinen, 
2001 (36)
Dermal thickness decreased from 1.8 to 1.4 mm.
Dermal thickness decreased from 1.7 to 1.4 mm.
No improvement.
Chapter 3 - Treatment options of  sclerotic skin diseases
100
UVA-1 in pseudoscleroderma 
Secondary cutaneous sclerosis, also called pseudoscleroderma, consists of  a wide 
range of  conditions. Examples of  a pseudoscleroderma are: chronic graft-versus-
host disease, drug-induced scleroderma-like disorders, traumatic scleroderma (e.g. 
burns), POEMS, metabolic disorders, genetic disorders, malignancies, radiation 
exposure, post-infection scleroderma, scleredema of  Buschke/adultorum and 
scleromyxedema.7,41 Table 2 gives a summary of  publications covering UVA-1 
phototherapy in pseudoscleroderma.
Extragenital lichen sclerosus/sclerosis (et atrophicus)
Lichen sclerosis (LSA) refers to a chronic, progressive dermatologic condition 
characterized by epithelial thinning, marked inﬂ ammation, and sclerotic dermal 
changes accompanied by symptoms of  pruritus and pain. Lichen sclerosis is a 
chronic inﬂ ammatory skin disorder that typically affects the vulva (or penis) and 
anus. In 15-20 % of  patients,42 lichen sclerosis is seen on other parts of  the body, 
especially the upper body, breasts, and upper arms (extragenital LSA). LSA is often 
resistant to local and systemic therapy.43 UVA-1 has been used in a limited number 
of  patients with extragenital LSA. The ﬁ rst case reports were described by Kreuter 
et al.32 in 2001. Two patients, resistant to previously used systemic and local 
therapy, were treated with LD UVA-1 for ten weeks. After 800 J/cm², the sclerotic 
skin lesions had almost completely cleared in both patients. In addition, ultrasound 
and histological specimens revealed no further signs of  sclerosis. One year later, 
Kreuter et al.44 performed an open study treating ten patients having extragenital 
LSA with LD UVA-1 therapy. All patients reported a remarkable softening and 
repigmentation of  the affected area. Moreover, a signiﬁ cant decrease of  skin 
thickness, as measured by ultrasound, was shown. Beattie et al. decribes seven 
patients treated with different doses UVA-1. Five patients improved with therapy. 
Three obtained moderate improvement and two had minimal improvement.45
Sclerodermic GVHD
Graft-versus-host disease (GVHD) is a complication of  hematopoietic cell 
transplantation. Approximately 10% of  patients suffering from chronic graft-
versus-host disease develop sclerodermic graft-versus-host disease of  the skin. The 
lesions on the skin resemble a cutaneous manifestation of  scleroderma.46 
In 2000, Grundmann-Kollmann et al.47 described a patient with chronic 
sclerodermic GVHD, resistant to chemotherapy. LD UVA-1 phototherapy 
was performed for six weeks in a cumulative dose of  600 J/cm² combined 
with mycophenolate mofetil therapy. All sclerotic lesions regressed following a 
cumulative dose of  240 J/cm². Histopathological examination revealed a reduction 
of  cellular inﬁ ltrate and sclerotic changes. Ultrasound revealed near normal values 
for skin thickness. In 2005, Wetzig et al.48 investigated the effectiveness of  
MD UVA-1 phototherapy in 10 patients with GVHD (lichenoid GVHD n=7, 
sclerodermic GVHD n=3). Two of  these three sclerodermic GVHD patients 
showed complete clearance and one an improvement of  affected area. Ständer 
et al.49 treated 5 patients with MD UVA-1 and 1 child with LD UVA-1 in 
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combination with various immunosuppressives. All patients showed softening of  
lesions and improved joint mobility. 
Calzavara Pinton et al.50 described 5 patients treated with MD UVA-1 therapy 
leading to complete resolution in three patients and partial improvement of  lesions 
in the other two patients. 
Scleredema: 
Scleredema (adultorum) is an uncommon condition with unknown 
pathophysiology. It is characterized by non-pitting induration of  the skin with 
occasional erythema.51 The aetiology is unknown.
Scleredema can be categorized into 3 subgroups: 
Type I: also called the classic type described by Buschke• 52 in 1902: These 
patients have a preceding febrile illness. The lesions disappear in several 
months to 2 years. This type makes up about 55% of  the cases of  scleredema 
adultorum.51 
Type II: These patients do not have a history of  infection or diabetes. This type • 
tends to follow a slow progressive course. The lesions that have been formed 
persist. Type II makes up about 25% of  patients.51
 Type III has been termed scleredema diabeticorum. This type is a slowly • 
progressive, non-resolving scleredema that occurs in diabetic patients. This 
type makes up about 20% of  cases.51 In this subgroup there is a predominance 
of  male patients. The pathogenetic mechanism of  the indurated skin has not 
yet been identiﬁ ed. The postulated mechanism is that hyperglycaemia leads to 
glycolisation of  the collagen.53
In 2004, the ﬁ rst case report of  successful UVA-1 therapy of  two scleredema 
patients was published, one patient had type II scleredema and the other had 
scleredema diabeticorum (scleredema of  Buschke type III).54 LD UVA-1 was used 
in both cases and all lesions were clinically resolved. Research has so far revealed 
successful UVA-1 treatment in six more scleredema patients.55,56 Eberlein-Konig 
et al.55 described a case report regarding scleredema adultorum with promising 
results after MD UVA-1 (50 J/cm²). Signiﬁ cant reduction in the degree of  skin 
thickness, a softening of  the skin and a marked improvement of  joint mobility was 
found. Moreover, ultrasound examination showed a signiﬁ cant decrease in skin 
thickness and density.
The other 5 cases were retrieved during a retrospective analysis of  92 patients with 
different diagnoses treated with UVA-1 in the United States of  America.56 All 5 
patients had scleredema adultorum. Four patients showed good clinical responses, 
whereas 1 patient dropped out after side effects (polymorphic light eruption, 
PMLE).
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Therapy Number of  
patients
Dose 
(J/cm²)
Cumulative 
dose 
(J/cm²)
Number of  
treatments
Evalution of  outcomes
LSA
LD UVA-1 2 20 800 40 C, H, U
LD, MD and HD 
UVA-1
7 different 192-2212 different C
LD UVA-1 10 20 800 40 C, H, U
GvHD
MD UVA-1 5 50 750-1650 15-33 C
MD UVA-1  5 50 1500 30 C
LD UVA-1 1 child 20 600 30 C
MD UVA-1 3 60 1800 30 C
LD UVA-1 1 20 600 30 C, H, U
Scleredema
LD UVA-1 1 20 600 30 C
1 with DM 10-20 560-1120 56 C
MD UVA-1 1 with DM 50 1750 35 C, U
MD/LD UVA-1 5 with DM unknown unknown unknown C
Necrobiosis
UVA-1 1 18,8 max dose 134 16 C
UVA-1 1 117,4 max dose 2056 15 C
UVA-1 1 55,2 1183 29 C
UVA-1 1 88,2 1673 51 C
UVA-1 1 15,4 90 15 C
UVA-1 1 26,6 486 24 C
Bleomycin
LD UVA-1 1 20 C
Pansclerotic PCT
MD UVA-1 1 40 1200 30 C
POEMS
LD UVA-1 1 30 1050 35 C
C=clinical criteria, H=histopathology, U=ultrasound, E=elastometry/cutometry, ISH=immunochemistry, 
ISH=in situ hybridisation, VAS=visual analog scale, PCR=polymerase chain reaction, FFT=fast Fourier transform method, 
DM=diabetes mellitus.
Table 2: UVA-1 phototherapy in pseudoscleroderma
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Results Author, year of  publication 
(reference-number)
Both patients showed almost complete clearance of  lesions. Ultrasound revealed a reduced 
dermal thickness, and histopathology revealed an almost normal collagen structure.
Kreuter et al., 2001 (32)
Five patients improved with therapy, three moderate, two minimal improvement. One relapsed 
within 3 months, another after 1 year.
Beattie et al., 2006 (45)
All patients showed remarkable softening and repigmentation of  the affected area. Ultrasound 
revealed a reduced dermal thickness and histopathology revealed a nearly normal collagen 
structure.
Kreuter et al., 2002 (44)
3 patients showed complete clearance of  lesions and two patients partial clearance (one patient 
with a severe generalized sclerodermoid involvement had softening of  the skin of  the trunk 
and face, while lesions on the limbs did not respond). Two patients showed relapse after 5 
months. 
Calzavara Pinton et al.,                          
2003 (50)
UVA-1 combined with various immunosuppressants: All patients showed softening of  skin 
lesions and improved joint mobility.
Ständer et al., 2002 (49)
Two patients showed a complete clearance of  lesions and one showed an improvement (skin 
involvement still not reduced to less than 25 percent of  affected area before treatment).
Wetzig et al., 2005 (48)
LD UVA-1 combined with mycofenolate mofetil: Sclerotic lesions regressed, joint mobility 
improved and ultrasound showed nearly normal skin thickness. Histologic examination 
showed reduction of  sclerotic changes.
Grundmann-Kollmann et al.,         
2000 (47)
Complete resolution after 30 treatments untill 16 months after therapy. Janiga et al., 2004 (54)
Complete resolution after 56 treatments untill 4 months after therapy.
Softening of  skin, improved mobility and ultrasound showed a reduction of  dermal thickness. Eberlein-Konig et al., 2005 (55)
One patient dropped out in connection with developing pruritic papules consistent with 
PMLE, other patients showed a moderate-good response. One patient had a relapse 15 
months after therapy.
Tuchinda et al., 2006 (56)
Minimal improvement. Beattie et al., 2006 (58)
Minimal improvement.
Resolved.
Minimal improvement.
Moderate improvement.
Moderate improvement.
Initially some improvement, treatment was temporary stopped. After resuming UVA-1 
therapy, no further improvement could be achieved.
Behrens et al., 1998 (59)
Clinical improvement. Karamﬁ lov et al., 2003 (60)
Clinical improvement. Schaller et al., 2001 (61)
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Necrobiosis lipoidica
Necrobiosis lipoidica (NL) is a skin disease that most often affects the shins. 
Typically several indurated shiny red-brown plaques appear. The centres may 
become yellowish and atrophic and may develop open sores that are slow to 
heal.57 NL may belong to the family of  the pseudoscleroderma skin diseases. 
One report58 documented six patients with NL on the shins, unresponsive to 
topical corticosteroids, UVB, and PUVA therapy. All reported patients were treated 
with different doses of  UVA-1 (total dose range 90-2056 J/cm²). NL completely 
resolved in one patient. Two patients showed moderate improvement in the overall 
disease severity, while two patients showed minimal improvement and one patient 
showed no inprovement. Patients with the shortest disease duration had the 
greatest response. One patient developed a PMLE.
Drug-induced scleroderma-like disorders
Several drugs can induce cutaneous sclerosis. Examples are: Vitamin K, bleomycin, 
interferon alfa, interleukin-2.7 Tuffanelli reported sclerotic side effects from 
pentazocine, isoniazid, valproate sodium, l-5-hydroxytryptophan and carbidopa, 
bromocriptine, nitrofurantoin and L-tryptophan.41 
The only case report about a patient with a drug associated scleroderma treated 
with UVA-1 was published in 1998. Behrens et al.,59 reported a case with a 
testicular seminoma who developed scleroderma after administration of  bleomycin. 
LD dose UVA-1 was given 3-4 times a week leading to initial improvement of  
the lesions. Unfortunately, the treatment had to be discontinued after 2 weeks. 
This discontinuation was not treatment related. After cessation of  therapy, a rapid 
progression of  sclerosis occurred. After resuming UVA-1 therapy, no further 
improvement could be achieved and the progression could not be stopped.
Pansclerotic porphyria cutanea tarda
In 2003 a case report was published by Karamﬁ lov et al.60 about a 63-years-old 
man who developed a generalized scleroderma, four years after being diagnosed 
with porphyria cutanea tarda (PCT). After intensive MD UVA-1 and intensive 
physiotherapy, the progression of  the skin disease was stopped and the sclerosis 
improved. The authors didn’t report any concern about treating a photosensitive 
disorder (PCT) with UVA light.
POEMS
POEMS is an abbreviation of  polyneuropathy, organomegalie, endocrinopathy and 
elevated levels of  a monoclonal protein and often scleroderma-like skin changes. In 
2001 a case was documented by Schaller et al.61 After ﬁ ve cycles of  chemotherapy 
during a six-month period, this patient didn’t show improvement of  muscular 
symptoms and monoclonal gammopathy, nor of  skin manifestations. Because 
of  serious side effects, the chemotherapy was discontinued. Three months after 
cessation of  therapy, LD UVA-1 phototherapy was given (cumulative dose 1050 J/
cm²). A fast and marked clinical improvement occured accompanied by a reduction 
of  skin thickness and improved mobility. 
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Biological effects of  UVA-1 with regard to sclerotic skin diseases
The precise action of  UVA-1 therapy remains obscure. Photo immunologic 
studies indicate that keratinocytes,62 epidermal Langerhans’ cells,63 T-helper 
cells, ﬁ broblasts and mast cells may be target cells in UVA radiation-induced 
immunomodulation.33 UVA-1 may reduce the number of  Langerhans cells and 
mast cells. UVA-1 irradiation has also been shown to initiate apoptotic cell death 
in dermal T-lymphocytes.64 A shift in the balance between proto-oncogenes 
and tumour suppressor genes towards the induction of  apoptosis has been 
demonstrated.65 
Figure 1 shows a summary of  the biological effects of  UVA-1 on sclerotic skin 
diseases.
Effects of  UVA-1 on fi broblasts
Irradiation with UVA-1 in vitro increased the collagenase production in cultured 
ﬁ broblasts.66,67 It has been shown that increased collagenase expression in 
irradiated plaques of  morphea accompanies improvement by UVA-1 therapy.68 
UVA can decrease the activity of  propyl-hydroxylase, an enzyme that stabilizes the 
triple helix structure of  collagen.69,70 UV radiation may also impair cross-linking 
of  collagen ﬁ bers.71
Several in vivo and vitro studies have shown that UVA-1 up regulates the 
speciﬁ c mRNA of  various Matrix Metalloproteinases (MMP’s) in cultured 
ﬁ broblasts.66-68,72-75 UVA-1 irradiation induces three members of  the MMP’s 
family. MMP-1, interstitial collagenase is one of  the three collagenases that are 
able to initiate cleavage to ﬁ brillar type I collagen, which comprises 90% of  skin 
collagen. Once cleaved by MMP-1, collagen can be further degraded by MMP-3 
and MMP-9.73
UVA leads to production of  hydrogen peroxide.76 Hydrogen peroxide increases 
IL=interleukin; INF=interferon; MMP=matrix metalloproteinase; MSH=melanocytes stimulating hormone; 
mRNA=messenger RNA; SMAD=small mothers against decapentaplegic; TGF=transforming growth factor
Figure 1: Schematic reproduction of the biological effects of UVA-1 on sclerotic skin 
diseases. 
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the mRNA levels of  collagenase/MMP-1 in human dermal ﬁ broblasts. Besides 
this, in morphea plaques irradiated with UVA-1, a stimulation of  Melanocytes 
Stimulating Hormone (MSH) was found. Alpha-MSH induces collagenase/
matrixproteinase-1 in human ﬁ broblasts.77 
Effects of  UVA-1 on infl ammatory cells and cytokines 
Interleukin-6 (IL-6) has been shown to increase the production of  collagen 
and glycosaminoglycanes in human ﬁ broblasts in vitro.78 Interleukine-8 (IL-8) 
is expressed mainly by ﬁ broblasts, neutrophils and macrophages. These pro-
inﬂ ammatory cytokines have been demonstrated at increased levels in the blood 
of  patients with localized scleroderma. Kreuter et al79 found a down regulation of  
IL-6 and IL-8 after UVA-1. 
Transforming growth factor beta (TGF-β), a cytokine with impact on cell growth, 
differentiation and biosynthesis of  connective tissue, plays a major proﬁ brotic role 
in the pathogenesis of  sclerotic skin diseases.80,81 TGF-β signalling is enhanced 
in sclerotic skin, which leads to an increased ﬁ broblast growth and collagen 
synthesis. TGF-β is an important ﬁ brogenic cytokine that enhances collagen 
production, inhibits MMP’s and stimulates their inhibitors.82 El-Mofty et al.34 
noticed a signiﬁ cant decrease in TGF-β RNA level, UV irradiation down-regulates 
type II TGF-β cell surface receptors and thereby impairs the ability to stimulate 
procollagen synthesis in ﬁ broblasts. Recently attention has been focussed on a 
family of  transcription factor proteins involved in TGF-β signal transduction 
from cell surface to the nucleus, the so-called SMADs (Small Mothers Against 
Decapentaplegic). In vitro and in vivo animal studies have implicated SMAD7 as 
a major inhibitory regulator of  the TGF-β–SMAD pathway.83,84 The expression 
of  SMAD7 is selectively decreased, whereas SMAD3 expression is increased 
in scleroderma skin. UVA-1 irradiation induces SMAD7.73 The pathogenetic 
relevance of  SMAD7 levels with respect to clinical improvement needs further 
investigation.
Aiba et al.85 reported in 1994 on a signiﬁ cant decrease of  CD34+ dendritic cells 
in lesional skin of  morphea patients. This ﬁ nding was conﬁ rmed by Skobieranda 
and Helm.86 According to Camacho et al30 UVA-1 effectiveness is associated 
with an increase in the number of  CD34+ dendritic cells in the dermis. The exact 
function of  CD34+ cells in the dermis is not yet elucidated. It is hypothesized 
that these cells are involved in the regulation of  ﬁ broblast activation or collagen 
production.30
A study performed by El-Mofty et al.34 showed that the effect of  UVA-1 is mainly 
obtained by the increased production of  MMP-1 and Interferon gamma (INF-γ), 
an antiﬁ brotic cytokine, and to lesser extent by decreasing TGF-β and collagen 
production.
INF-γ was reported to have an inhibitory effect on collagen synthesis. 
It can be concluded that UVA-1 has various effects that may contribute to the 
suppression or preventing exacerbation of  sclerotic skin diseases. 
 
Chapter 3 - Treatment options of  sclerotic skin diseases
107
Side effects
The main short-term side effects of  UVA-1 therapy are erythema, pruritus, xerosis 
cutis, tanning, and recrudescence of  a herpes simplex infection. While morphea 
lesions tend to pigment more than unaffected skin, it can actually lead to previously 
unattended lesions being noticed.2 One study performed by Stege et al. noted no 
side effects, such as burning, in observations of  more than a hundred patients 
treated with HD UVA-1 (130 J/cm²).27 UVA-1 irradiation produced negligible 
numbers of  sun burn cells.58 Generalized itch occasionally appears, but it usually 
responds well to emollients. Polymorphic light eruptions have been described as 
a possible side effect of  UVA-1 and other phototherapies.2 A report by Sacher et 
al.87 reported bullous pemphigoid as a possible side effect of  UVA-1 therapy in 
a patient with generalized morphea. Bullous pemphigoid after broadband UVA 
phototherapy or sunlight has been reported in some patients according to the 
literature.88-91
The major long-term risk is photo-aging and skin cancer. The induction of  dermal 
hyperplasic elastic ﬁ bres resulting in early skin aging of  4000-8000 J/cm² 
UVA-1 seems to be imminent.92,93 The induction of  collagenase released by 
dermal ﬁ broblasts mentioned immediately above is known to be an important co-
factor in inducing photo-aging, but is also effective for the treatment of  sclerotic 
skin diseases. Breuckmann et al.94 mentioned the initiation of  apoptotic cascades 
even after a low single dose of  80 J/cm² UVA-1 irradiation. Exposure to 
HD UVA-1 can induce squamous cell carcinomas in hairless mice.95,96 At 
present UVA-1 is regarded as being less carcinogenic than PUVA. More studies 
are warranted to investigate the potential long-term risk of  this long-wave 
phototherapy.
3.3.5 Conclusions
Sclerotic skin diseases can cause severe morbidity and disability. Current treatment 
of  sclerotic skin diseases usually consists of  various immunosuppressants. These 
drugs can lead to a wide range of  unwanted side effects, so there is a need for 
alternative therapeutic concepts.47 
UVA-1 therapy has demonstrated its value in the treatment of  sclerotic skin 
diseases, however no uniform scales for grading sclerotic skin diseases or measuring 
their progression or improvement after UVA-1 or UVA were used in the different 
studies. Many studies just cited showing “improvement’’ or “remarkable softening”, 
but these improvements were not quantiﬁ ed.  It was intended to review the studies 
found for their validity and efﬁ cacy, but this was difﬁ cult to perform, because of  
the relatively small sample sizes, absence of  placebo groups and lack of  double 
blind controlled studies. The latter is more difﬁ cult to perform in phototherapy, 
because of  the differences in UV cabin equipment, duration of  treatment and the 
degree of  tanning that differs in various phototherapies. In a few studies, patients 
received other therapies besides UVA. 
Questions about the optimal dose and treatment frequencies need to be 
systematically addressed. Most studies used LD UVA-1 therapy, as it is more 
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available than HD or MD UVA-1 phototherapy. Apparently, there are no large 
randomized controlled comparative trial results available. There is a lack of  
information about the period of  remission after UVA-1 and about the possibility 
of  combination therapy. Up to the present, good results are shown for all different 
doses (LD/MD/HD UVA-1), although only limited numbers of  patients have been 
treated with HD UVA-1 therapy.27 In a study performed by Stege et al.27 HD 
UVA-1 seemed more effective than LD UVA-1. Several other studies showed that 
using UVA-1 phototherapy in a dose of  20 J/cm², gives excellent results in patients 
with localized scleroderma.4,26,28,29,37-39 There is not sufﬁ cient data regarding 
use of  HD UVA-1 and comparative studies to make a clear assessment regarding 
the superiority of  LD, MD or HD UVA-1 therapy. One can hypothesize that the 
beneﬁ t-risk ratio is in favour of  LD therapy, as the potential of  long-term side 
effects is likely to be greater with increasing doses. 
Another interesting question is whether UVA-1 is signiﬁ cantly more effective than 
full spectrum UVA, which is widely available. Using 320-400 nm UVA in a dose 
of  20 J/cm² for 20 sessions in localized scleroderma, El-Mofty et al.33 reported 
impressive clinical response. The longer the wavelength used, the greater the 
depth of  penetration by ultraviolet waves. Therefore, most of  the UVA (320-400 
nm) energy does not penetrate into the depth, which selectively utilizes the longer 
wavelengths.37 This concentration of  radiation energy in the superﬁ cial skin raises 
some concern with regard to skin aging and carcinogenesis.70 However, there 
has been no randomized clinical controlled trial comparing the clinical response 
between 320-400 nm UVA and UVA-1 (340-400 nm), to conﬁ rm the hypothesis 
that UVA-1 is more effective in the treatment of  sclerotic skin diseases due to its 
greater depth of  penetration. 
UVA-1 treatment can shorten the active period of  localized scleroderma and 
pseudoscleroderma and prevent further disease progression, including joint 
contractures. Although long-term results are not yet available, UVA-1 might 
develop into a promising beneﬁ cial and well-tolerated treatment in the poor 
therapeutic armentarium of  sclerotic skin diseases. Long-term studies in large 
groups of  patients are clearly needed.
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LIST OF ABBREVIATIONS
GVHD Graft-versus-Host disease
HD High Dose (>70-130 J/cm²)
IL Interleukin
INF Interferon
J/cm² Joule per square centimeter
LD Low Dose (10-30 J/cm²)
LS Localized Scleroderma
LSA Lichen Sclerosis (et Atrophicus)
MD Medium Dose (>30-70 J/cm²)
MMP Matrix Metalloproteinase
mRNA Messenger RNA
MSH Melanocytes Stimulating Hormone
NB UVB Narrow band ultraviolet B
NL Necorbiosis Lipoidica
PMLE Polymorphic Light Eruption
PUVA Psoralen UVA, psoralen with UVA (320-340 nm)
SMAD Small Mothers Against Decapentaplegic
TGF Tumour Growth Factor
TNF Tumour Necrosis Factor
UV Ultraviolet 
UVA Ultraviolet A (320-400 nm)
UVA-1 Ultraviolet A-1, long wave ultraviolet A (340-400 nm)
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3.4  PERIOD OF REMISSION AFTER TREATMENT WITH UVA-1 
 IN SCLEROTIC SKIN DISEASES
3.4.1 Abstract
Background: Sclerotic skin diseases can cause severe morbidity and disability. UVA-1 
has shown to be an effective therapy for sclerotic skin diseases. However the period 
of  remission in these patients is not clear. In this study the effect and remission 
period of  UVA-1 phototherapy in various sclerotic skin diseases is described using 
a semi-quantative clinical score combined with the durometer score as an objective 
apparatus to measure the hardness of  the skin.
Objective: Our purpose was to determine the efﬁ ctiveness of  UVA-1 phototherapy 
and the duration of  remission in sclerotic skin diseases.
Methods: In this prospective study 10 patients with various sclerotic skin diseases 
were treated with UVA-1 phototherapy. The durometer was used to observe the 
hardness of  the skin. Hardness of  the skin was measured by one investigator at 
ten locations, distributed evenly on the representative sclerotic skin. Each spot was 
measured 3 times and the average of  each of  these measurements was summed to 
give the total durometer score. Durometer scores were recorded weekly until the 
ﬁ nal treatment date and 4 weeks after treatment. Clinical scores were carried out 
at the end date of  the treatment using a 6-point scale semi-quantative score. Long-
term effects were evaluated up to 29-46 months.
Results: The patients were treated with UVA-1 in a cumulative dose of  
1286 ± 58.8 (SEM) J/cm2, range 846-1470 J/cm2 divided over 5 times a week 
for 4 weeks. In all patients studied the sclerotic skin lesions were markedly softer 
after UVA-1 treatment. All durometer scores improved highly signiﬁ cant during 
the ﬁ rst three weeks of  treatment and borderline signiﬁ cant during the last week 
of  treatment. There was no signiﬁ cant improvement between the end of  UVA-
1 phototherapy and one month after ending the therapy (p > 0.05). All patients 
noted improvement of  the semi-quantative clinical score during treatment. 
Clinical improvement was associated with improvement of  the durometer score 
(conﬁ dence interval 95%). With a follow up until 46 months the remission 
period was stable up to 26 months in 6 patients. The duration of  sclerotic skin 
diseases before start of  treatment did not inﬂ uence improvement in the clinical or 
durometer score. One patient had an acute side effect of  minimal erythema. No 
other side effects, except tanning and fatigue, were noted.
Conclusion: UVA-1 is an effective treatment for sclerotic skin diseases with a long 
period of  remission and clinical improvement even in patients with a long history 
of  this skin disease. UVA-1 should be considered among the ﬁ rst approaches in the 
management of  sclerotic skin diseases.
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3.4.2 Introduction
Sclerotic skin diseases can cause severe morbidity and disability. The scleroderma 
disorders comprise a heterogeneous group of  conditions linked by the presence of  
sclerotic skin lesions. Scleroderma is a connective tissue disease characterized by a 
large amount of  thickened collagen. The disease scleroderma includes a wide range 
of  disorders, ranging from systemic sclerosis, cutaneous sclerosis as a component 
of  the eosinophilic fasciitis to localized scleroderma. Scleroderma is a primary 
cutaneous sclerosis. Secondary cutaneous sclerosis, also called pseudoscleroderma, 
consist of  a wide range of  conditions. Examples of  a pseudoscleroderma are: 
chronic sclerodermic graft-versus-host disease, drug-associated pseudoscleroderma, 
traumatic scleroderma (e.g. burns), metabolic disorders, genetic disorders, 
malignancies, radiation exposure, neurological disorders, post-infections and 
mucinosis, like scleredema of  Buschke and scleromyxedema. 
There is no satisfying therapy for sclerotic skin diseases. Numerous modalities 
including corticosteroids,1 methotrexate (MTX),2 plasmapheresis,3 sulfasalazine,4 
penicilline,5 penicillamin,6 anti-malarial drugs,7 interferon gamma,8 
imiquimod,9,10 vitamin E,11 vitamin D,12 retinoids,13 ciclosporin14 have been 
used. These treatments may give severe side effects. UVA-1 phototherapy has 
been shown to be effective in the treatment of  various sclerotic skin diseases.15 
However there is no literature about the period of  remission after treatment of  
UVA-1 in these skin diseases. In this study, a heterogeneous group of  patients with 
a sclerotic skin disease were treated and studied for effective remission.
3.4.3 Methods
Ten patients with severe sclerotic skin diseases were included in this prospective 
study. The patients were recruited from the outpatients’ clinic from the 
Dermatology Department of  the Radboud University Medical Centre Nijmegen, 
the Netherlands. Three patients suffered from scleredema diabeticorum, three 
patients were diagnosed as having eosinophilic fasciitis, one patient had widespread 
morphea, one patient was included with scleromyxedema, one patient had 
sclerotic skin after a trauma on her right leg and one patient was included with a 
pseudoscleredema after radio-active iodine treatment (table 1). The diagnosis was 
conﬁ rmed by dermatological, rheumatological and pathological and/or laboratory 
investigation. Duration of  symptoms, previous treatments and Fitzpatrick skin 
types were recorded. The Fitzpatrick skin type (I-VI) is a simple and useful method 
to categorize cutaneous sensitivities to ultraviolet radiation. 
The result is a classiﬁ cation of  6 different skin types: 
Type I: Very fair skin that always burns and never tans. • 
Type II: Fair skin that always burns easily and tans minimally. • 
Type III: Medium skin that sometimes burns and always tans. • 
Type IV: Light brown skin that rarely burns and always tans. • 
Type V: Dark brown skin that never burns and tans profusely. • 
Type VI: Dark brown or black skin that never burns and is deeply pigmented. • 
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Material
For irradiation the Waldmann 7001 UVA cabin was used, which emits photons 
with wavelengths of  340-400 nm. The hardness of  the skin was examined by 
means of  a hand-held type durometer with an afﬁ xed weight of  approximately 
400 grams (model 1600-OO; rex Gauge Co, Glenview, III, USA). In this way, the 
measurements were carried out with a constant weight, not allowing additional 
pressure. For measurements, the durometer was used at 24°C room temperature 
and rested by gravity against the skin. The durometer is ﬁ tted with a calibrated 
gauge that registers linearly divided units on a scale of  0 to 100. At the bottom 
of  the durometer, there is a small, inferior indenter that is retractable and is 
responsible for the measurements registered on the gauge. Hardness of  the skin 
was measured by one investigator at ten locations, distributed evenly on the 
representative sclerotic skin. Each spot was measured 3 times and the average of  
each of  these measurements was summed to give the total durometer score. The 
locations were selected preferably on sites where no bony structures were present 
directly beneath the skin. 
Schedule
During the ﬁ rst visit, photographs of  the measurement points were taken to 
guarantee the same locations were used on all future visits. Durometer scores were 
recorded before treatment and then every week until the ﬁ nal treatment date. Four 
weeks afterwards, the patients were seen by the same doctor and another evaluation 
including durometer measurement was carried out. The patients were treated with 
total body irradiation of  approximately 70 J/cm2 (e.g. medium dose UVA-1) per 
day, 5 times a week for 4 weeks with a total average cumulative dose of  1286 J/
cm2 (table 2). During treatment patients wore eye goggles to protect against UVA 
radiation. Additional therapies were restricted to the use of  bland emollients that 
had been applied once daily in the evening. This emollient was not applied shortly 
before or after the UVA-1 treatment.
Clinical scores (patients assessments) were carried out at the end date of  the 
treatment using a semi-quantative score of  a 6 point scale as follows: 
1 = excellent improvement, deﬁ ned as recovered 
2 = good improvement, deﬁ ned as nearly recovered, slight remaining problems 
3 = moderate improvement, deﬁ ned as some recovery, but clear remaining 
problems
4 = mild improvement, deﬁ ned as minor recovery, with evident remaining 
problems
5 = no improvement, deﬁ ned as no improvement in the disease activity/function
6 = worsening, deﬁ ned as a worsening of  the disease activity/function, 
i.e. worsening of  the sclerosis or function
The end of  remission was deﬁ ned as the timepoint at which worsening was 
experienced by the patients and observed by the doctor. Patients were seen every 
three months and if  necessary more frequently. Side effects and long-term results 
were recorded. 
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3.4.4 Statistical analysis
Statistical analysis was performed using SPSS 14.0 software. Statistical hypotheses 
are formulated solely for the purpose of  having them rejected of  refuted. Null 
hypotheses Ho: Assumes that the hardness of  the skin in sclerotic skin diseases will 
not decrease by UVA-1 therapy. With a level of  signiﬁ cance set to 5% (probability-
level of  0.05), we have conﬁ dence of  95% that the null hypotheses will be rejected. 
Comparisons between the weeks of  treatment were assessed by means of  two-
sided paired t-tests. Differences were considered statistically signiﬁ cant as 
p < 0.05 and highly signiﬁ cant as p < 0.01. p 0.05-0.10 was considered to be 
borderline signiﬁ cant.
3.4.5 Results
The mean age of  the 10 patients (4 males, 6 females) was 56.6 years ± 2.8 (SEM), 
range 44-72 years. Nine patients were Caucasians, whereas one was Indian-Surinam 
Creole. The mean duration of  symptoms was 7.7 ± 1.8 (SEM) years, range 
1.3-20 years. Fitzpatrick skin types range from II to VI. Eight patients received no 
treatments for at least 3 months. In 2 patients, therapy consisted of  a low dose of  
Prednisone (2.5 and 10 mg/day). The previous treatments are designated in table 
1. UVA-1 treatment was well accepted and completed by all patients. The mean 
total dose was 1286 ± 58.8 (SEM) J/cm2, range 846-1470 J/cm2. The follow up 
duration was 29-46 months. All patients noted clinical improvement: Four patients 
noted an excellent improvement, three patients good improvement, two patients 
noted moderate improvement and one patient noted mild improvement (table 2). 
In all patients the durometer scores improved highly signiﬁ cantly during the ﬁ rst 
three weeks of  treatment (p < 0.01) and borderline signiﬁ cant during the last week 
of  treatment (p = 0.08). The baseline mean durometer score was deﬁ ned as 100%. 
Sex 
(M=male, 
F=female)
Age     
(years) 
Diagnose Duration 
of  sclerotic 
disorder 
till UVA-1 
(years)
Previous 
treatments
Fitzpatrick 
Skintype
M 52 Scleredema diabeticorum 10 VI
F 58 Scleredema diabeticorum 20 III
F 49 Scleredema diabeticorum 11 II
F 56 Eosinophilic fasciitis 3 Prednisone, MTX II
M 67 Eosinophilic fasciitis 3 Prednisone, MTX IV
F 65 Eosinophilic fasciitis 4 Prednisone, MTX II
M 49 Morphea 10 III
M 54 Scleromyxedema 3 PUVA II
F 72 Traumatic scleroderma 6 II
F 44 Drug associated pseudoscleroderma 1.3 II
MTX=methotrexate, PUVA=psoralen with UVA
Table 1: Characteristics of patients with sclerotic skin disease treated with UVA-1 
phototherapy
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Diagnose Duration of  
scleroderm 
disorder 
till UVA-1            
(years.months)
Total dose 
(J/cm2)
Result of   
UVA-1, 
clinical 
score 
(1-6)
Remission period 
(months)
Scleredema diabeticorum 10.0 1175 1 26
Scleredema diabeticorum 20.0 1400 1 stable, follow up ≥ 36
Scleredema diabeticorum 11.0 1470 1 30
Eosinophilic fasciitis 3.0 1160 3 stable, follow up ≥ 33
Eosinophilic fasciitis 3.0 1375 4 12
Eosinophilic fasciitis 4.0 1374 2 2
Morphea 10.0 1400 1 4
Scleromyxedema 3.0 1260 2 8
Traumatic scleroderma 6.0 1400 2 stable, follow up ≥ 41
Drug associated pseudoscleroderma 1.4 846 3 stable, follow up ≥ 29 
 Table 2: Long term effects of UVA-1 in various sclerotic skin diseases
During the treatment period the mean durometer score improved signiﬁ cantly 
from 100% to 73.6%, a decrease of  26.4% (p < 0.01). There was no signiﬁ cant 
difference in durometer score between the end of  UVA-1 treatment (4 weeks of  
treatment) and one month after treatment (p > 0.05). With a signiﬁ cance of  
p < 0.05 the null hypotheses can be rejected and it can be concluded that UVA-1 is 
an effective treatment for sclerotic skin diseases (ﬁ gure 1). 
The durometer was used before treatment and every week till the end date of  treatment and one month after 
treatment. The baseline mean durometerscore is deﬁ ned as 100%.
Figure 1: The mean durometer scores +/- CI 95% of the patients treated with UVA-1 
phototherapy.
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One patient used 2.5 mg Prednisone/day at start of  the treatment. During 
phototherapy the Prednisone could be stopped. One patient with an eosinophilic 
fasciitis kept the same dose of  Prednisone of  10 mg/day, which he had already 
received for many years. The other patients did not use immunosuppressives (wash 
out time of  at least 3 months). With follow up tests occurring up to 46 months 
after the initial treatment, the remission period was 26 months or longer in 6 
patients. There was no correlation between the duration of  sclerotic skin disease 
before the start of  ultraviolet A-1 treatment and the clinical or durometer score 
improvement. 
During and after the phototherapy no UV-induced side effects, such as 
polymorphic light eruption, itch, xerosis cutis or recrudescence of  a herpes simplex 
infection were observed. One patient with a skin type Fitzpatrick II showed 
minimal erythema on the affected skin. All the patients experienced fatigue during 
treatment. All the patients were tanned. With a follow up range of  29-46 months, 
no skin cancer or actinic damage was detected in this patient population.
3.4.6 Discussion
Sclerotic skin diseases include a wide range of  disorders. In this study, UVA-
1 medium dose therapy was carried out in various sclerotic skin diseases, like 
morphea, eosinophilic fasciitis, scleromyxedema and scleredema diabeticorum.
Several methods to measure the clinical improvement of  sclerotic diseases have 
been advocated but have never been validated.16 Objective measurements with 
ultrasonography, laser Doppler ﬂ owmetry have been described. Biopsy, however, 
has the disadvantage of  being invasive and time consuming. The durometer proved 
reliable in the assessment of  a sclerotic skin disease (morphea) with low inter- and 
intraobserver variability.17 In this study using the durometer, clear improvement 
was seen in various sclerotic skin diseases. It should be noted that the environment 
and other factors, such as localization of  the measurements points, may exert 
inﬂ uence the obtained durometer results. 
Although our study was performed under controlled conditions; photographs of  
the points were taken to guarantee the same locations were used on all visits; the 
durometer was used by one investigator; patients were measured in the same room 
(24°C room temperature) and in the same anatomic position.
Unlike UVB, UVA-1 can reach the subcutis. In 1981 an UVA-1 lamp emitting 
radiation predominantly in the 340-400 nm ranges described was developed.18 
There are various UVA-1 sources. The ﬂ uorescent lamp cubicles allow only low 
(10-30 J/cm²) or moderate (40-70 J/cm²) doses. The high output metal halide 
sources allow up to 130 J/cm² (high doses). The precise action of  UVA-1 therapy 
is unknown. It may reduce the number of  Langerhans cells and mast cells and 
induces T-lymphocyte apoptosis. Irradiation of  broadband UVA-1 increased the 
collagenase production in cultured ﬁ broblasts. It has been shown that increased 
collagenase expression in irradiated plaques of  morphea accompanies improvement 
by UVA-1 therapy.19 UVA-1 up regulates the speciﬁ c mRNA of  various matrix 
metalloproteinasen in cultured ﬁ broblasts, probably due to their lower anti-oxidant 
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capacity.20-22 UVA-1 irradiation has also been shown to initiate apoptotic cell 
death in dermal T-lymphocytes. A shift of  the balance between proto-oncogenes 
and tumor suppressor genes towards the induction of  apoptosis have been 
found.23 
All patients showed clear improvement after a four weeks course of  medium dose 
UVA-1 therapy. Six patients had a period of  remission for at least 2 years, despite 
the often-long duration of  the sclerotic skin disease. There was no relation between 
the duration of  sclerotic skin diseases or skin types and the clinical or durometer 
score improvement. Sclerotic skin diseases can show spontanous remission. 
However this patientgroup suffered from a long lasting disease (mean 7.7 years), 
therefore spontaneous remission was unlikely. 
The main acute reverse reactions of  UVA-1 are erythema, polymorphic light 
eruption, itch, xerosis cutis, tanning, and recrudescence of  a herpes simplex 
infection. One patient had an acute side effect of  erythema. All the patients 
were tanned. The major long-term risk is photo-aging and skin cancer. In the 
present study, with a follow up of  29 up to 46 months no skin cancer or actinic 
damage was observed. All the patients suffered fatigue during treatment. Possible 
explanations may be the heat production in the cabin combined with a long 
treatment time or the immunosuppressive action of  UVA-1. Of  special interest 
is the clear improvement of  patients with scleredema diabeticorum, a condition 
where only limited treatment options are available. Scleredema diabeticorum is a 
slowly progressive, non-resolving scleredema in diabetic patients. Often the patients 
are obese and have multiple complications surrounding the diabetes.
The pathogenetic mechanism of  the induration of  skin is postulated to be caused 
by glycolisation of  the collagen due to hyperglycemia.24
In this study the patients with a scleredema diabeticorum showed improvement 
with a long remission period after medium dose UVA-1 phototherapy. UVA-1 also 
proved to be effective in eosinophilic fasciitis and scleromyxedema. Eosinophilic 
fasciitis (also called Shulman’s syndrome or diffuse fasciitis with eosinophilia) is an 
uncommon disorder of  unknown aetiology and poorly understood pathogenesis.25 
Eosinophilic fasciitis is characterized by symmetrical indurations of  the skin.26 The 
onset is acute and clinical symptoms include erythema, swelling and indurations 
of  the extremities that are accompanied by eosinophilia. Scleromyxedema is also a 
rare connective tissue disorder, which has been associated with paraproteinemias. 
Scleromyxedema is characterized by yellow-red papules on the head, neck, arms, 
and upper trunk, commonly occurring over thickened, indurated skin.27 These 
lesions can be confused with scleroderma. Middle-aged adults are most commonly 
affected.
The present study is to our knowledge, the ﬁ rst study where the effect of  UVA-1 
phototherapy in various sclerotic skin diseases is examined using the durometer as 
an objective apparatus to measure the hardness of  the skin. This is also the ﬁ rst 
investigation were the period of  remission is described after treatment of  UVA-1 in 
various sclerotic skin diseases.
In conclusion: UVA-1 therapy has demonstrated its value in the poor therapeutic 
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armentarium of  sclerotic skin diseases with a long period of  remission and clinical 
improvement even in patients with a long history of  sclerotic skin disease.
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3.5  SCLEREDEMA DIABETICORUM CASE SERIES: 
 SUCCESSFUL TREATMENT WITH UVA-1
3.5.1 Abstract
Background: Treatment of  scleredema is challenging. Scleredema diabeticorum is a 
minor but often unrecognized complication of  diabetes mellitus. It is characterized 
by non-pitting indurations of  the skin with occasional erythema. Scleredema is 
an uncommon skin condition with poor therapeutic options. The aetiology is 
unknown.
Observation:  We report our experience with 3 patients with a scleredema 
diabeticorum seen at the Radboud University Medical Centre Nijmegen. All 
patients had a history of  complicated diabetes. The diabetes had been difﬁ cult to 
regulate in the past. Patients A and B were treated with medium dose UVA-1, 
35 J/cm² per session, total cumulative dose of  1400 J/cm² and patient C was 
treated with 80 J/cm² UVA-1 per session, cumulative dose of  1360 J/cm². The 
durometer was used as an objective apparatus to measure the hardness of  the skin.
Results: In all patients the skin softened and the mobility of  their necks and 
shoulders improved substantially. The durometer scores improved each week till 
end of  the treatment. Patient A noted an excellent improvement, the other two 
patients noted good improvement.
 
Conclusion:  This is, as we could ﬁ nd in the literature, the ﬁ rst series of  scleredema 
diabeticorum patients treated with UVA-1, whereby an objective apparatus has 
been used to determine the hardness of  the skin. In these three patients a rapid 
and objective improvement of  scleredema diabeticorum was shown after UVA-1 
therapy. This form of  phototherapy may be a treatment option for patients with 
this disabling and often therapy-resistant disease.
3.5.2 Introduction
Scleredema is an uncommon condition with unknown pathophysiology. It is 
characterized by  non-pitting induration of  the skin with occasional erythema 
(ﬁ gure 1). The aetiology is unknown.
Limited options are available to treat patients with scleredema diabeticorum. 
We report herein the effect of  UVA-1 treatment in three patients with severe 
scleredema diabeticorum.
3.5.3 Case-reports
Patient A: A 51-year-old-man presented with a ten-year history of  a thickening of  
the skin on his back, neck and shoulders. There had been no infection. He had an 
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insulin dependent diabetes mellitus since aged twenty years old. His medical history 
revealed a myocardial infarction, which was treated with a primary Percutaneous 
Transluminal Coronary Angioplasty (PTCA) and medication. There was no 
evidence of  diabetic neuropathy, retinopathy or nephropathy. The diabetes had 
been difﬁ cult to regulate throughout the previous twenty years. On examination, a 
non-pitting induration of  his back, neck and shoulders was observed. His neck and 
shoulder mobility was severely limited. No other skin abnormalities were seen. No 
spinal or joint abnormalities were found.
Full blood count, liver function, kidney function and electrolytes were normal, 
there was no gammopathy nor eosinophilia. The histological ﬁ ndings include a 
broad dermis with mucin between thickened collagen bundles, consistent with a the 
clinical diagnosis of  scleredema diabeticorum (ﬁ gure 2). 
Patient B: A 52-year-old-women with an eleven-year history of  pain in the upper 
back and limited motion of  her shoulders and neck. Her medical history revealed 
type I diabetes since childhood and a polyneuropathy due to the diabetes. On 
examination we found an indurated skin on her back, neck and shoulders. The 
skin elsewhere appeared normal. The mobility of  her neck and both shoulders 
was severely limited. A biopsy of  the lesional skin showed a thickened dermis with 
Figure 1: Clinical picture of patient C, with scleredema diabeticorum
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Figure 2: Histopathology: mucin between thickened collagen bundles
broad collagenﬁ bers separated by clear spaces. The alcian blue staining revealed 
mucin between the broad collagen bundles.
Patient C: A 66-year-old man had a six-year history of  progressive tightening of  the 
skin on his back, upper arms and neck. He had suffered with insulin-dependent 
diabetes mellitus since he was seven-years-old. Complications of  his endocrine 
disorder were severe: Retinopathy, neuropathy and several myocardial infarcts. His 
diabetes had been difﬁ cult to control in the past. On examination a hardening of  
the skin was found on his back and neck. The ﬂ exion and extension of  his cervical 
spine was limited to 15º and 20º (normal ± 45º). Abduction of  both shoulders was 
limited to 120 degrees (normal ±180º). A biopsy was consistent with the clinical 
diagnosis of  scleredema diabeticorum. 
Figure 3: Durometer scores. The baseline mean durometer score was defined as 100%
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3.5.4 Methods
Patients A and B were treated with medium-dose UVA-1 therapy, 35 J/cm² per 
session, cumulative dose 1400 J/cm² (Waldmann 7001). 
Patient C was treated with high-dose UVA-1 therapy, 80 J/cm² per session, 
cumulative dose of  1360 J/cm² (Waldmann, Sellamed 24000).
The durometer, model 1600-OO; rex Gauge Co, Glenview, III, USA, was used 
as an objective apparatus to measure the hardness of  the skin. In this way 
measurements were carried out with a constant weight that did not allow additional 
pressure. The durometer is ﬁ tted with a calibrated gauge that registers linearly 
divided units on a scale from 0 to 100.1 Hardness of  the skin was measured at the 
same ten points, distributed equally on the back. Each point was measured 3 times. 
The average of  these points were summed, leading to the total durometer score. 
The baseline mean durometer score was deﬁ ned as 100%. The points were selected 
preferably on sites where no bony structures were present directly beneath the skin. 
During the ﬁ rst visit, photographs of  the selected measuring points were taken to 
guarantee consistency in measuring the same locations at every subsequent visit.
Clinical scores were evaluated through the patient at the end date of  the treatment 
using a semi-quantative scale as follows:
1 = excellent improvement, deﬁ ned as recovered 
2 = good improvement, deﬁ ned as nearly recovered, slight remaining problems 
3 = moderate improvement, deﬁ ned as some recovery, but clear remaining 
problems
4 = mild improvement, deﬁ ned as minor recovery, with evident remaining 
problems
5 = no improvement, deﬁ ned as no improvement in the disease activity/function
6 = worsening, deﬁ ned as a worsening of  the disease activity/function, 
i.e. worsening of  the sclerosis or function
3.5.5 Results
Patient A: Evident clinical improvement was seen every week up to 3 weeks after 
starting the UVA-1 therapy. His clinical score was excellent (score 1). The mobility 
and abduction of  his shoulders improved signiﬁ cantly. The durometer scores 
showed signiﬁ cant improvement up to the end of  treatment (ﬁ gure 3).
Patient B: Evident clinical improvement was seen every week up to the end of  
treatment. Her clinical score was good improvement (score 2). The mobility and 
ﬂ exion of  her neck and  abduction of  her shoulders improved signiﬁ cantly. The 
durometer scores improved each week up to the end of  treatment (ﬁ gure 3).
Patient C: There was a clinical reduction in the degree of  tightness of  the skin. After 
6 sessions, the patient noticed a marked improvement in his range of  motion. At 
the end of  treatment the ﬂ exion and extension of  the cervical spine improved 
to 40º. The abduction of  the left shoulder improved to 130º and the right one to 
150º. His clinical score was 2, noted as a good improvement. Durometer scores 
improved each week up to the end of  treatment (ﬁ gure 3).
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3.5.6 Discussion
The ﬁ rst description of  the condition now known as scleredema adultorum of  
Buschke has been attributed to Curzio in 1752 by Touraine and co-workers2 in 
their 1936 review of  the disease. It was not until 1902 that another description of  
the disease appeared when Abraham Buschke3 described a 46-year-old carriage 
varnisher who developed skin hardening beginning in the neck and spreading to 
involve all parts of  his body except those distal to the palms and thighs.4 
Scleredema can be categorized into 3 subgroups:
Type I: also called the classic type described by Buschke in 1902. All such • 
patients have a preceding febrile illness and the lesion that has formed will 
disappear in several months to 2 years. This type makes up about 55% of  the 
cases of  scleredema adultorum.5 
Type II: These patients do not have a history of  an infection or diabetes. This • 
type tends to follow a slow progressive course and the lesions that has been 
formed will persist. Type II makes up about 25% of  patients.5
Type III has been termed scleredema diabeticorum. This type is a slowly • 
progressive, non-resolving scleredema that occurs in diabetic patients. This 
type makes up about 20% of  cases.5 Unlike for the other subgroups there is a 
predominance of  male patients. The pathogenetic mechanism of  the indurated 
skin is not revealed. There has been speculation that hyperglycemia leads to 
glycolisation of  the collagen.6 
Mutzhas et al. published in 1981 an article about a new apparatus with high 
radiation energy between 320-460 nm.7 In the centre where this phototherapy 
became available, UVA-1 is be a useful addition to the phototherapy that had been 
previously available. The precise mechanism of  actions is unknown. Irradiation of  
UVA-1 increased the collagenase production by cultured ﬁ broblasts, which could 
be the patho-physiologic mechanism that explains the good effect of  UVA-1. 
There are several side effects of  UVA-1. The UVA-1 cabin produces heat. The 
main acute reverse reactions are erythema, polymorphic light eruption, itch, 
xerosis cutis, tanning, and recrudescence of  a herpes simplex infection. The most 
important long term expected side effect is photo-aging and photo carcinogenesis, 
although no literature is current available about the long term effect of  UVA-1 
therapy.
In 2004 the ﬁ rst case report of  successful UVA-1-therapy of  two scleredema 
adultorum patients was published by Janiga et al.8 Our research has so far revealed 
six more scleredema patients with successful UVA-1 treatment9,10 being reported 
upon. This is, as we could ﬁ nd in the literature, the ﬁ rst series of  scleredema 
diabeticorum patients treated with UVA-1, where an objective apparatus has been 
used to determine the hardness of  the skin. In the present case series, the clinical 
improvement of  scleredema diabeticorum after UVA-1 was quantiﬁ ed by objective 
measurements using durometry. This form of  phototherapy may be a treatment 
option for patients with this disabling and often therapy-resistant disease.
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4.1  SUMMARY AND CONCLUSIONS
This chapter summarises and integrates the studies which were designed according 
to the aims and questions formulated in the introduction of  the thesis.
In the introduction (chapter 1) the classiﬁ cation and epidemiology of  localized 
scleroderma and eosinophilic fasciitis, including two paragraphs dedicated to 
pseudoscleroderma and systemic sclerosis were described. Subsequently several 
treatment options of  sclerotic skin diseases and the scoring methods that were used 
were explained. 
Finally the goal of  this thesis was described and compromised of  two aims.
AIM I Understand the physical burden and psychological distress 
in patients with a sclerotic skin disease.
Question Ia What is the prevalence of  physical symptoms of  itching, pain 
and fatigue in patients with localized scleroderma or eosinophilic 
fasciitis?
Question Ib What is the level of  psychological distress of  anxiety or depressed 
mood and what are the contributors to this distress in patients 
with localized scleroderma or eosinophilic fasciitis?
As described in chapter 2.1, in the research of  chronic skin diseases, attention is 
increasingly being directed to the consequences of  the disease on a patients’ quality 
of  life. It is well known that most chronic skin diseases negatively affect the quality 
of  life of  patients, but no information is provided about the physical burden and 
psychosocial functioning of  patients with a localized sclerotic skin disease. 
The prevalence of  physical symptoms of  itching, pain and fatigue in patients with 
sclerotic skin diseases was evaluated by means of  validated questionnaires. In order 
to assess the level of  physical symptoms VAS and deﬁ ned cut-off  scores were used. 
This study shows that a substantial proportion of  the patients with a localized 
sclerotic skin disease experienced physical symptoms. Fatigue, pain or itching was 
experienced in approximately 62% of  all patients. Fatigue was the most reported 
symptom with 55% of  all patients experiencing fatigue and more then half  of  
these patients experiencing severe fatigue. Pain and itching was reported in at least 
20% of  all patients. The severity of  physical symptoms were correlated with a 
lower disease related quality of  life. Pain and fatigue were also related to a more 
extended self-reported skin severity and fatigue to a shorter duration of  disease. 
A second study (chapter 2.2) examined the psychological distress, with a focus on 
anxiety and depressed mood in patients with morphea or eosinophilic fasciitis as 
well as possible predictors for psychological distress. 
Thirty-eight percent of  all patients with a localized sclerotic skin disease scored at 
levels comparable to psychiatric outpatients on anxiety and/or depressed mood and 
can be considered as psychologically at risk. Of  all patients, particularly patients 
with a generalized morphea and eosinophilic fasciitis reported the highest degree 
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of  distress and suffered from heightened levels of  anxiety and depressed mood. 
Higher levels of  depressed mood and anxiety were signiﬁ cantly related to a more 
extended self  reported skin severity, more pain and fatigue and a higher impact of  
the disease on daily life, more stigmatization, more helplessness and less acceptance 
and less social support. Illness cognition of  less acceptance most conveniently 
predicted psychological distress in patients with a localized scleroderma or 
eosinophilic fasciitis.
The most important conclusions of  this part of  the thesis are summarized below:
Fatigue, pain and, to a lesser extent, itching have a high prevalence in patients • 
with a localized scleroderma or eosinophilic fasciitis (chapter 2.1).
Psychological distress was generally impaired in patients with a localized • 
scleroderma or eosinophilic fasciitis, particularly in patients with a generalized 
morphea and eosinophilic fasciitis. Higher levels of  psychological distress were 
signiﬁ cantly related to a more extended self  reported skin severity, more pain 
and fatigue and a higher impact of  the disease on daily life, more stigmatization, 
illness cognitions of  greater helplessness and less acceptance and less perceived 
social support (chapter 2.2).
AIM II Determine the therapeutic effectiveness and tolerability of  
different classes of  treatment for sclerotic skin diseases.
Question IIa Does tacrolimus 0.1% ointment induce clinical improvement in 
patients with active plaque morphea? 
Question IIb Is MTX an effective, well-tolerated treatment for sclerotic skin 
diseases and additionally, does MTX give rise to a long period of  
remission?
Question IIc Is UVA-1 effective in patients with a sclerotic skin disease and 
what is the period of  remission?
Question IId Does UVA-1 decrease the tightness of  the skin in patients with 
scleredema diabeticorum?
So far, the only report describing the positive effects of  topical tacrolimus in 
the treatment of  patients with morphea regarded uncontrolled case studies of  
seven patients. To conﬁ rm and expand these data a randomized controlled pilot 
study was undertaken and described in chapter 3.1 in which topical tacrolimus 
0.1% was compared to petrolatum in 10 patients with active plaque morphea in a 
double blind prospective approach. The scleroderma plaques treated with topical 
tacrolimus 0.1% improved, resulting in a signiﬁ cant reduction of  the durometer 
scores and clinical feature scores. A statistically signiﬁ cant difference was seen 
between tacrolimus and emollient treatment. No serious side effects were observed. 
 
With regard to chapter 3.2, the opportunity was utilised to use unique patient 
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information going back ten years at the combined Rheumatology-Dermatology 
clinic in the Radboud University Medical Centre Nijmegen. Many patients with 
a hardening of  the skin were treated with Methotrexate (MTX) or MTX with 
Corticosteroids (MTX+CS). An investigation into the effectiveness, side effects and 
period of  remission of  MTX in sclerotic skin diseases was undertaken. 
Both treatment strategies (MTX and MTX+CS) were effective. Patients with a 
relapse after discontinuation of  MTX, still responded to a second course of  MTX 
and even to a third course of  MTX. Serious side effects were seen in 6 patients 
(10%). Fifty-one percent of  the patients treated with MTX and 73% of  the patients 
treated with MTX+CS reached remission after one treatment course with a median 
follow up time of  almost 5 years. MTX was still effective in patients with long 
existing disease. 
For chapter 3.3, all publications about the effectiveness, clinical and biological 
effects as well as side effects of  UVA-1 phototherapy in sclerotic skin diseases 
were collected from 1996 to 2007. UVA-1 therapy has demonstrated its value in 
the treatment of  sclerotic skin diseases. However, due to a lack of  randomized 
controlled trials and studies in large patient groups, it is difﬁ cult to draw 
ﬁ rm conclusions on the long term effectiveness, optimal dose and treatment 
frequencies. UVA-1 has various effects that may contribute to the suppression or 
prevention of  exacerbation of  sclerotic skin diseases. UVA-1 treatment can shorten 
the active period of  localized scleroderma and pseudoscleroderma and prevent 
further disease progression, including joint contractures. UVA-1 might develop 
into a promising beneﬁ cial and well-tolerated treatment in the poor therapeutic 
armentarium of  sclerotic skin diseases. 
Since there was no literature available on the period of  remission of  UVA-1, 
relevant data was collected and the period of  remission in 10 patients with various 
sclerotic skin diseases was thoroughly investigated in chapter 3.4. UVA-1 shows to 
be an effective treatment for sclerotic skin diseases with a long period of  remission 
and clinical improvement even in patients with a long history of  a sclerotic skin 
disease. With a follow up period up to 46 months the remission period was stable 
for up to 26 months in 6 patients. The duration of  sclerotic skin diseases before 
starting treatment did not inﬂ uence improvement in the clinical or durometer score. 
Side effects were mild. Although no skin malignancy occured, long-term studies in 
large groups of  patients are needed.
Additionally, chapter 3.5 describes the successful outcome of  UVA-1 in 3 patients 
with scleredema diabeticorum. A fast, clinical and objective improvement occured.
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The most important conclusions of  the last part of  the thesis are summarized 
below:
The ﬁ rst double blind, controlled pilot study comparing tacrolimus 0.1% • 
ointment with petrolatum in morphea, shows that tacrolimus 0.1% ointment is 
an effective and safe, treatment for active plaque morphea (chapter 3.1).
 MTX is an effective treatment for various sclerotic skin diseases, even in • 
patients with a long history of  the hardening of  the skin, based on our study at 
chapter 3.2. Side effects noted were mild. Retreatment was successful and a long 
period of  remission was achieved in the majority of  patients (chapter 3.2).
 UVA-1 phototherapy is effective in the treatment of  sclerotic skin disorders • 
based on the data retrieved from literature. However, the limited number of  
research, especially of  randomized controlled trials and research in a large 
group of  patients, makes it impossible to draw ﬁ rm conclusions on the degreee 
of  efﬁ cacy of  UVA-1 therapy and its optimal dose and treatment regimens for 
scleroting skin disorders (chapter 3.3).
 In our study, UVA-1 shows to be an effective treatment for sclerotic skin • 
diseases with a long period of  remission and clinical improvement even 
in patients with a long history of  a sclerotic skin disease. UVA-1 might be 
considered among the ﬁ rst approaches in the management of  sclerotic skin 
diseases (chapter 3.4).
 UVA-1 phototherapy may be a treatment option for patients with a • 
scleredema diabeticorum. In the three patients described, a rapid and objective 
improvement in the scleredema diabeticorum was shown during UVA-1 therapy 
(chapter 3.5).
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4.2  FUTURE SUGGESTIONS
Based on the ﬁ ndings and discussions in this thesis, several suggestions for further 
research can be made.
The studies of  chapter 2 describe that physical symptoms, fatigue, pain and itching 
have a high prevalence and the psychological distress was generally impaired 
in patients with a localized scleroderma and eosinophilic fasciitis. It would be 
interesting to compare different diagnostic categories, such as generalized morphea 
with eosinophilic fasciitis. Larger groups of  patients with a sclerotic skin disease 
have to be investigated. Also patients with an active sclerotic disease could be 
compared with patients during a chronic course of  the sclerotic disease. All 
ﬁ ndings should be compared with a control group.
The pilotstudy in chapter 3.1 shows that tacrolimus 0.1% ointment is an effective 
and safe, treatment for active plaque morphea. Future investigation is needed to 
conﬁ rm the results studying larger groups of  patients with morphea. It would also 
be interesting to perform histopathology studies before and after a ﬁ xed period of  
treatment with this calcineurin inhibitor.
Chapter 3.2: Future prospective investigation about the effectiveness of  MTX is 
worthwhile using larger groups of  patients with a sclerotic skin disease and using 
validated assessments, such as durometerscores or quality of  life scores. 
Chapter 3.3 and 3.4: Future studies about the efﬁ cacy of  UVA-1 should focus on 
large double blind controlled studies. Comparative studies should performed to 
make a clear assumption on the superiority of  LD, MD or HD UVA-1 therapy and 
if  UVA-1 is more effective than full spectrum UVA. Combination therapies, e.g. 
MTX and UVA-1 are worthwhile to investigate, especially regarding effectiveness 
and side effects. Questions about the optimal dose and treatment frequencies need 
to be further examined. Long term studies could provide more information about 
the period of  remission after UVA-1 and the long term effects of  this long wave 
phototherapy.
Although different therapeutic options were examined, large randomized controlled 
studies are clearly needed to construct an evidence based quideline for the 
therapeutic management of  these patients, in order to optimize the medical care for 
these patients and guide the patients to a better quality of  life. 
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4.3  KORTE SAMENVATTING EN CONCLUSIES
In dit proefschrift werd de uitgebreidheid van moeheid, pijn en jeuk bij patiënten 
met een gelokaliseerde sclerodermie dan wel een eosinoﬁ ele fasciitis onderzocht. 
Vervolgens werden de psychosociale effecten van deze huidaandoeningen 
geëvalueerd. Ten slotte werden meerdere behandelingsmogelijkheden voor 
sclerotische huidaandoeningen onderzocht. 
Hoofdstuk 1 beschrijft de classiﬁ catie en het klinisch aspect van gelokaliseerde 
sclerodermie (morfea) en eosinoﬁ ele fasciitis (1.1.2). Aansluitend aan deze indeling 
wordt een paragraaf  gewijd aan pseudosclerotische ziektebeelden (1.1.3) en 
systemische sclerosis (1.1.4). Vervolgens worden diverse behandelingsmodaliteiten 
beschreven voor verharde huidaandoeningen (1.2). De scoringsmethoden die 
gebruikt zijn in de onderzoeken worden uitgelegd in hoofdstuk 1.3. Tenslotte wordt 
in hoofdstuk 1.4 de doelstellingen en bijbehorende vragen van het proefschrift 
gedeﬁ nieerd, te weten:
Doelstelling 1:
Ia Wat is de prevalentie van fysieke symptomen als jeuk, pijn en moeheid 
bij patiënten met een gelokaliseerde sclerodermie dan wel een eosinoﬁ ele 
fasciitis?
Ib Wat is de uitgebreidheid van psychologisch onwelbevinden met de nadruk 
op angst en depressief  gevoel en welke factoren leveren een bijdrage aan dit 
onwelbevinden bij mensen met een gelokaliseerde sclerodermie dan wel een 
eosinoﬁ ele fasciitis?
Doelstelling 2:
IIa Geeft tacrolimus 0.1% zalf  klinische verbetering bij patiënten met een 
actieve plaque morphea? 
IIb Is MTX een effectieve, goed getolereerde behandeling voor sclerotische 
huidaandoeningen en geeft MTX een lange remissieduur bij deze 
huidaandoeningen?
IIc Is UVA-1 een effectieve behandeling voor patiënten met een sclerotische 
huidaandoening en vervolgens wat in de remissieduur van dit langgolvige 
licht bij patiënten met een sclerotische huidaandoening?
IId Geeft UVA-1 een verminderde hardheid van de huid bij patiënten met een 
scleroedema diabeticorum?
Deze vragen werden in hoofdstuk 2 en 3 beantwoord aan de hand van originele 
artikelen. 
Hoofdstuk 2 vermeldt de fysieke symptomen en psychosociale gevolgen van 
morphea en eosinoﬁ ele fasciitis. In eerste instantie werd er door middel van een 
gestandaardiseerde vragenlijst geëvalueerd hoeveel klachten mensen ervaren met 
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betrekking tot moeheid, pijn en jeuk bij de verharde huidaandoening. Daarbij werd 
gebruik gemaakt van de VAS scores en vooraf  vastgestelde ‘cut-off ’ scores. 
In een tweede onderzoek werd gekeken naar de mate van psychologisch 
onwelbevinden, waarbij de nadruk werd gelegd op depressieve gevoelens en angst. 
Daarnaast werd er met behulp van meerdere regressie analyses onderzocht welke 
factoren een rol spelen in dit psychologisch onwelbevinden.
In hoofdstuk 3.1 wordt in een pilot studie de effectiviteit en bijwerkingen 
van topicale tacrolimus 0.1% in de behandeling van actieve plaque morphea 
geëvalueerd. 
Voor hoofdstuk 3.2 heb ik unieke patiënteninformatie mogen gebruiken van ruim 
10 jaar gezamenlijke Reumatologie-Dermatologie poli in het UMC St. Radboud, 
waarbij vele patiënten met een verharde huidaandoening zijn behandeld zijn met 
Methotrexaat (MTX). Ik heb samen met mijn co-auteurs gekeken naar het effect, 
de bijwerkingen en de remissieperiode van MTX bij sclerotische ziektebeelden. 
Hoofdstuk 3.3 geeft een literatuurstudie weer over de effectiviteit, bijwerkingen 
en het gebruik van UVA-1 bij gelokaliseerde sclerodermie, eosinoﬁ ele fasciitis en 
pseudosclerodermie. Vervolgens wordt de remissie periode beschreven aan de 
hand van 10 patiënten met een (pseudo)sclerodermie of  eosinoﬁ ele fasciitis die 
vanaf  2003 zijn behandeld met medium dosis UVA-1 lichttherapie in het UMC St. 
Radboud (hoofdstuk 3.4)
In hoofdstuk 3.5 wordt de succesvolle UVA-1 therapie bij drie patiënten met een 
scleroedema diabeticorum beschreven. 
De belangrijkste conclusies uit dit proefschrift staan hieronder beschreven.
Moeheid, pijn en in mindere mate jeuk hebben een hoge prevalentie bij • 
patiënten met een gelokaliseerde sclerodermie en eosinoﬁ ele fasciitis
(hoofdstuk 2.1).
Mensen met een gelokaliseerde sclerodermie of  eosinoﬁ ele fasciitis hebben een • 
toegenomen psychologisch onwelbevinden, dit geldt met name voor patiënten 
met een gegeneraliseerde morphea of  een eosinoﬁ ele fasciitis. Psychologisch 
onwelbevinden is signiﬁ cant gerelateerd aan een uitgebreidere verharde 
huidaandoening, meer pijn en moeheid, hogere impact van de ziekte op het 
dagelijks leven, meer stigmatisatie, meer hulpeloosheid, minder ziekte acceptatie, 
en minder ontvangen sociale steun (hoofdstuk 2.2).
Naar aanleiding van het eerste dubbel blind gerandomiseerde pilot studie, • 
waarbij tacrolimus 0.1% zalf  werd vergeleken met vaseline album (gedurende 
twaalf  weken), blijkt tacrolimus 0.1% zalf  een veilige en effectieve behandeling 
te zijn van actieve morphea plaques (hoofdstuk 3.1).
Chapter 4 - Summary, conclusions and future suggestions
139
MTX blijkt een effectieve behandeling voor verscheidene sclerotische • 
huidaandoeningen, zelfs bij patiënten met een lang bestaande verharde huid. De 
bijwerkingen van MTX bleken mild. Een herhaalde behandeling was succesvol 
en een lange remissieperiode werd bewerkstelligd in een meerderheid van de 
patiënten (hoofdstuk 3.2).
UVA-1 fototherapie is een effectieve behandeling voor sclerotische • 
huidaandoeningen gebaseerd op de gegevens uit de literatuur. Echter door een 
gemis aan gedegen kwalitatief  goede onderzoeken, zoals gerandomiseerde, 
gecontroleerde trials, en onderzoeken met grote populaties, wordt het 
onmogelijk harde conclusies te trekken over de mate van effectiviteit, optimale 
dosering en behandelingsstrategie van UVA-1 lichttherapie bij sclerotische 
huidaandoeningen. De lange termijn bijwerkingen van UVA-1 zijn nog niet 
bekend (hoofdstuk 3.3). 
Uit onze studie blijkt UVA-1 een effectieve behandeling voor sclerotische • 
huidaandoeningen met een lange remissieperiode en goede klinische effecten, 
zelfs bij patiënten met een lang bestaande verharde huid. UVA-1 behandeling 
kan overwogen worden als een eerste aanpak van sclerotische huidaandoeningen 
(hoofdstuk 3.4).
UVA-1 lichttherapie kan een behandelingsoptie zijn voor mensen met een • 
scleroedema diabeticorum. In de drie scleroedema diabeticorum patiënten 
die behandeld zijn met UVA-1 lichttherapie trad een snelle en objectiveerbare 
verbetering op van de hardheid van de huid (hoofdstuk 3.5).
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voortgeborduurd op jouw onderzoeken! 
Dick de Hoop, mijn maatje! Onze vele goede gesprekken, je enthousiaste verhalen 
over Mozambique, je opbeurende woorden en al je hulp hebben zoveel waarde 
voor mij gehad. Ik ben trots op het feit dat jij je met zoveel toewijding inzet voor 
Afrika. Ik hoop dat we samen nog vaak over dit fantastische werelddeel mogen 
praten en terug kunnen kijken op een waardevolle tijd. 
Michelle van Rossum, dank voor je luisterende oor! We hebben veel leuke tijden 
beleefd, maar ook zware…het blijft onbegrijpelijk als er weer een vriendin zo jong 
sterft… De dank voor je welgemeende interesse in mij is groot!
Jan Boezeman, dank voor je hulp bij de statistische bewerkingen van het MTX 
artikel!
Tevens gaat mijn dank uit naar: Rianne Gerritsen, prof. Eckart Haneke, Marcel 
Pasch, Pieter van der Valk en Carine van der Vleuten. Dank voor jullie stimulerende 
inbreng en prettige werksfeer tijdens mijn opleiding en onderzoeksperiode. 
Angelina, we zijn bijna tegelijk begonnen na een lang voortraject. Deze “Joego” 
(uitspraak van Angelina zelf), nu dermatoloog in Breda, is toch wel mijn voorbeeld 
geweest. Je hebt een geweldige zelfspot en een enorme drive, het was een waar 
genoegen met je te mogen werken. Je hebt gelijk, ik hou meer van uitdagingen 
en een rustig leventje past niet bij mij! Je voorstel om samen op 1 dag te kunnen 
promoveren, zou bijna uitgekomen zijn. 
Annechien, kamergenote je bent me net voor geweest op het gebied van 
promoveren, ik ben jou voor op het gebied van die ene ouwe l@ll@nsport… Dank 
voor het halen van de vele kopjes thee, je steun en tips. Succes met het afronden 
van de opleiding tot dermatoloog. 
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Rieke en Martijn, heel veel dank voor jullie hulp met SPSS. Beide veel succes met 
de afronding van jullie eigen proefschrift!
Alle mensen van de administratie, het secretariaat, de verpleging op de ATB, 
polikliniek en afdeling C10, ontzettend bedankt voor jullie praktische en morele 
ondersteuning. Francis, Ilse en Particia, dank voor al jullie hartverwarmende 
interesse, lieve berichtjes, telefoontjes en super, maar dan ook supergezellige 
etentjes!!! Speciale dank gaat tevens uit naar de lichtverpleegkundigen, naar Pauline 
en Ineke, naar Marisol en de fotografen, Anja en Jan! 
Tamara en Nadine, jullie inzet heeft geresulteerd in een artikel. Een superresultaat 
dus, iets om trots op te zijn. Succes met jullie verdere carrière!
Hans Alkemade, Bert van Bergen, Nico Crombag en de rest van het dermatologie 
team van het Canisius-Whilhelmina Ziekenhuis wil ik bedanken voor de 
geweldige leuke en leerzame tijd die ik met en bij jullie heb gehad. Nadat jullie 
vele ouderejaars assistenten opgeleid hadden, kwam ik met slechts twee maanden 
algemene poli ervaring bij jullie stage lopen. Goede zet, want wat een diversiteit aan 
huidziekten zien jullie dagelijks op de polikliniek!
Mijn oud collega’s Adinda, Angelina, Annechien, Bas, Delphine, Demia, Else, 
Jeanette, Jorn, Jose, Judith, Jurgen, Lenny, Maartje, Mandy, Manon, Maria, Marijke, 
Marjolein, Marloes, Michelle, Milan, Quintus, Rieke, Roland, Rosanne, Saskia, 
Susan, Tim en Wijnand. Dank voor jullie ﬂ exibiliteit en collegialiteit en jullie 
stimulerende werksfeer tijdens mijn opleiding tot dermatoloog. 
Dank aan Francisca Kamphuis-Wolters, jaargenoot en anesthesist in het 
Twenteborg ziekenhuis, we waren elkaar uit het oog verloren. Dank voor je 
telefoontje precies op het juiste moment. Het heeft het zo moeten lopen, daar zijn 
we beide van overtuigd. 
Dan ben ik nu toegekomen aan het bedanken van de belangrijkste mensen in mijn 
leven…
Graag wil ik mijn (schoon)familie en mijn vrienden bedanken voor jullie oprechte 
interesse en toegewijde vriendschap. Jullie hebben altijd in mij geloofd en zijn er 
altijd voor mij geweest. Dank familie Lynch uit Wales en familie Versmissen! 
Een speciaal woord van DANK gaat uit naar Gerry en Anita. Fantastisch, wat een 
correctie werk hebben jullie verzet! Nooit was iets teveel en ik hoefde nooit lang te 
wachten op jullie reacties. Super!
Mariet, een moeder kan nooit vervangen worden, maar jij komt wel heel dicht 
in de buurt! Dank voor al je steun, (moeder)liefde, zorgzaamheid en toewijding. 
Onze band, is ondanks de afstand, zo enorm sterk! Ik ben er trots op dat je mijn 
paranimf  bent. 
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Manon, het begon met Klok en Kroft in 1992 en zie nu… Onze vriendschap is 
uniek. Ja Manon dit ‘proefje’ (citaat uit India, 1996) is nu afgerond en wederom 
speel jij een rol in dit wetenschappelijke onderzoek. Wat hebben wij samen veel 
gelachen en meegemaakt. Ik wil je op deze manier laten weten dat je een topper 
bent. Je bent dan ook niet voor niets mijn paranimf. 
Enny Beverdam, Paul Ossenkoppele, Marjolein van Steveninck-Wensing, Carla 
Roosen, en de rest van het dermatologie en verrichtingencentrum team van het 
Twenteborg ziekenhuis te Almelo, wil ik danken. Ik werk met veel plezier in een 
ziekenhuis waar de dermatologie op zeer hoog niveau bedreven wordt. Door dit 
niveau en de continue innovaties in Almelo, weet ik zeker dat dit specialisme me 
blijft boeien en ik me kan blijven ontwikkelen! Het is een waar genoegen met 
ambitieuze, lieve, oprechte, eerlijke mensen te mogen werken. Dank! 
Dank onder andere Anne ter Meulen†, Sabine Claassen†, Susan, Tamara, Martijn, 
Esther, Bernice, Gerry, Peter, Jantine, Frederic, Marie-José, William, Remon, Sheila, 
Roel, Caroline, Sylvia, Thei, Willem, Milan, Sioe Lie, Nicol, Theo, Willem-Jan, 
Astrid en de vriendengroep uit Oldenzaal. Jullie betrokkenheid en vriendschap is 
heel wat waard!
Alle mensen waar ik veel om gaf  en geef  en er niet meer bij mogen zijn, wil ik 
danken dat ik ze heb leren kennen. Uit het oog is absoluut niet uit het hart! 
Mama, … vooral JIJ hoort in het dankwoord thuis. We hebben te kort tijd gekregen 
samen te zijn. Door je overlijden, hetgeen ik nooit had verwacht, is mijn leven 
drastisch veranderd. Iets wat verdriet blijft geven, maar ook mijn kijk op wat 
belangrijk is in het leven heeft veranderd. Nog bijna dagelijks denk ik aan je. Ik heb 
mijn drive en gevoel voor rechtvaardigheid echt niet van een vreemde, en jij ook 
niet! Ik moet vaak aan jouw moeder denken. Jammer dat jullie dit niet meer mee 
kunnen maken…
Als allerlaatste richt ik het woord tot mijn man, Gerard. Je was en bent er altijd 
voor mij. Je geduld, optimisme, relativerend vermogen en vooral veel humor waren 
voor mij de inspirator om door te gaan. Je adviezen, rust en warme hart brachten 
mij weer met beide benen op de grond. Inderdaad, alles is betrekkelijk. Dank voor 
de lay-out van dit boekje, dat kon ik met een gerust hart bij jou onder brengen. 
Maar vooral dank dat je er altijd voor me bent geweest de afgelopen 15 jaar! Wat 
hebben we samen al veel meegemaakt, lieﬁ e! Je mening over promoveren, kan ik 
niet bijstellen. Je hebt helemaal gelijk. Hopelijk kunnen we nu snel terug naar het 
‘schone en nijvere Twente!’ En…, als alles goed blijft gaan, genieten van de laatste 
maanden zwangerschap!
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Stellingen behorend bij het proefschrift
Impact and therapeutic options of  
sclerotic skin diseases
I Moeheid, pijn en in mindere mate jeuk hebben een hoge prevalentie bij patiënten met 
een gelokaliseerde sclerodermie of  eosinofi ele fasciitis. (dit proefschrift) 
II Mensen met een gelokaliseerde sclerodermie of  eosinofi ele fasciitis hebben een 
toegenomen psychologisch onwelbevinden. (dit proefschrift) 
III Tacrolimus 0.1% zalf  lijkt een veilige en effectieve behandeling te zijn voor patiënten 
met een beperkte actieve plaque morphea. (dit proefschrift) 
IV MTX blijkt een effectieve behandeling voor verscheidene sclerotische 
huidaandoeningen, zelfs voor patiënten met een lang bestaande verharde huid. 
Herhaalde behandeling lijkt succesvol. (dit proefschrift) 
V UVA-1 fototherapie is een veelbelovende behandeling voor sclerotische 
huidaandoeningen gebaseerd op de gegevens uit de literatuur. Echter door een gemis 
aan gedegen kwalitatief  goede onderzoeken, zoals gerandomiseerde, gecontroleerde 
trials, en onderzoeken met grote populaties, is het moeilijk harde conclusies te trekken 
over de mate van effectiviteit, optimale dosering en behandelingsstrategie van UVA-1 
lichttherapie. (dit proefschrift) 
VI UVA-1 lijkt een effectieve behandeling voor een breed spectrum van sclerotische 
huidaandoeningen met een lange remissieperiode en goede klinische effecten, zelfs bij 
patiënten met een lang bestaande verharde huid. (dit proefschrift) 
VII UVA-1 behandeling kan overwogen worden als een eerste aanpak bij patiënten met een 
scleroedema diabeticorum. (dit proefschrift) 
VIII Wie het ernstigst tracht eerlijk te zijn, wordt het meest gewantrouwd. (K. Verstee)
IX Geld bederft het karakter, tenminste als men er één heeft. (W. Eschker)
X Als arts, maar ook als onderzoeker, komt de eigenschap nieuwsgierigheid goed van pas.
XI De zorg wordt steeds zakelijker, terwijl deze zaken zorgelijk gaan worden.
XII “The world today is hungry, not only for bread…but hungry for love; hungry to be 
wanted... to be loved” (Moeder Teresa)
XIII Alles wat vrouwen doen moeten ze twee maal zo goed doen als mannen om half  zo 
goed te worden gevonden. Gelukkig is dat niet zo moeilijk. (C. Witthon)
XIV Volg je ideaal, maar idealiseer dit niet.
E.B.M. Kroft-Bult 
Dermatoloog, Twenteborg Ziekenhuis te Almelo
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Uitnodiging
Hierbij wil ik u en uw partner 
graag uitnodigen voor het 
bijwonen van de verdediging van 
mijn proefschrift, getiteld:
Impact and therapeutic 
options of  sclerotic skin 
diseases
De promotieplechtigheid zal 
plaatsvinden op 
donderdag 11 december 2008 
om 15.30 uur in Aula Major 
van de Radboud Universiteit 
Nijmegen, Comeniuslaan 2 te 
Nijmegen.
Aansluitend zal er een receptie 
plaatsvinden. 
Gezien de aard van de 
plechtigheid wordt u vriendelijk 
verzocht geen kinderen mee te 
nemen naar de promotie. Bij de 
receptie zijn ze vanzelfsprekend 
van harte welkom.
The scleroderma skin disorders comprise a heterogeneous group of  
conditions linked by the presence of  sclerotic skin lesions. It can manifest 
itself  as a small indurated plaque to conditions that may cause a signifi cant 
functional and cosmetic deformity. Localized scleroderma is a primary 
cutaneous sclerosis. Examples of  localized scleroderma are plaque 
morphea, linear morphea and deep morphea. Additional eosinophilic 
fasciitis can be distinguished, although the question remains whether 
eosinophilic fasciitis is a seperate disease or a variant of  deep morphea. 
Scleroderma-like disorders, also called pseudoscleroderma or secondary 
scleroderma, are disparate conditions mimicking cutaneous localized 
scleroderma, e.g. chronic sclerodermic graft-versus-host disease, drug-
induced scleroderma-like disorders, mucinosis such as scleredema of  
Buschke/adultorum and scleromyxedema. 
This thesis is focused upon localized scleroderma, eosinophilic fasciitis and 
pseudoscleroderma and does not only give a detailed description of  the 
physical burden and psychological distress in patients with a sclerotic skin 
disease, but also studied the therapeutic effectiveness and tolerability of  
different classes of  treatment for sclerotic skin diseases. 
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